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1 SUMMARY 
 
This thesis is about the following key issues: 
 
1. Characterization of the APP/PS1KI mouse model of Alzheimer`s disease (AD) 
under aspects of changes in cholesterol metabolism, behavioural changes and 
neuropathological markers, e.g. neuron loss and neuroinflammation.  
2. Characterization of transgenic mice transgenic for glutaminyl cyclase (mQC) 
AβN3Q-42 (TBA2) and AβN3E-42 (TBA1). Mice were analyzed under aspects of 
expression of transgene on mRNA and/or protein level.  In mQC mice I assessed 
also activity data for glutaminyl cyclase in brain, plasma and peripheral organs. 
Furthermore, double-transgenic mice transgenic for AβN3E-42 and mQC to were 
bred to prove the in vivo potential of mQC to catalyze cyclization of AβN3E-42 to 
AβN3(pE). The question to answer was, if any of these models would meet the 
criteria as a model for sporadic AD. Moreover, the APP/PS1KI mice model was 
analyzed for aggregation of AβN3(pE) at 2 and 6 months of age. 
 
The results from this work allow to draw the following key assertions: 
 
Ad 1.: A phenotypical analysis of the APP/PS1KI model using behavioral tests for working 
memory and motor performance, as well as an analysis of weight development and body 
shape was performed. At the age of 6 months, a dramatic, age-dependent change in all of 
these properties and characteristics was observed accompanied by a significant reduced ability 
to perform working memory and motor tasks. The APP/PS1KI mice were smaller and showed 
development of a thoracolumbar kyphosis, together with an incremental loss of body weight. 
While two month-old APP/PS1KI mice were inconspicuous in all of these tasks and 
properties, there is a massive age-related impairment in all tested behavioral paradigms. 
Abundant hippocampal CA1 neuron loss was detected by high precision design based 
sterology starting at 6 months of age in the APP/PS1KI mouse model, which coincides with 
the onset of motor and memory deficits.  
Moreover, by use of realtime RT-PCR and immunohistochemical methods, I found broad 
evidence for neuroinflammation, micro- and astroglia activation in 6-month-old APP/PS1KI 
mice, while 2-month old mice appeared to be normal. 
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Regarding the analysis of cholesterol metabolism in APP/PS1KI mice, I determined a 
significant decline of plasma cholesterol in APP/PS1KI mice compared to control mice at 6 
months of age, when AD-like pathology is already extensively present in these animals, while 
at two months of age no difference was observed. I also analyzed levels of 24(S)-
hydroxycholesterol in plasma to test the reliability of this molecule as a plasma biomarker for 
progression of AD. However, I did not detect any correlation between the levels of 24(S)-
hydroxycholesterol and the onset of pathology in APP/PS1KI mice. 
 
Ad 2.: The mouse models TBA1 and TBA2 are based on neuron specific expression of Aβ3E-
42 and Aβ3Q-42, which were fused to the pre-pro-sequence of murine thyrotropin-releasing 
hormone.  
In mice heterozygous for AβN3E-42 (TBA1) and mQC, I found evidence for the in vivo 
formation of AβN3(pE) driven by enzymatic catalysis of glutaminyl cyclase (QC) in three 
month old TBA1/QC mice compared to TBA1 and mQC single transgenic, as well as 
wildtype control mice. 
In TBA2 mice,  massive neurological impairments became apparent eight weeks after birth, 
which was likely due to Purkinje cell degeneration. Purkinje cells showed abundant staining 
for Aβ, including Aβ3(pE), and ubiquitin, and were decorated by micro- and astrogliosis. 
Extracellular Aβ deposits appeared at the site of Purkinje cell degeneration. The results 
suggest that Aβ3(pE)-42 due to its high stability and aggregation propensity triggers Aβ 
accumulation. The correlation of substantial neuron loss and formation of Aβ3(pE), provides 
evidence that modified Aβ species foster neurotoxicity. Therefore, reduction or clearance of 
those amyloidogenic peptides should be considered as novel treatment strategies. 
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ZUSAMMENFASSUNG 
Die vorliegende Arbeit beschäftigt sich mit zwei thematischen Schwerpunkten: 
 
1. Ein Teil der Promotionsschrift beschäftigt sich mit der Fortsetzung der 
Charakterisierung des APP/PS1KI Mausmodells. Neben einer Untersuchung des 
Cholesterolmetabolismusses wurden diese Tiere insbesondere auch 
verhaltensbiologisch charakterisiert. Weiterhin wurde der bei diesen Tieren 
altersabhängig auftretende Nevenzellverlust mithilfe stereologischer Methoden 
quantifiziert und die Entzündungspathologie im Gehirn dieser Tiere zu 
verschiedenen Altersstufen mittels immunhistochemischer Untersuchungen und 
real-time RT-PCR untersucht. 
 
2. Der zweite Teil dieser Arbeit beschäftigt sich mit der Charakterisierung dreier 
neuer transgener Mauslinien, die jeweils heterozygot transgen für das Enzym 
Glutaminyl-Cyclase (mQC) oder für die Proteine AβN3E (TBA1-Linie) bzw. AβN3Q 
(TBA2) waren.  
Die mQC-transgenen Tieren wurde hinsichtlich der Expression und Aktivität des 
Transgens charakterisiert. 
Das Metalloenzym Glutaminyl Cyclase setzt AβN3E bzw. AβN3Q als Substrat in 
vitro zu Pyroglutamat AβN3(pE) um. Ziel unserer Untersuchungen zum 
Pyroglutamat AβN3(pE) war es, die Aggregationseigenschaften und die 
Neurotoxizität dieses speziellen Aβ-Peptides in vivo zu analysieren. Durch 
Kreuzung wurden Mäuse erzeugt, die sowohl heterozygot transgen für mQC als 
auch AβN3E (TBA1-Linie) waren. In diesem doppelt transgenen Tiermodell sollte 
geklärt werden, ob die mQC die Umsetzung zum Pyroglutamat AβN3(pE) auch in 
vivo katalysieren kann. In diesem sogenannten TBA1/QC- und im TBA2-
Tiermodell wurde die in vivo Aggregation von AβN3(pE) untersucht. Außerdem 
wurde auch das APP/PS1KI-Tiermodell im Hinblick auf die altersabhängige 
AβN3(pE)- Bildung hin analysiert. 
 
Bezogen auf die zuvor angeführte Fragestellung hat diese Arbeit zu folgenden 
Ergebnissen geführt: 
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Ad 1.:  In dieser Arbeit wurde eine phänotypische Analyse des APP/PS1KI 
Tiermodells der Alzheimer Erkrankung durchgeführt, das im Alter von sechs Monaten 
viele der pathologischen Merkmale aufweist, wie sie auch für das humane 
Krankheitsbild beschrieben sind. Neben verhaltensbiologischen Untersuchungen des 
Arbeitsgedächtnis und der motorischen Leistungen dieser Tiere, wurden auch die 
altersabhängige Entwicklung des Körpergewichtes und der Körperform erfasst. Im 
Alter von sechs Monaten zeigten APP/PS1KI Mäuse signifikante Auffälligkeiten 
bezüglich aller untersuchten Parameter. Bei allen Tests zum Arbeitsgedächtnis und zu 
den motorischen Fähigkeiten zeigte sich ein stark herabgesetztes Leistungsvermögen 
sechs Monate alter APP/PS1KI Tiere im Vergleich zu PS1KI Kontrolltieren gleichen 
Alters. Im Alter von zwei Monaten wurden bei den APP/PS1KI Tiere hingegen noch 
keine diesbezüglichen Auffälligkeiten festgestellt. Insbesondere die Einschränkungen 
bei der Leistungsfähigkeit des Arbeitsgedächtnisses lassen sich dabei gut durch den 
mittels stereologischer Methoden festgestellten Neuronenverlust von 33% im CA1-
Band des Hippocampus bei sechs Monate alten APP/PS1KI Tieren erklären.  
 
Ebenso war im Gehirn sechs Monate alter APP/PS1KI Tieren eine ausgeprägte 
Entzündungspathologie feststellbar. Mittels immunhistochemischer Färbungen und 
real-time RT-PCR wurden eine Vielzahl gängiger Marker für Neuroinflammation 
sowie Micro- und Astrogliaaktivierung positiv getestet. 
 
Bei der Analyse des Cholesterolmetabolismus stellte ich im Vergleich zu 
Kontrolltieren  in sechs Monate alten APP/PS1KI Tieren eine signifikante Abnahme 
der Konzentration von Cholesterol im Plasma fest. Bei zwei Monaten war hier 
ebenfalls noch kein Unterschied feststellbar. Ebenso wurden die Konzentrationen von 
24(S)-hydroxycholesterol altersabhängig in APP/PS1KI  und Kontrolltieren bestimmt, 
um die Eignung dieses Moleküls als Plasma-Biomarker für den Verlauf der 
Alzheimer-Erkrankung zu untersuchen. In den untersuchten Tieren war jedoch kein 
Zusammenhang zwischen der Entwicklung der Plasmakonzentration von 24(S)-
hydroxycholesterol und dem Fortschreiten der Alzheimer-Pathologie erkennbar. 
 
Ad 2.: Die transgenen Mausmodellen TBA1 und TBA2 exprimieren 
neuronenspezifisch die N-terminal trunkierten Aβ-Varianten AβN3E bzw. AβN3Q. In 
drei Monate alten TBA/QC Mäusen, die heterozygot für das Enzym Gluaminyl 
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Cyclase (mQC) und AβN3E waren, gelang der in vivo Nachweis der Bildung von 
Pyroglutamat AβN3(pE) durch katalytische Umwandlung von AβN3E durch das Enzym 
Glutaminyl Cyclase. 
In den TBA2 Mäusen, die im Vergleich zu den TBA1 Tieren etwa xfach höhere 
AβN3(pE)-Werte im Gehirn zeigen, zeigten sich bereits im Alter von acht Wochen 
schwere neurologische Beeinträchtigungen, die vermutlich auf die gezeigte 
Degeneration der Purkinje-Zellen im Kleinhirn zurückzuführen ist. Diese Zellen in den 
TBA2-Tieren zeigten eine deutliche immunhistochemische Färbung für Aβ,  AβN3(pE) 
wie auch Ubiquitin und zeigten darüber hionaus Merkmale einer bestehenden Micro- 
und Astrogliose. Soweit sich im Gewebe eine Degeneration der Purkinje-Zellen zeigte, 
fanden sich dort auch extrazelluläre Ablagerungen von Aβ. Auf Grundlage dieser 
Befunde könnte AβN3(pE) aufgrund seiner höheren Stabilität und seiner stärkeren 
Aggregationsneigung der Wegbereiter einer sich dann weiter entwickelnden 
Plaquepathologie bei der Alzheimer Krankheit sein, indem es als Keimbildner die 
ersten extrazellulären amyloiden Aggregate bildet, an die sich anschließend weitere 
Formen von Aβ anlagern können. Dass sich in den TBA2-Tieren neben der 
Akkumulation von AβN3(pE)  auch Indizien für einen auftretenden Neuronenverlust 
zeigen, deutet auf das neurotoxische Potential dieser N-terminal modifizierten Aβ-
Variante hin. Eine Verminderung der QC-vermittelten Bildung von AβN3(pE) im 
menschlichen Gehirn weist daher möglicherweise den Weg zu neuen Therapieansätzen 
in der Alzheimererkrankung. 
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2 INTRODUCTION  
2.1 ALZHEIMER`S DISEASE 
 
Alzheimer`s disease nowadays is the most common neurodegenerative disease of the elderly. 
Referring to the affected patients, AD is characterized by proceeding memory deficits and 
ongoing loss of daily-life abilities. First signs of the early disease state are short-term memory 
loss and visual-spatial confusion, often accompanied by aphasia, disorientation or 
disinhibition. Many patients start to show changes in their behavior and therefore, for 
example, confront their social surrounding with formerly unknown violent outbursts or in 
contrast distinct passivity.  Accordingly, close relatives are often the first ones that get aware 
of these early changes in the character and behaviour of a person that is on the way to develop 
early stage AD. With the disease taking its course, proceeding cognitive decline is met in 
addition by deterioration of musculature and a loss in mobility. Patients in the final stage are 
unable to perform even the most simple tasks like walking or eating without assistance, suffer 
from incontinence of the bladder and/or the bowel. Patients affected by late stage AD speak 
often very disorganized. Also, patients in this state of disease require permanent supervision. 
In Germany, this care is mostly achieved by close relatives of the demented persons. 
Therefore, besides the mentioned direct effects of AD on an affected person, AD also has a lot 
of impact on the social surrounding of the patient and often one family member signs out of 
its job to afford the time needed to take care. A further problematic social issue connected to 
AD is, that 80% of family members taking care of demented persons are themselves already 
in an advanced age between 50 and 75 years and therefore find themselves sometimes also not 
any more in best health condition. 
 
In economic figures in 2006 in Germany 800.000 persons were living with a diagnosis of AD 
causing direct healthcare costs of 20 bn Euros. These numbers are estimated to rise until 2040 
to between 1.5 and 2.0 million AD patients inflicting direct costs of about 50 bn Euros. 
prediction underlines the economic and social challenge ageing societies are going to face due 
to Alzheimer`s disease and related forms of dementia. 
 
Despite the unquestioned economic potential of an effective cure targeting AD still none such 
has come to market or is known to appear in the horizon of the next few years. However a 
couple of standard therapy medications are already available to AD patients. Though, all of 
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these drugs do not target the underlying disease mechanism but deliver at least some 
symptomatic benefit , however without any slowdown in the total progress of the disease. 
 
In terms of economical turnover, drugs from the group of acetylcholinesterase inhibitors 
(ChEIs) and NMDA receptor antagonist have greatly gained in importance.  
 
In short, inhibitors of the enzyme acetylcholinesterase (AChE) aim to the detected decrease of 
the neurotransmitter acetylcholine due to reduced activity of cholinergic neurons in AD 
patients, which has been proposed to have some impact on the memory loss in AD. 
Acetylcholine is degraded by AChE. Therefore, inhibition of AChE stabilizes levels of 
acetylcholine in the brain and helps to delay some loss of memory symptoms in AD for a few 
months.  
Another approach to overcome some of the symptoms of memory decline in AD with overall 
moderate efficacy is based on the finding that in AD excessive activation of N-methyl-D-
aspartate (NMDA) receptors may finally lead to the degeneration of cholinergic cells.  
NMDA- receptor antagonists block the sustained activation of the receptor by glutamate that 
may occur under pathological conditions in AD. Thus, NMDA receptor function is attenuated. 
Epidemiological studies also suggested potential for NSAIDs, estrogen, HMG-CoA reductase 
inhibitors (statins) or tocopherol (vitamin E) to prevent AD. However, prospective, 
randomised studies have not convincingly been able to demonstrate clinical efficacy. (Hull et 
al. 2006) Besides these therapeutic approaches a wide variety of suggestions has been made 
how to reduce the risk of getting affected by AD including intake of red vine containing 
flavonoids with antioxidant activity, intake of omega-3-fatty acids, Gingko Biloba extracts, B- 
vitamins and others more. Also certain aspects of behaviour like intellectual activity are 
thought to have a beneficial overall influence. However, all these therapies and supplements 
lack, that they do not address the underlying disease pathomechanism. 
 
2.2 FAMILIAL AND SPORADIC TYPE OF ALZHEIMER`S DISEASE 
 
AD subdivides in so called familial or early onset AD and secondly sporadic AD, the latter 
representing the far more prominent part of people concerned. Spoken in numbers, 90 - 95% 
of AD cases appear in a sporadic manner with proceeding age as the major identified risc 
factor, while only 5 - 10% of the disease cases are genetically based (Tanzi 1999). Mutations 
typical for this familial early onset type of AD are associated with the genes encoding the β-
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amyloid precursor protein (hAPP, chromosome 21), the presenilin 1 (PS1, chromosome 14), 
and the presenilin 2 (PS2) gene (on chromosome 1). These mutations foster abnormal 
processing of the amyloid precursor protein and therefore ameliorate overproduction of 
amyloid beta peptides Aβ1-40 and Aβ1-42. Additionally, the e4 allele of apolipoprotein E 
(ApoE) has also been shown to be associated with a increased risk for late-onset AD (St 
George-Hyslop 2000). 
However, the causes of sporadic type of AD with age as the major identified risc factor still 
remain opaque, though extensive research efforts address this issue. Widely discussed is the 
influence of environmental agents (e.g., heavy metals), intrinsic factors (e.g., cytokines), and 
dietary factors (e.g., cholesterol) (Lahiri et al. 2007). 
 
 
 
Fig. 1: (A) Missense mutations in the βAPP gene (HCHWA-D: amyloidosis Dutch type; FAD: familiar 
Alzheimer disease). Data taken from (St George-Hyslop 2000) (B) Genetic mutations implicated in 
familiar or sporadic onset of Alzheimer`s disease (according to (St George-Hyslop 2000)). 
  
 
 Page 15/137 
2.3 NEUROPATHOLOGICAL HALLMARKS OF ALZHEIMER`S 
DISEASE IN HUMAN 
 
On a neuropathological level brains of AD patients suffer from a devastating extent of neuron 
loss accompanied by extensive formation of senile plaques consisting of amyloid beta (Aβ) 
and appearance of neurofibrillary tangles of hyper-phosphorylated tau-protein. Furthermore, 
vascular deficits and a pathology of inflammation are clearly associated with the AD affected 
brain. 
 
2.3.1 AMYLOID BETA PLAQUE DEPOSITION 
 
The formation of senile plaques consisting mainly of amyloid β peptides is one of the most 
typical and also prominent changes occurring in brains affected by AD, though it is also 
known, that people developing plaque pathology do not necessarily develop symptoms of AD. 
However, it is still a most widely accepted hypothesis, that production and aggregation of the 
amyloid β protein (Aβ) is a key event in the pathology of AD (Van Broeck et al. 2007). The 
role of extracellular Aβ-plaques in the process of AD is widely established under the term 
“Amyloid-β hypothesis”, which assumes a dysfunction in the processing of amyloid precursor 
protein (APP) as the crucial trigger for AD onset (Hardy & Allsop 1991). 
 
A revised version of the β-amyloid hypothesis was introduced by Wirths et al., based on the 
finding that Aβ accumulation takes place at first in the intraneuronally space while 
extracellular formation of plaques is a subsequent event (Masters et al. 1985; Wirths et al. 
2004). Because extracellular plaque load was found not to be correlated with striking events 
of AD pathology like neuron loss, Wirths et al focused on the development of AD symptoms 
depending on levels of intraneuronal Aβ. Evidence for this hypothesis was derived from the 
finding of deficits in behaviour, synaptic transmission or long-term potentiation well before 
first signs of plaque pathology in several transgenic mouse models of AD (Holcomb et al. 
1998; Hsia et al. 1999; Moechars et al. 1999). The physiological potential of intracellular Aβ 
was also supported by the finding, that  this pool of  Aβ represents an early and integral 
component of the pathogenesis of the human muscle disorder IBM (Askanas et al. 1993; 
Mendell et al. 1991).  Additionally, immunohistochemical analysis of postmortem DS and 
APP transgenic mouse brains by use of C-terminally specific antibodies directed against Aβ1-
42 gave evidence for an age-dependent increase of this neurotoxic Aβ-species within neurons 
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(Busciglio et al. 2002; D'Andrea et al. 2001; Gouras et al. 2000; Tabira et al. 2002; Wirths et 
al. 2004). Meanwhile, the importance of intracellular Aβ has been underlined by a broad 
range of studies (Glabe 2001; Gouras et al. 2005). Most convincing, in an APP/PS1KI mouse 
model of AD a strong correlation between early accumulation of intraneuronal Aβ in CA1/2 
region of the hippocampus already from 2 months of age on and an extensive neuron loss 
(~50%) in this area of the hippocampal pyramidal cell layer was reported (Casas et al. 2004).   
 
 
Fig. 2: Two versions of the Amyloid β hypothesis: Sequence of pathogenic events leading to AD pathology 
is shown in the classical understanding according to Hardy et al. (right part of figure) and in a revised 
version according to Wirths et al. (left part of figure) that focuses on the contribution of intraneuronal 
accumulation of Aβ42 to the development of AD pathology. Both vicious cascades may interfere and 
contribute in parallel as well to the cognitive decline symptomatic for AD affected patients, as suggested 
by horizontal arrows. 
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Aβ is formed in the brain by enzymatic cleavage of the amyloid precursor protein (APP). APP 
is a protein with a single transmembrane domain (Gandy & Petanceska 2000). APP mRNA 
splicing undergoes in various ways leading to the generation of at least 8 distinct isoforms, 
namely APP677, APP695, APP696, APP714, APP733, APP751, APP752 and APP770. 
APP695 is the most common isoform in the brain (Golde et al. 1990; Sandbrink et al. 1997). 
 
Fig. 3: Schematic representation of the APP protein, including the Aβ sequence, cleavage sites of α-, β-, 
and γ-secretase, important mutations in the APP protein related to familial AD and binding sites of 
important antibodies. 
 
In AD, the focus is on two distinct pathways of APP processing. The first anticipated non-
pathogenic and therefore referred to as non-amyloidogenic pathway is characterized by 
subsequent cleavage of APP by the enzyme α-secretase in the first step, which leads to release 
of α-APP, and further processing by γ-secretase to set free the N-terminally truncated Aβ 
fragment “p3” from the still membrane retained carboxy APP terminal “C83” (Carter & Lippa 
2001).  By α-secretase processing APP is being cut within the Aβ sequence at position 17 in 
the Aβ domain, therefore p3 can be referred as Aβ17-40/42.  In consequence, α-cut of APP 
prevents the formation of Aβ1-40/42 which are the most prominent Aβ-species in AD affected 
brains. The mechanism of α-secretase regulation remains unclear. However, three members of 
the ADAM family of proteases (a disintegrin and metalloprotease), namely ADAM 9, 10 and 
17, have been supposed to represent the main candidates for α-secretases (Hiraoka et al. 
2007). 
 
Aβ1-40/42 are both formed via the so called amyloidogenic pathway, in that APP is first 
processed by the enzyme β-secretase to generate the amino terminal of Aβ and to set free the 
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so called β-APPs. Subsequently to action of β-secretase membrane retained C99 is being cut 
by the enzyme γ-secretase, which finally leads to generation of Aβ1-40 and Aβ1-42 (Van Broeck 
et al. 2007). β-Secretase has been reported to be a type I transmembrane glycosylated aspartyl 
protease, while γ-secretase has been identified to be a high-molecular-weight protein complex 
including the four proteins Aph-1, Pen-2, nicastrin and PS (Guntert et al. 2006; Van Broeck et 
al. 2007).  Though the exact intracellular cleaving sites of  γ-secretase and the nature of this 
enzyme are still not fully understood, it is well described that γ-secretase breakdown of APP 
metabolite leads in parallel to a short- and a long-tailed  Aβ  metabolite as well, namely Aβ1-40 
and Aβ1-42 (Carter & Lippa 2001).  
 
 
Fig. 4: Non-amyloidogenic and amyloidogenic pathway of APP processing by subsequent proteolytic 
cleavage by α-/γ-secretase (non-amyloidogenic pathway) or β-/γ-secretase (amyloidogenic pathway) 
leading to the generation of Aβ1-40/42. 
 
The cleavage sites of the enzymes involved in APP processing are all near or at those 
positions in APP, where AD related mutations of APP have been found. Furthermore, it has 
been shown, that all FAD-linked mutations in the genes of APP, PS1 and PS2 induce an 
increase in the generation of Aβ. Notably the mutations in PS1 and PS2 have been shown to 
enhance the production of Aβ1-42 in vitro and in vivo (Takeda et al. 2004; Xia 2000). All this 
underlines the possible influence of familial autosomal AD mutations to direct APP 
processing to the amyloidogenic or non-amyloidogenic pathway (Hardy & Selkoe 2002).  
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While Aβ1-40 in human AD patients is the far most abundant Aβ species with an estimated 
1000-fold excess compared to Aβ1-42, the latter one has been shown to be much more prone to 
aggregation and to obtain highly neurotoxic properties (Selkoe 2001). 
 
2.3.2 NEUROFIBRILLARY TANGLES 
 
Formation of neurofibrillary tangles (NFT) represents a second intracellular phenomenon 
associated to AD pathology in the human brain. NFTs appear as bundles of abnormal 
filaments called paired helical filaments (PHF), composed of highly phosphorylated forms of 
the ~55  kDa microtubule-associated protein tau. It is widely believed that the high degree of 
phosphorylation of PHF-tau is a critical event linked to microtubule disorganization and 
generation of neurofibrillary lesions typically occurring in AD pathology (Boutajangout et al. 
2002). Though tau is encoded by a single gene, alternative splicing of corresponding RNA 
leads to multiple distinct isoforms of this protein. Six tau isoforms are known in the human 
brain (Wagner et al. 1996). Tau has been reported to bind to microtubules and to promote 
microtubule assembly in vitro (Goedert & Jakes 1990). Tau protein is assumed to be 
functional in the formation and maintenance of axons, due to the finding that antisense 
oligonucleotide mediated down-regulation of tau expression in primary cerebellar neurons 
impairs the generation of new axons in these cells (Wagner et al. 1996). The phosphorylation 
process of tau takes place at serine/threonine residues preceding a proline and has been shown 
to be mediated by a number of proline-directed kinases including e.g. members of the 
mitogen-activated protein kinase (MAPK) family, glycogen synthase 3α (GSK3α) or 
glycogen synthase 3β (GSK3β) or CDK5. At the cellular level, hyperphosphorylated tau is 
mostly found in the somatodendritic compartment of the neurons (Zheng et al. 2002). 
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Fig. 5: Tau malfunction in AD: In a healthy neuron (top), tau stabilizes the microtubules (blue lines) that 
transport materials to the nerve terminals. In AD, tau is unable to bind to the microtubules and forms 
abnormal aggregates, the so called paired helical filaments (PHF-tau). This process fosters degeneration of 
microtubules and induces impaired neuronal functioning (graphics taken from Marx 2007). 
 
The mechanism by that tau makes an impact on AD pathology is still a matter of discussion. 
Rapoport et al. reported about the ability of tau to induce β-amyloid induced neurotoxicity in 
vitro. Cultured hippocampal neurons expressing either mouse or human tau showed clear 
signs of neurodegeneration upon incubation with fibrillar Aβ, while no such effects were 
observed in tau-knockout mice under same treatment conditions (Rapoport et al. 2002). On 
the other hand, Zheng et al. demonstrated in vitro, that Amyloid β can induce tau 
hyperphosphorylation in rat primary septal cultures (Zheng et al. 2002). Additionally, 
hyperphosphorylated tau aggregates have been speculated to disrupt cellular transport, 
(Mandelkow et al. 2003) cellular geometry, and neuronal viability (Cummings et al. 1998). 
 
2.3.3 HIPPOCAMPAL SHRINKAGE, NEURON LOSS AND SYNAPTIC 
DEFICITS 
 
GENERAL REMARKS 
 
In AD patients, the decline of synaptic density in the brain showed to be the most suitable 
marker correlating with the extent of cognitive loss during the disease process compared to 
e.g. plaque pathology, NFTs, neuron loss, and transmitter deficits (Coleman & Yao 2003). 
Two independent studies revealed a correlation coefficient of 0.7 between synapse density 
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and cognitive status of AD patients (Coleman & Yao 2003). In well accordance with the event 
of synapse loss, Reddy et al. analyzed levels of synaptic protein in brains of AD patients and 
reported about a loss of presynaptic (synaptotagmin, synaptophysin, and Rab 3A), synaptic 
membrane proteins (Gap 43 and synaptobrevin) and postsynaptic proteins (neurogranin and 
synaptopodin) in AD patients compared to healthy controls (Reddy et al. 2005). Synaptic 
decline appeared to be more severe in the frontal cortex compared to the parietal cortex of AD 
patients (Reddy et al. 2005).  
Neuron loss in AD represents a further marker of cognitive decline. Shepherd et al. reported 
about a neuron loss in frontal superior cortex of 36% in early onset AD cases and of 22% in 
sporadic AD cases compared to healthy controls (Shepherd et al. 2007). Neuron counting in 
the entorhinal cortex (EC), that is believed to obtain a crucial role as a gateway connecting the 
neocortex and the hippocampal formation, showed a 32% neuron loss in EC in cases with a 
mild form of AD. The EC lies in a critical path in neural systems related to memory. It 
receives afferents from widespread association and limbic areas, projects to the dentate gyrus 
of the hippocampal formation, receives afferents from the hippocampus, and sends afferents 
back to association neocortex. The EC is a region highly vulnerable in AD and layers II and 
IV of the EC were shown to be among the first regions affected with tangles in Down 
syndrome and in normal aging. In layer II of the EC, which gives way to the perforant 
pathway, a decrease of even 60% and of 40% in layer IV of the EC was determined in a group 
of mild AD cases. In severe cases of AD, numbers of neurons in layer II decreased by ~90%, 
and the number of neurons in layer IV decreased by ~70% compared with controls, while in 
cognitive normal controls neuron numbers remained constant between 60 and 90 years of age 
(Gomez-Isla et al. 1996). 
 
The hippocampal formation of the brain is the region that shows the most prominent atrophic 
changes in consequence of AD affection. In AD patients Bobinski et al. found a MRI-based 
decline of hippocampus volume of about 30% compared to healthy controls and a 40% 
volume loss of the hippocampal formation when applying histological methods in the same 
material (Bobinski et al. 2000). A broad range of MRI-based studies propose the event of 
hippocampal atrophy as a relatively specific marker of AD in its early stages (Bobinski et al. 
2000; Jack et al. 2002; Silbert et al. 2003).  Also a strong correlation between hippocampal 
atrophy and cognitive decline has been reported by several groups (Chetelat et al. 2003; Jack 
et al. 2002; Petersen et al. 2000). Though, other studies suggest MRI-assessment of entorhinal 
cortex volume as a more suitable marker for diagnosis of early stage AD compared to 
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hippocampal volume, allowing also better differentiation between mild cognitive impairment 
MCI and early stage of AD (Pennanen et al. 2004). 
 
RELATED PROJECT 
 
The APP/PS1KI mouse model for Alzheimer’s disease (AD) exhibits robust brain and spinal 
cord axonal degeneration and hippocampal CA1 neuron loss starting at 6 months of age. It 
expresses human mutant APP751 with the Swedish and London mutations together with two 
FAD-linked knocked-in mutations (PS1M233T and PS1 L235P) in the murine PS1 gene. Aim 
of this study was a phenotypical analysis of this model using behavioral tests for working 
memory and motor performance, as well as an analysis of weight development and body 
shape. Furthermore, an exact quantification of the neuron loss occurring in APP/PS1KI mouse 
model was performed at 6 and 12 months of age by use of high precision design based 
stereology methods (Schmitz et al. 2004). 
According to the prevailing amyloid β hypothesis Aβ amyloid plaques, mainly consisting of 
the 40- to 42-residue amyloid-β peptide (Aβ), take a central part in the typical Alzheimer’s 
disease (AD) related pathological cascade. However, lately intraneuronal amyloid-β 
pathology has gained in importance (for review Wirths et al. 2004). Aβ peptides are derived 
from the larger amyloid precursor protein (APP) by consecutive proteolytical cleavages. 
Whereas the majority of all AD cases occurs sporadic, a small percentage of familial early-
onset AD cases develops due to mutations in APP or in the Presenilin (PS1, PS2) genes, the 
latter proteins being an integral part of the β-secretase complex (reviewed in Bayer et al. 
2001). Until recently, modeling axonal degeneration and neuronal loss remained elusive. 
APP23 transgenic mice yielded a small loss of pyramidal neurons of the hippocampal 
formation, (Calhoun et al. 1998) which does not reflect the dramatic reduction in AD patients 
(Gomez-Isla et al. 1996). Mild neuron loss has also been documented around amyloid plaques 
in PSAPP mice (Urbanc et al. 2002). This gap has recently been closed because significant 
neuron loss in the hippocampus has been described in two APP/PS1 mouse models with 
multiple mutations, (Schmitz et al. 2004) or using knock-in mutations (Casas et al. 2004). 
Schmitz et al. used human APP751 transgenic mice with the Swedish and London mutations 
(APP751SL), which had been crossed with the human mutant PS1 (M146L) transgenic line. 
In 17 month-old APP/PS1 M146L mice, there was a 35% reduction of CA1-3 neurons, an 
extent larger than could be explained only by amyloid plaque pathology (Schmitz et al. 2004). 
Casas et al. used the same APP751SL mice and crossed them with PS1 knock-in mice 
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harboring two human PS1 mutations (M233T/L235P) in the endogenous mouse PS1 gene. 
The latter transgenic model is named APP/PS1KI, displaying more than 50% CA1 neuron 
loss at 10 months of age, starting at approximately 6 months of age preceded by robust 
intraneuronal Aβ accumulation (Casas et al. 2004). Early pathological alterations before onset 
of plaque deposition that might be related to intraneuronal Aβ accumulation have also 
previously reported in other mouse models. These include deficits in synaptic transmission 
(Hsia et al. 1999) or changes in behavior and deficits in long-term potentiation (Moechars et 
al. 1999). 
It is well established that APP undergoes fast axonal transport (Koo et al. 1990) and plays an 
important role in axonal and synaptic processes. Abnormal axons spatially distinct from the 
hallmark lesions of AD (plaques and tangles) are evident as focal axonal swellings that 
correspond to axonal cargoes and transport proteins (Stokin et al. 2005). Recently axonal 
deficits and degeneration have been described in AD (Dai et al. 2002) and in different APP 
transgenic mouse models overexpressing human APP in brain and spinal cord (Stokin et al. 
2005; Wirths et al. 2006) including APP/PS1KI mice (Wirths et al. 2006). These axonal 
alterations manifest as varicosities and spheroids, which mostly contain abnormal 
accumulations of mitochondria, organelles and other axonally transported material like 
neurofilaments, synaptic proteins or APP. Stokin et al. have pointed out that inhibition of 
axonal transport leads to increased intraneuronal Aβ accumulation (Stokin et al. 2005). 
Interestingly, intraneuronal Aβ accumulation precedes axonal degeneration in APP/PS1 
models (Wirths et al. 2006; Wirths et al. 2006). Aberrant intraneuronal Aβ accumulation 
resulted in impaired axonal integrity in the APP/PS1 mouse models. 
 
It is well established that AD patients suffer from working memory deficits (Baddeley et al. 
1991). However, motor performance deficits have also been described to occur in AD patients 
e.g. gait disturbances, disturbed activity level and balance, as well as general motor signs 
(Alexander et al. 1995; O'Keeffe et al. 1996; Pettersson et al. 2002; Scarmeas et al. 2004). 
Since APP/PS1KI mice develop severe age-dependent axonal degeneration, (Wirths et al. 
2006) as well as loss of hippocampal CA1/2 neurons starting at the age of 6 months (Casas et 
al. 2004), the aim of the present study was to investigate these mice with respect to 
impairment in motor performance and working memory, neuron loss and hippocampal 
shrinkage.  
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2.3.4 INFLAMMATION OF THE BRAIN 
 
GENERAL REMARKS 
 
The occurrence of neuroinflammation meanwhile is a well accepted constant feature of AD. 
The process of plaque formation together with the formation of neurofibrillary tangles and 
neuronal degeneration is widely thought to play a key role for beginning inflammation in 
human AD cases (Arnaud et al. 2006). While the event of inflammation in the brain was 
formerly believed to be a peripheral phenomenon to the disease, meanwhile the hypothesis of 
neuroinflammation as one of the potential triggers for neurodegeneration and other 
pathological hallmarks of AD gains in acceptance (Arnaud et al. 2006; Streit et al. 2004).  
Actually, the three main pathological hallmarks of AD like deposition of aggregated Aβ, 
intraneuronal neuritic tau pathology and the brain-specific inflammatory response are 
speculated to be linked by the fact that proinflammatory microglia, reactive astrocytes and 
their associated signalling cascades inflicting cytokines and chemokines are associated with 
the biology of the microtubule associated protein tau, Aβ speciation and aggregation (Lukiw 
& Bazan 2000; Moore & O'Banion 2002). 
 
The importance of inflammation in the pathogenesis of AD was indirectly confirmed by 
epidemiological investigations that revealed a decreased incidence of AD in subjects using 
anti-inflammatory drugs, especially the non-steroidal anti-inflammatory drugs (NSAIDs) 
(Wyss-Coray 2006). However clinical trials designed to inhibit inflammation have failed in 
the treatment of AD patients suggesting that anti-inflammatory agents have more protective 
than therapeutic effect. Despite ongoing research, the extent to which neuroinflammation 
contributes to disease pathogenesis is still not fully understood. Moreover it is also not clear 
whether the inflammation in AD brains represent a protective reaction to neurodegeneration 
or it is rather a destructive process that contributes to further loss of brain function (Akiyama 
et al. 2000). 
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RELATED PROJECT 
 
Though the occurrence of inflammatory events represents a phenomenon well described for 
Alzheimers disease (AD), the extent to which and the way how inflammatory processes 
interdigitate with the pathology of the disease are still a matter of intense surveillance.  
The process of plaque formation together with the occurrence of neurofibrillary tangles and 
neuronal degeneration is widely thought to play a key role for beginning inflammation in 
human AD cases. In a classical understanding, tissue damage and chronic presence of highly 
inert abnormal material is a main cause of inflammation. In parallel it is often suggested that 
in AD plaques of Aβ, tangles and the event of neurodegeneration with the exposition of 
intracellular DNA and neurofilaments to the extracellular environment in the followup are the 
main trigger for the activation of several general inflammation pathways in human brains 
affected by AD. Human plaque pathology is characterized by diffuse Aβ deposits developing 
an amyloid core positive for staining with thioflavin-S or Congo-Red, with proceeding 
pathology that is accompanied by gradual accelerating cognitive dysfunction. While, in 
human, most cases of AD appear sporadically, about 10% of patients are being stroked by so-
called early-onset AD, that is induced by range of different mutations in amyloid precursor 
protein (APP), presenilin 1 (PS1) or presenilin 2 (PS2).  
Usually, transgenic mice capable of modelling the pathogenic processes associated with AD 
are produced by implementation of these familial autosomal dominant (FAD) mutations – 
based on the idea of the β-amyloid hypothesis assuming amyloid plaques to be the primary 
driver to propel the progress of AD (Chishti et al. 2001; Dudal et al. 2004; Ozmen et al. 2005; 
Richards et al. 2003). In numerous of these animal models of AD inflammation is a well 
described phenomenon.  Most of them share several pathological characteristics of AD, e.g. 
extracellular amyloid peptide (Aβ) deposition in neuritic plaques often associated with 
activated microglia and surrounded by reactive astrocytes, and/or intracellular deposits of 
hyperphosphorylated Tau protein observable as the so called neurofibrillary tangles (NFT). 
However, though a lot of transgenic mouse models of AD available today manage to 
recapitulate AD pathology including behavioural deficits more or less extensively, still no 
current transgenic model is able to completely reflect all relevant features of this disease 
(Dodart et al. 1999; Eriksen & Janus 2007; Gordon et al. 2001). 
 
Aim of this study is the analysis of the inflammation situation of the APP/PS1KI mouse 
model of AD introduced by Casas et al. (Casas et al. 2004). 
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This APP/PS1KI model is characterized through fast and aggressive formation of AD 
pathology and excels through an age-related neuron loss that is to be missed in most other 
transgenic animal models of AD. Neuron loss was detected to take place in the CA1/2 
pyramidal cell layer of the hippocampus to an extent of 42% at 12 months of age with a 
macroscopically evident loss already at six months of age (see chapter 4.1.6). The 
histopathological onset of AD according to Aβ build-up starts in these mice with massive 
accumulation of intraneuronal Aβ already in the second month of life of these mice (Casas et 
al. 2004). Generally, plaque pathology in APP/PS1KI mice is preceded by the accumulation 
of oligomeric, fibrillar and various N-modified Aβ species in brain and spinal cord motor 
neurons in young mice (Wirths et al., 2006). No behavioural phenotype was detected in these 
mice at 2 months of age compared to age matched PS1KI control mice according to motor or 
cognitive deficits. Additionally, no neuronal loss was present at 2 months of age. Based on the 
finding that APP/PS1KI mice appear to be normal at 2 months of age, I decided to analyze 
these young mice for signs of early inflammation.  
 
At six months of age APP/PS1KI mice show strong impairments in their working and spatial 
memory performance and own a significant neuron loss in the CA1/2 pyramidal cell layer of 
the hippocampus (Casas et al. 2004). As a follow-up process to intracellular accumulation of 
Aβ six-month-old APP/PS1KI mice show abundant extracellular plaque pathology, dystrophic 
neurites and astrogliosis. Plaques of APP/PS1KI mice harbour a broad variety of N-truncated 
isoforms of Aβ (Casas et al. 2004). 
 
Summing up, APP/PS1KI mice pattern typical pathological and behavioural hallmarks of AD 
model the human process of AD quite well. Therefore, they represent a suitable model for 
studying human-like AD-pathological processes. 
 
Therefore, the APP/PS1KI mouse model is of interest to examine the development of 
inflammation in relation to the progress of the disease pathology. In difference to most other 
studies of inflammation in the ageing brain, I analyzed a broad range of inflammation markers 
from the field of cytokines and cytokine receptors, toll like receptors, transcription factors and 
acute phase proteins and looked as well for proteins involved in metal homeostasis and 
oxidative stress defense e.g. from the group of metallothioneins because of the presumed 
accelerating impact of free radicals on inflammatory processes. I analyzed the expression of 
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the genes of interest primarily by qPCR and validated some of the candidates found to be 
significantly changed in APP/PS1KI mice compared to control mice by Western Blot or 
immunohistochemical methods on the protein level. The scope of this study is to assign 
certain states of inflammation to certain states in the pathological processes inflicted with AD. 
Because the causality between AD and inflammation is still unclear, a closer look to the order 
of time by that changes in the expression of inflammation genes take place in comparison to 
the upcoming of typical AD pathological characteristics is of interest. Such information may 
help to answer the question, if inflammation of the brain is just a side effect of AD pathology 
or if inflammatory processes may contribute their deadly deed to the progress of cognitive 
decline in AD patients. 
 
2.3.5 CHOLESTEROL AND 24(S)-HYDROXYCHOLESTEROL IN 
PLASMA AS POTENTIAL BIOMARKERS OF ALZHEIMER`S 
DISEASE 
 
GENERAL REMARKS 
 
Until today, for AD no biomarker is readily available to aid diagnosis or monitoring of this 
common neurodegenerative disorder (Hye et al. 2006). However, while diagnosis of AD is 
still made primarily on clinical grounds, early diagnosis of AD would be an indispensable tool 
to initiate symptomatic treatment of this disease e.g. with acetylcholine esterase inhibitors as 
one of the current standard theraphies (Blennow 2005). In a large series of studies numerous 
potential biochemical biomarkers for AD have been investigated from various tissues 
including blood (Zhang et al. 2004) and cerebrospinal fluid (Hampel et al. 2004). Most of 
these studies report about decreased Aβ1-42 and increased tau and phosphor-tau in CSF of AD 
affected patients compared to non-demented persons (Blennow & Hampel 2003; Sunderland 
et al. 2005). However, broad appliance of CSF scans for early AD diagnosis is questioned by 
the circumstance, that the method of lumbar puncture, especially repeatedly, represents a 
relatively invasive procedure discomfitting to a lot of patients. Contrastingly, blood and 
plasma are easily accessible body fluids. Moreover, the fact that around 500 mL of CSF are 
absorbed into the blood every day renders obvious, that suitable AD biomarkers can be found 
also by specific plasma analysis (Hye et al. 2006). 
 
Cholesterol represents an inevitable component of all cell mebranes and is important as a 
structural component and as a modulator of cell fluidity as well (Sjogren et al. 2006). 
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Cholesterol is synthesized in the liver. Another main source of cholesterol is its uptake by diet 
from animal products. Total cholesterol plasma levels increase steadily with age in men and 
women between ages 20 and 65 (Sjogren et al. 2006). Epidemiological, biochemical and 
genetic evidence links cholesterol to Alzheimer`s disease, as it has been demonstrated that 
cholesterol modulates APP processing (Wirths et al. 2006).  
 
Recently, Mielke et al. reported in a population-based 70-year-old birth cohort followed for 
18 years that increasing levels of plasma total cholesterol at ages of 70, 75, and 79 are related 
to a reduced risk of dementia between ages 79 and 88 (Mielke et al. 2005). However, the 
association of high levels of plasma cholesterol with a decreased risk of AD is in contrast to 
other reports that suggest high total plasma cholesterol to be a risk factor for later dementia 
(Kuusisto et al. 1997). 
 
Furthermore, also 24(S)-hydroxy-cholesterol has been discussed as a predictive biomarker for 
the incidence of Alzheimer disease. Therefore, I analyzed mice of the genotypes APP/PS1KI, 
APP, PS1KI and wildtype mice for age-dependent changes in levels of plasma cholesterol and 
24(S)-hydroxycholesterol between the distinct genotypes.  
 
24(S)-hydroxycholesterol has been suggested as a suitable biomarker for AD. 24(S)-
hydroxycholesterol is a specifical degradation product of brain cholesterol (Kolsch et al. 
2001, Kolsch et al. 2003, Lutjohann et al. 2002). Brain cholesterol is assumed to represent a 
permanent pool of exclusively locally synthesized cholesterol that is protected from exchange 
with the periphery by its unability to cross the blood-brain-barrier (Bjorkhem & Meaney 
2004). The main elimination reaction of cholesterol from the brain occurs by its conversion to 
24(S)-hydroxycholesterol by enzymatic activity of CYP46, which is exclusively expressed in 
human brain, (Lutjohann et al. 2002, Dietschy & Turley 2001). It has been shown that 24(S)-
hydroxycholesterol in contrast to cholesterol is capable of crossing the blood-brain-barrier and 
therefore can be detected in easily accessible body fluids like plasma or serum (Bjorkhem et 
al. 2001). In AD patients the levels of 24(S)-hydroxycholesterol have been shown to be 
significantly elevated in early stages of the disease, potentially due to disruptions in the blood-
brain-barrier. The higher efflux of 24(S)-hydroxycholesterol has been hypthothesized to be a 
result of neuron loss or an altered cholesterol metabolism in AD (Locatelli et al. 2002). 
Additionally, lower levels of cholesterol normalized 24(S)-hydroxycholesterol levels in 
plasma have been described in more advanced cases of AD, (Bretillon et al. 2000, Kolsch et 
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al. 2004). Therefore elevated 24(S)-hydroxycholesterol plasma levels have been discussed as 
an easily accessible biomarker for the diagnosis of AD in early stages of the disease. 
Although there are also reports about increased levels of 24(S)-hydroxycholesterol in CSF 
and plasma of AD patients, up to now there is no clear evidence for the suitability of plasma 
24(S)-hydroxycholesterol as an early-onset marker for AD (Irizarry 2004, Schonknecht et al. 
2002, Teunissen et al. 2003). 
 
 
 
Fig. 6: Model of cholesterol homeostasis in the brain. Neurons synthesize cholesterol in cell bodies. 
However, additional cholesterol can be supplied to axons from glia-derived lipoproteins. Cholesterol and 
apo E are synthesized by glial cells (astrocytes) and associate to form lipoprotein particles. These 
lipoproteins can bind to neuronal surface receptors of the LDL receptor family. Excess cholesterol in the 
brain is converted to 24(S)-hydroxycholesterol in neurons, crosses the blood–brain barrier, enters the 
plasma and is delivered to the liver for excretion into bile. 
 
RELATED PROJECT 
 
To check for pathology-dependent changes of plasma cholesterol and 24(S)-
hydroxycholesterol, levels of total cholesterol and 24(S)-hydroxycholesterol were determined 
in plasma of wildtype, APPSL, PS1KI ans APP/PS1KI transgenic mice. This latter mouse 
model has been shown to feature massive neuron loss in the hippocampus starting at an age of 
six months besides amyloid plaque formation starting already at two to three months of age. 
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This transgenic mouse model carries M233T/L235P knock-in mutations in presenilin-1 and 
overexpresses mutated human β-amyloid precursor protein. These mice recapitulate very well 
typical features of AD like dystrophic neuritis, synaptic dysfunction and behavioural deficits 
as well as neuronal loss. 
Because the cause of the disease is very well described in this model of AD, it also 
volunteered to check the validity of 24(S)-hydroxycholesterol or total plasma cholesterol as a 
suitable biomarker for AD. 
 
2.4 MODELLING OF HUMAN ALZHEIMER`S DISEASE IN 
TRANSGENIC MICE 
 
2.4.1 OVERVIEW ABOUT TRANSGENIC MOUSE MODELS OF 
ALZHEIMER`S DISEASE  
 
Transgenic mouse models of AD have greatly contributed to our understanding of this 
disease`s pathogenesis. Transgenic mice models generally are designed on basis of mutant 
genes as they have been found in human early onset or familial cases of AD. They display to a 
higher or lower extent the neuropathological features that are seen as typical for human AD 
like aberrant Aβ aggregation, formation of NFT`s, neuron loss and synaptic deficits as well as 
a broadly established scenery of neuroinflammation in the brain. Transgenic mice models 
overexpressing human mutant APP typically show increased production of amyloid β and 
reveal a more or less severe pattern of diffuse or compact amyloid plaques in 
immunhistochemical stainings. These mice display also mostly synaptic transmission deficits, 
that are detectable well before the build-up of massive plaque pathology. Some of these APP 
based models also display features like neurodegeneration or cognitive deficits. The 
combination of APP trangens with an additional overexpression of PS1 further increases 
production of Amyloid β and significantly accelerates the development of an AD like 
phenotype and pathology respectively.  
 
Other mice models contain a human mutant tau transgene as can be found in familial forms of 
frontotemporal dementia, for which extensive tangle formation is a dominant characteristics. 
Oddo et al. reported about a 3-fold transgenic mouse model, harbouring mutant transgenes for 
tauP301L, APPK670N,M671L and PS1M146V. This model shows plaque pathology, tangles and also 
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displays synaptic transmission deficits. In the next chapter, the focus is on the so called 
APP/PS1KI mouse model of AD, which was first described by Casas et al. in the year of 2004 
(Casas et al. 2004). 
 
2.4.2 THE APP/PS1KI MOUSE MODEL OF ALZHEIMER`S DISEASE  
 
GENERAL REMARKS 
 
Casas et al. reported in 2004 about a new transgenic mouse model with altgogether five 
mutant transgens, that are related to human early onset AD cases (Casas et al. 2004a). In 
detail, these mice carry the Swedish (K670N/M671L) and London (V717I) mutation in the 
APP gene controlled by the THY1-promotor, which drives gene expression specifically in 
neurons. In these mice, the APP751 isoform is expressed. Additionally, these mice carry two 
knock-in mutations in the PS1 gene at codons M233T and L235P. Due to the choosen knock-
in stategy, expression of these mutations takes place under control of the endogenous 
promotor. These mutations were specifically chosen because of their linkage to very early 
onset FAD at 29 (L235P) and 35 (M233T) years of age. 
 
The predominant species of Amyloid β in these mice is Aβx-42.  Calculated over total amyloid 
βplaque load, a relative share of Aβx-42 of 85% was determined at an age of already 4 months. 
This ratio showed a further age-dependent increase, while 4 months old APPSL littermated 
revealed only a 30% share of Aβx-42. This indicates, that presence of FAD-linked PS1KI 
mutations in APP/PS1KI mice contribute significantly to the formation of Aβx-42. By 
immunohistochemical methods first plaque deposition using 4G8 antibody could be detected 
at 2.5 months of age in the subiculum area in APP/PS1KI mice compared to six months of age 
in APPSL mice. APP/PS1KI mice display widespread and numerous round compact Aβ 
deposits within the cortical, hippocampal, and thalamic areas. This is in contradiction to 
APPSL mice, which show only very few deposits restricted to the areas of the subiculum and 
deeper cortical neuronal layers. 
 
Detailed analysis of the hippocampal CA1-3 subfield and of the dentate gyrus showed, that 
APP/PS1KI mice show a significant reduction of the hippocampal pyramidal cell layer 
thickness, that was found to be particularly prominent in the CA1 region at 6 months of age  
in female mice to an extent of 33%. Assessment of neuron loss by high-precision design-
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based stereology showed a neuron loss in CA1 hippocampal subfield of 42% in female 
APP/PS1KI mice of 12 month of age (see chapter 4.1.6).  
 
It is to note, that by macroscopic analysis some CA1 neuron loss was present as early as 6 
months of age in the brains of female APP/PS1KI mice but not in males, suggesting a gender 
effect in these mice (Casas et al. 2004).  
This gender effect experienced a closer analysis in APPSL mice, where in 3.5 month old mice 
well before onset of plaque pathology female mice showed significant higher levels of soluble 
Aβ and an elevated ratio of C99/APP as well compared to mal littermates (Schafer et al. 
2007). 
 
APP/PS1KI mice showed also prominent axonopathy, and actually Aβ is controversially 
discussed to work as a trigger for aberrant axonal transport in the pathophysiology of AD, 
finally ameliorating motor deficits as frequently observed in patients with AD. 
Immunohistochemical and ultrastructural analysis by electron microscopy in APP/PS1KI 
mice revealed characteristic axonal swellings, spheroids, axonal demyelination and ovoids, 
which are myelin remnants of degenerated nerve fibers, in an age dependent manner. 
Furthermore, abundant accumulation of intraneuronal N-modified Aβ, Thioflavine S-positive 
material and ubiquitin was found within the somatodendritic compartment of neurons. These 
pathological findings were confirmed in neurons of the brain and the spinal cord (Wirths et al. 
2006). 
 
RELATED PROJECT 
 
A further strinking feature of the APP/PS1KI mouse model besides the expression of Aβx-42  is 
the progressive development of a complex pattern of N-truncated variants and dimers of 
Amyloid β that parallels well the composition of Aβ species observed in human AD brains. In 
detail, human Aβ isovariants 2/3-42, 4/5-42, 8/9/10/11-42, 12/13/14-42 and most notably 
pyroglutamate Aβ (Aβ3(pE)) wered determined by proteomic analysis of brain lysates of 
10 months old APPSLPS1KI mice in a two-dimensional western-blot (Casas et al. 2004). It is 
to emphasize, that the APP/PS1KI mouse model was the first to show accumulation of 
Aβ3(pE), which stands in the focus of the TBA1 and TBA2 mouse model because of its striking 
neurotoxic potential (see chapter). 
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The APP/PS1KI mouse model was the first transgenic AD mouse model, that was reported to 
combine a strongly increasing extracellular plaque pathology, consisting of a wide variety of 
N- and C-terminal truncated isoforms of Aβ, with a preceding accumulation of intracellular 
Aβ species especially in the CA1/2 region of the hippocampus. This was speculated to trigger 
neuron loss, that occurs as early as 6 months in this mouse model in the pyramidal cell layer 
of the hippocampus and is quantified to reach 33% in 6 months old APP/PS1KI mice. 
 
Aim of this project was to analyze in a quantitative way the accumulation of N-terminal 
truncated or racemized Aβ peptides - especially Aβ3(pE) -  in 2 and 6 month old APP/PS1KI 
mice by Sandwich-ELISA measurements and immunohistochemical stainings. 
 
2.4.3 IN VIVO FORMATION OF PYROGLUAMATE Aβ IN TBA1 AND 
TBA2 MICE 
 
GENERAL REMARKS 
 
One of the most coherent arguments pointing against the Amyloid-β hypothesis, is the 
finding of constant and abundant deposition of Aβ in the brains of elderly subject without 
any signs of cognitive decline. One suggested reason for this finding is speculated to be 
founded in differences of plaque composition in human AD brains and those of non AD-
affected but plaque-bearing healthy controls (Piccini et al. 2005). Piccini et al. showed, that 
soluble Aβ aggregates as found in AD are characterized by a predominance of N-truncated 
variants of Aβ over the full-length protein Aβ1-42. The authors noted, that Aβ3(pE) was the 
most prevailing N-truncated Aβ species in AD affected brains. Harigaya et al. reported 
already before, that Aβ3(pE) contributes to the total plaque load in AD patients up to an extent 
of 25% (Harigaya et al. 2000). Piccini et al. suggested, that the enrichment of Aβ3(pE) in 
plaques could be explained as consequence of a partial gain in resistance to extracellular 
aminopeptidase activity due to the cyclization of N-terminal glutamate of Aβ3-42 (Piccini et 
al. 2005). 
  
Already before, it has been a well established fact, that amyloid plaques do not consist of 
only a few full length, unmodified Aβ proteins like Aβ1-40 and Aβ1-42. Already in 1992, Mori 
et al. first described the presence of Aβ3(pE) using mass spectrometry of purified Aβ protein 
from AD brains, which explains the difficulties in sequencing the amino-terminus (Mori et 
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al. 1992). They reported that 10-15% of the total Aβ isolated by this method begins at 
position 3 with Aβ3(pE)). Iwatsubo et al. analyzed the composition of diffuse plaques from 
cerebral and cerebrellar cortex, neostriatum and hypothalamus of Down`s syndrome, 
Alzheimer`s disease and non-demented healthy control brains. First, they found by use of 
carboxy-terminal antibodies, that diffuse plaques show a positive staining for Aβx-42 but were 
negative for Aβx-40. This finding strongly suggests, that Aβx-42 variants are much more prone 
to aggregation than Aβx-40 variants (Iwatsubo et al. 1996). Most interestingly, strong 
immunoreactivity was found in these diffuse plaques for N-terminal modified or truncated 
variants of Aβx-42. In detail, Iwatsubo et al. reported besides strong accumulation of AβN1(L-
Asp), which represents the unmodified natural form of Aβ1-42, also massive aggregation of 
AβN1(L-isoAsp), AβN1(D-Asp), and also for pyroglutamate Amyloid β (Aβ3(pE)). 
Additionally, weak staining patterns were detected for pyroglutamate AβN11-42(pE) and for 
AβN17(Leu) (Iwatsubo et al. 1996). Lemere et al. reported in 29 year old Downs Syndrome 
patients immunoreactivity for Aβ3(pE) in a larger number of plaques than AβN1-42, the former 
showing a stronger age-dependent increase than the latter (Lemere et al. 1996). A similar 
finding was reported by Saido et al., who found Aβ3(pE) to represent the predominant species 
of Aβ in senile plaques of aged individuals (Saido et al. 1996). The authors speculated 
Aβ3(pE) aggregation to precede the aggregation of the full length protein AβN1-42 and 
suggested the increased aggregation predisposition of Aβ3(pE) to have its reason in the bigger 
hydrophobicity of this Aβ species due to the loss of one positive and two negative charges 
due to formation of the lactam functional group (Saido et al. 1996). The phenomenon of 
Aβ3(pE) aggregation preceding that of full length Aβ variants was also reconsidered by 
Lemere at al., who found in Downs Syndrome patients of age 27 or older positive and 
stronger immunoreactivity for Aβ3(pE) at earlier and all ages as well than for AβN1-42 (Lemere 
et al. 1996). In general, N-terminal deletions enhance aggregation of β-amyloid peptides in 
vitro (Pike et al. 1995). Besides higher aggregation propensity (He & Barrow 1999; Schilling 
et al. 2006) and stability (Kuo et al. 1998b), Aβ3(pE) shows an increased toxicity compared to 
full-length Aβ (Russo et al. 2002). In the latter study, Russo et al. have shown, that Aβ3(pE)-
40/42 supplemented to the culture media affect cultured neuron and astrocyte survival to a 
significant higher extent compared to corresponding full-length peptides and, moreover, 
show resistance to degradation by astrocytes. However, other studies reported that the 
toxicity of Aβ3(pE)-40/42 is similar to that of Aβ1-40 and Aβ1-40 (Tekirian et al. 1999), and that 
Aβ3(pE) is not the major variant in AD brain (Lemere et al. 1996).  
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RELATED PROJECT 
 
Recently, Schilling et al. have demonstrated in situ that pyroglutamate-modified peptides 
display an up to 250-fold acceleration in the initial formation of Aβ aggregates (Schilling et 
al. 2006), and presented in vitro evidence that the cyclization of glutamate at position 3 of Aβ 
is driven enzymatically by glutaminyl cyclase (QC) (Schilling et al. 2004).  
 
Fig. 7:  Formation of Aβ starting at position 3 with pyroglutamate Aβ3(pE) is catalyzed by glutaminyl 
cyclase (QC). N-terminal Aβ starting with glutamate (Aβ3E) or glutamine (Aβ3Q) at position 3 serve as 
substrates for QC activity to generate Aβ3(pE) (Schilling 2007). Aβ3(pE) is a dominant peptide in Alzheimer’s 
disease brain (Saido et al. 1995), and aggregates 250 times faster than posttranslationally unmodified Aβ 
peptides in vitro (Schilling et al. 2006). The conversion of pyroglutamate from N-terminal glutamate is 
slow, in contrast to pyroglutamate formation from glutamine. Pharmacological inhibition of QC activity 
in cell culture (Schilling 2007) and in the tg2576 APP transgenic mouse model (Schilling 2007) leads to 
reduced Aβ3(pE) levels. 
 
While in human Alzheimer`s disease as well as in Downs syndrome only a small proportion 
of Aβ peptides start at position 1 with aspartate (AβN1D), the majority starts at position 3 with 
pyroglutamate (Aβ3(pE)) (Kuo et al. 1997; Saido et al. 1995), and ends at position 42 (Piccini 
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et al. 2005). Aβ starting with N-terminal glutamine (Aβ3Q) is a better substrate for cyclization 
by glutaminyl cyclase (QC) as Aβ starting with N-terminal glutamate (Aβ3E) (Cynis et al. 
2006; Schilling et al. 2004). To check the ability of QC to drive the formation of Aβ3(pE) in 
vivo I characterized in a first step a mQC transgenic mouse for overexpression of QC. In the 
next step, two mouse lines transgenic for substrates of QC to form Aβ3(pE) by QC catalysis 
were designed. These two transgenic mouse lines were expressing either AβN3E-42 (Thy1/β-
amyloid-1; TBA1) or AβN3Q-42 (Thy1/β-amyloid-2; TBA2). TBA1 and TBA2 mice were 
checked for development of accumulation of Amyloid β and especially Aβ3(pE) and analyzed 
for hereby induced phenotypical changes. TBA1 and TBA2 mice showed mQC activity at 
endogenous levels. To verify the in vivo potential of mQC to catalyze the formation of 
Aβ3(pE), heterozygous mQC mice were crossed with heterozygous TBA1 mice and analyzed  
for increased accumulation of Aβ3(pE). 
 
Fig. 8: Constructs to generate the transgenic mice and expression profile in brain at 2 months of age. (a). 
Aβ1-42 starts at position 1 with aspartate (D), Aβ3E-42 at position 3 with glutamate (E), and Aβ3Q-42 with 
glutamine (Q). Both N-truncated Aβ3E-42 and Aβ3Q-42 peptides can be converted by QC activity to generate 
Aβ3(pE)-42 (Fig. 7). (b) Schematic drawing of the transgenic vectors. TBA1 and TBA2 transgenic mice 
express either Aβ3(E)-42 or Aβ3(Q)-42 under the control of the Thy1 promoter and are fused to the signal 
peptide of TRH. QC transgenic mice express the murine QC minigene (mQpct) under the control of the 
CAG promoter. 
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3 MATERIALS AND METHODS 
 
3.1 STATISTICAL ANALYSIS 
  
Differences between groups were tested with either one-way analysis of variance (ANOVA) 
followed by post-hoc Bonferroni's multiple comparison tests, paired t-test for pair-wise 
comparisons or unpaired t-tests as indicated in the figure legends. All data were given as 
means ± s.e.m. Significance levels were given as follows: ***P < 0.001; **P < 0.01; 
*P < 0.05. All calculations were performed using GraphPad Prism version 4.03 for Windows 
(GraphPad Software, San Diego, CA, USA). 
 
3.2 IMMUNOHISTOCHEMISTRY AND HISTOLOGY 
 
Mice were anaesthetized and transcardially perfused with ice-cold phosphate-buffered saline 
(PBS) followed by 4% paraformaldehyde. Brain samples were carefully dissected and post-
fixed in 4% phosphate-buffered formalin at 4 °C. Immunohistochemistry was performed on 
4 µm paraffin sections. The following antibodies were used: 4G8 (Aβ17-24, Signet), GFAP 
(Chemicon), Iba1 (Waco), ubiquitin (DAKO), AT8 (Innogennetics), PS199 (Biosource), 
activated caspase-3 (Chemicon), calbindin (Swant) and against Aβ with pyroglutamate at 
position 3 (a generous gift of Dr. Takaomi Saido). Biotinylated secondary anti-rabbit and 
anti-mouse antibodies (1:200) were purchased from DAKO. Staining was visualized using 
the ABC method, with a Vectastain kit (Vector Laboratories) and diaminobenzidine as 
chromogen. Counterstaining was carried out with hematoxylin. For fluoresecent stainings 
AlexaFluor488- and AlexaFluor594-conjugated antibodies (Molecular Probes) were used. 
 
 
 
 
 
 
 
 
  
 
 Page 38/137 
Primary antibodies 
 
Name Usage Dilution Manufacturer 
WO-2  
 
Anti-human 
Aβ (Aβ5-8) 
1:5000 (WB) Prof. Gerd Multhaup, FU 
Berlin 
GFAP Anti-mouse 1:5000 (WB) DAKO 
Iba1 Anti-mouse (IHC) Waco 
β-Actin Anti-mouse 1:2000 (WB) Sigma 
S100A6 Anti-mouse 1:3000 (ICH) generous gift of R. Pochet 
Transferrin Anti-mouse 1:2000 (WB) Stressgen 
AβN1(D) Anti-human 1:500 (IHC) Takaimo Saido, RIKEN 
Institute, Japan 
AβN1(rD) Anti-human 1:500 (IHC) Takaimo Saido, RIKEN 
Institute, Japan 
AβN3(pE) Anti-human 1:250 (IHC) Takaimo Saido, RIKEN 
Institute, Japan 
4G8 Anti-human 1:1000 (IHC) Senetec 
 
HRP-linked scondary antibodies 
Goat-anti-rabbit immunoglobulins (DAKO, P0448, Denmark) 
Goat-anti-mouse immunoglobulins (DAKO, P0447, Denmark) 
Rabbit-anti-goat immunoglobulins (DAKO, P0449, Denmark) 
 
Biotinylated secondary antibodies 
Rabbit-anti-mouse immunoglobulins (DAKO, E0465 Denmark) 
Swine-anti-rabbit immunoglobulins (DAKO, E0353 Denmark) 
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3.3 TRANSGENIC MICE 
 
APP/PS1KI mice 
 
The generation of APP/PS1KI mice has been described in detail in Casas et al. 2004 (Casas et 
al. 2004). In brief, human mutant APP751, harboring the Swedish and London mutations 
(APP751SL) is expressed under the control of the murine Thy-1 promoter, whereas murine 
PS1 with two FAD-linked mutations (PS1 M233T and PS1 L235P) is expressed under the 
control of the endogenous mouse PS1 promoter (“knockin”). All mice named as PS1KI were 
homozygous for PS1 knock-in mutations; the APP/PS1ki mice harbored one additional 
hemizygous APP751SL transgene. All animals were handled according to German guidelines 
for animal care. 
 
mQC, TBA1 and TBA2 mice 
 
For generation of murine thyrotropin-resleasing hormone - Aβ fusion proteins mTRH-Aβ3E-42 
and mTRH-Aβ3Q-42 (see Fig. 8) the respective cDNAs were inserted into vector pUC18 
containing the murine Thy-1 sequence applying standard molecular biology techniques. 
Murine QC was isolated from insulinoma cell line β-TC 3. The mQC cDNA was cloned into 
vector pTG-CAG. All constructs were verified by sequencing. The transgenic mice were 
generated by male pronuclear injection of fertilized C57Bl6 oozytes (PNI, generated by 
genOway, Lyon, France). The injected oocytes were then implanted into foster mothers for 
full term development. The resulting offspring (3 founders of each line) were further 
characterized for transgene integration by PCR analysis and after crossing to C57Bl6 wildtype 
mice for transgene expression by RT-PCR (n=3-5 each line). The line with highest transgene 
mRNA expression was selected for further breeding (named TBA1 and QC mice). TBA1 and 
QC transgenic appeared healthy and showed no evidence for neurological abnormalities. Only 
1 of the 3 founders of the TBA2 PNI gave birth to offspring (TBA2 mouse model). All 
animals were handled according to German guidelines for animal care 
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3.4 GENOTYPING 
 
DNA-Isolation from mouse tails 
 
Stock solutions: 
1 x Lysis buffer: 
 
• 100 mM Tris/HCl pH 8.5     
• 5 mM EDTA      
• 0.2 % SDS       
• 200 mM NaCl     
dissolved in. H2O (Millipore) 
Before use Proteinase K was added (10 µL*ml-1). 
 
Protocol 
 
1. 500 µL of lysis buffer were added to each mouse tail and shaken overnight at 55 °C 
and 400 rpm in a heating block. 
2. Centrifugation for 10 min at 13000 rpm 
3. The supernatants were transferred to a new 1.5 mL tube containing 500 µL of  
isopropanole. 
4. Samples were vortexed for DNA precipitation and centrifuged for 10 min at 
13000 rpm. 
5. Pellet was washed by vortexing in 500 µL of 70% ethanole and again centrifuged for 
10 min at 13000 rpm. 
6. The supernatant was discarded and rests of ethanole removed by pipetting 
Pellet was dried on a heating block at 37 °C 
7. Pellet was dissolved in 70 µl H2O (Aqua ad iniectabilia) (37°C, 30 – 45 min or 
overnight at 4°C) 
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Polymerase chain reaction (PCR) 
 
Polymerase chain reation leads to exponential amplification of a DNA fragment. 
General protocol for a total 10µL volume 
0,5 µL Primer forward (10 pM stock concentration) 
0,5 µL Primer reverse (10 pM stock concentration) 
1 µL 10 x PCR-Puffer 
1 µL dNTPs (200 µM stock concentration) 
5.9 µl H2O 
0.1 µL Taq-Polymerase 
1 µL diluted DNA (25 ng of genomic DNA) 
 
PCR genotyping strategy for APP/PS1KI mice 
primer sequences: 
APP-1: 5`-GTA GCA GAG GAG GAA GAA GTG-3` 
APP-2: 5`-CAT GAC CTG GGA CAT TCT C-3` 
 
The PCR on tail DNA was carried out in a volume of 25 µL with a PCR-product of 491 bp 
length and was run according to the following cycling parameters: 
 
Reaction mix  Reaction conditions   
Genomic mouse 
DNA 
25 ng step Temp/time cycles 
Primer 2.5 µL 
(f.c.: 25 pmol) 
denaturing 94°C/300s 1x 
dNTPs 2.5 µL 
(f.c.: 20 µM) 
denaturing 94°C/60s 35x 
10 x Reaction 
buffer 
2.5 µL annealing 55°/60s 35x 
MgCl2 f.c.:1.5 mM extension 72°C/90s 35x 
Taq polymerase 2.5 U completion 72°C/300s 1x 
Reaction volume 25 µL    
Table 1: protocol for APP genotyping (f.c.: final concentration). 
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PCR genotyping strategy for mQC, TBA1 and TBA2 mice 
 
The screening for detection of the random integration of the transgene was achieved by PCR 
amplification. Two PCRs were designed (see Figure 4): 
-  PCR1 is designed to efficiently detect the transgene random integration event. The 
selected primer pair allows the amplification of a short DNA sequence within the 
transgene sequence, yielding a specific 505-bp PCR product. 
- PCR2 is designed to assess the integrity of the transgene integration event. The selected 
primer pair allows the amplification of a DNA sequence extending from 5’ region of 
promoter and 3’ region of Thy1 gene yielding a specific 6279-bp 7413-bp PCR product. 
As the Thy1 promoter cassette is derived from mouse genomic sequence, the PCR screen, 
used to investigate the integrity of the transgene integrity, also lead to the amplification of 
a 7413-bp product from the endogenous Thy1 gene. 
 
 
 
 
Fig. 9: PCR genotyping methodology: Localisation of primers used for the detection of random 
integration and transgene integrity. The corresponding amplification product sizes are indicated. Bold 
line represents plasmid backbone sequences. Half arrows illustrate the primers’ localisation. Figures are 
not depicted to scale. The same structure has the TRH-AβN3E(3-42) transgene construct. 
 
 
 
Primer 
pair 
Primer 
name 
Primer sequence 5’-3’ expected 
PCR size 
1 GX3425 
GX3426 
5’- AGTAATGAAGTCACCCAGCAGGGAGG -3’ 
5’- TGATCCAGGAATCTAAGGCAGCACC -3’ 
505 bp 
Table 2: PCR genotyping TBA1 & 2 
 
 
 
 
  
 
 Page 43/137 
 
Reaction mix  Reaction 
conditions 
  
Genomic mouse 
DNA 
40 ng step Temp/time cycles 
Primer 0.5µL 
(f.c.: 2.5 pmol)  
denaturing 94°C/180s 1x 
dNTPs 20 µM denaturing 94°C/45s 35x 
10 x Reaction 
buffer 
1 µL annealing 58°/60s 35x 
MgCl2 2 mM extension 72°C/60s 35x 
Taq polymerase 0.5 U completion 72°C/300s 1x 
Reaction 
volume 
20 µL    
Table 3: Protocol for genotyping by PCR: TBA1 & 2. 
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Genotyping of mQC mice 
 
Primer pair Primer 
name 
Primer sequence 5’-3’ expected PCR 
size 
1 mQC3 
mQC4 
5’-GCCACGGATTCAGCTGTGC-3’ 
5’-GAATGTTGGATTTGCTGCTC-3’ 
302 bp 
Table 4: PCR genotyping mQC. 
 
 
 
 
 
 
 
 
 
Reaction mix  Reaction 
conditions 
  
Genomic mouse 
DNA 
100 ng step Temp/time cycles 
Primer 2 µL (10 pmol denaturing 94°C/180s 1x 
dNTPs 2 µL (f.c.: 20 µM) denaturing 94°C/45s 35x 
10 x Reaction 
buffer 
2 µL annealing 58°/60s 35x 
MgCl2 1.6 µL (f.c.2 mM) extension 72°C/60s 35x 
Taq polymerase 0.5 U completion 72°C/300s 1x 
Reaction 
volume 
20 µL    
Table 5: Protocol for genotyping by PCR: mQC. 
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3.5 mRNA QUANTIFICATION FOR TBA1 AND TBA2 MICE 
 
For Real-Time PCR (TBA1 & 2) the following primers were used:  
Primer pair Primer 
name 
Primer sequence 5’-3’ expected PCR 
size 
1 Aß3-42-for 
Aß3-42-rev 
5’-TTGAGGAAAGACCTCCAGC-3’ 
5’-CATGAGTCCAATGATTGCACC-3’ 
168 bp 
Table 6: Primers for amplification of Aβ3E and Aβ3E. 
 
 
1 µg of total RNA was reverse transcribed and Real-Time PCR was performed using the 
fluorescent dye SYBR-Green I according to the following protocol: 
 
 
 
 
 
 
 
Reaction mix  Reaction 
conditions 
  
cDNA 1 µL (1:5 
Dilution) 
step Temp/time cycles 
Primer 15 pmol denaturing 95°C/ 600s 1x 
2x Reaction Mix 12.5 µL denaturing 94°C/15s 40x 
SYBR-Green I 0.5 µL annealing 55°/30s 40x 
H2O 8 µL extension 72°C/30s 40x 
Reaction 
volume 
25 µL Melting Curve 55°C - 95°C/ 
30s 
1x 
Table 7: Protocol for mRNA quantification by RT-PCR. 
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3.6 STAINING OF PARAFFIN-SECTIONS 
1. Deparaffinize   2x5 min xylol 
10 min 100% ethanol 
5 min 95% ethanol 
2. Block in methanol  200 mL PBS 
2 mL 30% H2O2 
for 30min 
3. Descending ethanol-series 5 min 95% EtOH 
1 min 70% EtOH 
1 min distilled water 
4. microwave treatment 10 min (in 0.01M citrate buffer pH 6.0 (citric acid monohydrate) 
5. cool down for 15 min 
6. wash 1min in distilled water. 
7. wash 15 min PBS + 0,1% Triton-X100 
8. wash 1 min with PBS 
9. –optional- incubate sections in 88% formic acid for 3 min 
10. wash with PBS  
11. unspecific block for 1 h in PBS +10% FCS (fetal calf serum) 
+4% dry milk (40mg/ml) 
12. Discard blocking solution and add primary antibody in PBS including 10% FCS  
Incubate over night at room temperature or 4 °C 
13. wash 15 min with PBS+ 0,1% Triton-X100 
14. Incubation with secondary antibody in PBS including 10% FCS for 1 h at 37 °C 
15. wash 15 min with PBS 
16. Incubation with ABC-Vectastain-Complex (prepare at least 30 min before use and 
keep and 4 °C)(Vector Laboratories) for 1.5 h at 37 °C 
PBS +10% FCS, +1:100 Lösung A, +1:100 Lösung B   
17. wash 15 min with PBS 
18. stain with 3,3-diaminobenzidine-tetrahydrochloride (25 mg/mL in 50 mM Tris/HCl 
pH 7.5,DAB, Sigma) 
19. ascending ethanol-series,  1 min 70% ethanol 
5 min 95% ethanol 
10 min 100% ethanol 
10 min Xylol 
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3.7 HPLC-ASSAY FOR DETERMINATION QC-ACTIVITY IN PLASMA 
The QC activity was assessed by quantification of the QC-mediated cyclization of 
Glutaminyl-beta-naphthylamin to pyroglutamyl-beta-naphthylamin by use of a HPLC based 
assay. The measurement was carried out using a HPLC system “La chrome”, manufactured by 
Merck-Hitachi and a RP18 LiChroCART 125-4 column supplied by Merck KGaA. For the 
separation, a gradient of water and acetonitrile containing 1% TFA each was used p.r.t. as 
follows: 
Time 
(min) 
Eluent A 
Acetonitrile/TFA( 1%) 
Eluent B 
Water/TFA (1%) 
0 23 77 
8 45 55 
10 95 5 
15 95 5 
20 23 77 
Table 8: HPLC-protocol for measurement of QC -activity in tissue lysates and EDTA-plasma.  
 
Detection of glutaminyl-beta-naphthylamine and pyroglutamyl-beta-naphthylamine  
was performed by use of a Diode Array Detector L7455 manufactured by Hitachi Corp. at a 
wavelength of 280 nm. All measurements were carried out at room temperature. The 
concentration of pyroglutamyl-beta-naphthylamine was calculated using a standard curve.  
 
Sample Preparation 
Determinations of QC-activity were performed using tissue homogenates from brain, liver, 
kidney and plasma.  The plasma was centrifuged at 4 degrees and 13000 rpm for 10 min and 
applied for the QC-assay.  Besides, the plasma of the control group could be used directly 
unwatered for measurement (100 µL), while that of the QC-mice had to be diluted at first 1:25 
with MOPS-buffer (c: 25 mM, pH 7. 0).  Tissue of brain, liver and kidney was mixed in 
40fold volume lysis buffer and homogenized by use of a Downs homogenizer.  The lysis-
buffer (pH 7. 5) consisted of Tris-base (10 mM), EDTA (5mM), Triton (0. 5%) and glycerole 
(10%).  Triton concentrations of 0.5% or less showed to have no influence on protein 
detection by the Bradford method.  
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Subsequently, the samples were treated with an ultrasonic stick (16 cycles, intensity 70%) and 
afterwards centrifuged  (25 min, 13000 rpm, 4 °C).   The supernatants were taken and 
immediately used for the measurement (100 µL).   
 
Determination of QC-activity 
 
After the sample preparation, every measurement of pyroglutamyl-beta-naphthylamine was 
carried out according to the following protocol, which has been identical for measurement of 
the standard curve with affinity purified QC enzyme and of the time-turnover-graphs with QC 
from the homogenized tissue samples.  
In a 1.5 mL tube, 500 µL substrate solution (Glutaminyl-beta-naphthylamine, c: 100 µM, in 
MOPS-buffer ,c: 25 mM, pH 7. 0) were mixed with 400 µL N-ethyl-maleimide solution (c: 
250 µM in MOPS-buffer, c: 25 µM, pH 7. 0) as a cysteine-protease-inhibitor. The mixture 
was allowed to equilibrate to 30 °C for 10 min in a heating block at 350 rpm. After 
equilibration, the reaction was started by addition of 100 µL of cell lysate or plasma to a total 
volume of 1000 µL. The reaction mixture was then incubated for 45 min at 30 °C at 350 rpm.  
From the total reaction volume, samples (100 µL) were removed after 0, 4, 8, 12, 16, 20, 24, 
35 and 45 min. To stop the ongoing conversion from glutaminyl-beta-naphthylamine into 
pyroglutamyl-beta-naphtylamine, these samples were immediately heated for 5 min in boiling 
water to inactivate the enzyme glutaminyl-cyclase. Afterwards, the samples were immediately 
frozen at -20 °C. The experiment was run in three replicates at the same time. Prior to analysis 
using HPLC, all samples have been frozen once. For the measurement the samples were 
thawed out and thereafter centrifuged for 10 min at 13000 rpm at room temperature before 
starting the measuring process on the HPLC system. Then 25 µL of the sample were diluted 
1:1 with water bidest and mixed. This solution was injected completely with a 100 µL 
Hamilton syringe into the 20 µL sample loop of the HPLC system. Between the 
measurements, the Hamilton syringe was cleaned two times with water bidest, two times with 
acetone and thereafter two times with water bidest again. Before drawing the syringe with a 
new sample the needle was rinsed two times (2x 3 µL) with the new sample.  
The resulting peak areas for pyroglutamyl-beta-naphthylamine (Rt: ~6. 8 min, the retention 
time of glutaminyl-beta-naphthylamine was found around Rt: ~4. 85 min) were converted into 
concentrations of pyroglutaminyl-beta-naphthylamine by use of the standard curve. The 
resulting figures were plotted in a time (x-axis) - turnover (y-axis) - diagram. The initial 
velocity of the reaction converting glutaminyl-beta-naphtylamine into pyroglutaminyl-beta-
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naphtylamine was calculated by linear regression mostly over the first 20 minutes of the time-
turnover-diagram  
 
3.8 QUANTIFICATION OF Aβx-42 AND AβN3(pE) BY ELISA 
Brains were weight in frozen state and directly homogenized in a Dounce-homogenizer in 
2.5 ml 2% SDS, containing complete protease inhibitor (Roche). Homogenates were sonified 
for 30 s and subsequently centrifuged at 80.000 g for 1 min at 4 °C. Supernatants were taken 
and directly frozen at –80 °C. The resulting pellets were resuspended in 0.5 ml 70% formic 
acid (FA) and sonified for 30 s. Formic acid was neutralized with 9.5 ml 1 M and aliquots 
were directly frozen at –80 °C. SDS and FA lysates were used in appropriate dilutions for 
both Aβx-42 and AβN3(pE). ELISA measurements. ELISA measurements were performed 
according to the protocol of the manufacturer (IBL Co., Ltd. Japan). For statistical analyses, 
Aβx-42 and Aβ3(pE) concentrations resulting from SDS and formic acid extractions were 
cumulated. 
 
3.9 RNA PREPARATION AND REVERSE TRANSCRIPTION 
Deep frozen brain hemispheres stored at -80 °C were homogenized in 1 ml of Trizol reagent 
per 100 mg tissue using a glas-teflon homogenizer (10 strokes, 600 rpm). RNA extraction was 
performed according to the protocol of the manufacturer (Invitrogen). 
Reverse transcription and DNAseI treatment of the purified RNA samples was carried out 
using QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany) according to the 
protocol of the supplier. 
 
3.10 QUANTITATIVE RT-PCR 
 
Quantitative real-time RT-PCR was performed using a Stratagene MX3000P Real-Time 
Cycler. 10 ng of cDNA were used per reaction. For quantification I used the SYBR-green 
based 2x SensiMix DNA Kit containing ROX as an internal reference dye (peqLab, 
Germany). As not denoted otherwise, all oligonucleotid primers were purchased as validated 
Primer Sets from Quiagen (QuantiTect Primer Assays). The following primers were ordered 
at MWG-Biotech, Germany: 
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- MCSF-R  
for: 5’-GACCTGCTCCACTTCTCCAG-3’ 
rev: 5’-GGGTTCAGACCAAGCGAGAAG-3’ 
- MHCII  
for:5’-CTGATGGCTGCTCATCCTGTG-3’; 
rev: 5’-TTCTGTTTTCTGTATGCTGTCC-3’ 
 
Statistical analysis of quantitative Real-Time PCR measurements was done by the use of the 
Relative Expression Software Tool V1.9.6 (REST) (Pfaffl et al. 2002).  The expression ratio 
results of the investigated transcripts are tested for significance by a Pair Wise Fixed 
Reallocation Randomisation Test and plotted using standard error (SE) estimation via a 
complex Taylor algorithm (Pfaffl et al. 2002). In figures, levels of significance were labelled 
as follows: ***P < 0.001; **P < 0.01; *P < 0.05. 
 
3.11 WESTERN-BLOT 
Deep frozen brain hemispheres stored at -80 °C were homogenized using a glas-teflon 
homogenizer at 650 rpm in PBS buffer containing 2% SDS (pH7.4, supplemented with 
complete protease inhibitor cocktail (Roche)). The amount of buffer was adjusted to the brain 
weight in a 8:1 ratio. Lysates were centrifuged at 4 °C and 16.000 rpm for 1 h. Proteins 
contained in SDS-brain lysates of APP/PS1KI and PS1KI mice were separated using 
SDS/Polyacrylamide-gel-electrophoresis in a 8% SDS-glycine-gel. 20 µg protein were 
applied per lane. Proteins were transferred using semidry blotting for 25 min at 20 V on 
PVDF membranes (BioRad) according to the manufacturers protocol.  
Membranes were blocked in 10% non-fat dry milk in TBS-T buffer containing 0.05% Tween-
20 for 1 hour. Primary antibody incubation was performed overnight in TBS-T buffer at 4 °C 
followed by a two-hour incubation with HRP-conjugated secondary antibodies (DAKO) at 
room temperature. Blots were developed using enhanced chemiluminescence. 
Developed X-ray films were quantified using Quantity one software package (BioRad) with 
beta-Actin as a reference gene. Statistics of blot data were calculated using GraphPad Prism 
v4.03.  
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3.12 PHOTOMETRIC MEASUREMENT OF PROTEIN 
CONCENTRATION 
Measurement of protein concentration was performed by use of the commercially available 
Roti-Quant universal solution (C. Roth). Detection of proteins after this method is based on 
the biuret reaction. Absorbance was measured by use of a photometer at 595 nm. 
Concentrations of proteins were calculated by comparison with an calibration curve derived 
from BSA samples with a range in concentration from 0 – 20 mg*mL-1. All samples were 
measured in a transparent 96-well culture plate. In each well 2 µL of sample were diluted with 
200 µL of detection solution Roti-Quant universal and incubated for 30 min at 37 °C before 
measurement. 
 
3.13 AGAROSE GEL ELECTROPHORESIS 
Analytical separation of DNA and RNA was performed by agarose gel electrophoresis under 
non denaturing conditions. This method works by enforced movement of negative charged 
nucleic acids directed to the anode in an electrical field. The nucleic acids separate in the gel 
depending on their size. Agarose concentration was adapted between 0.7 and 3.0% to the size 
of the nucleic acids to be separated. Gels were prepared in TBE buffer. Ethidiumbromide was 
added to a final concentration of 1 µg*mL-1. Gels were run under a voltage of 170 V. A 
suitable DNA ladder was loaded on the gel to enable analysis of the size of the separated 
nucleic acid fragments. Gels were analyzed under UV-light-transillumination conditions at a 
wavelength of λ = 366 nm. Ethidiumbromide intercalates into the double-strand structure of 
DNA or RNA, which leads to an increased fluorescence of the bound pigment compared to 
the unbound species. Finally, the gel was pictured for documentation purposes. 
 
3.14 X-RAY EXAMINATION 
For conventional x-ray examination the specimen were positioned in a supine position on the 
examination table of a Siemens Siregraph D X-ray unit. Images were taken in a.p. and lateral 
projection. Images were obtained using 40 kV and 5 mAs current. The images were 
transferred to a Powermac G5 running Osirix 2.3.1 for post-processing.  
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3.15 BEHAVIOUR TESTS 
Clasping Test 
To test clasping behavior, mice were suspended by the tail for 30 s and the hindlimb-clasping 
time was scored. A duration of 0 sec clasping was given a score of 0, 1-10 s a score of 1, 10-
20 s a score of 2 and a clasping of more than 20 s a score of 3 (Nguyen et al. 2005). 
 
Balance Beam 
Balance and general motor function were assessed using the balance beam task. A 1 cm dowel 
beam is attached to two support columns 44 cm above a padded surface. At either end of the 
50 cm long beam a 9 x 15 cm escape platform is attached. The animal is placed on the center 
of the beam and released. Each animal is given three trials during a single day of testing. The 
time the animal remained on the beam is recorded and the resulting latencies to fall of all 
three trials are averaged. If an animal remains on the beam for whole 60 s trial or escapes to 
one of the platforms, the maximum time of 60 s is recorded (Arendash et al. 2001; Wirths et 
al. 2006). 
 
String Suspension Task 
As a test of agility and grip strength, a 3 mm cotton string is suspended 35 cm above a padded 
surface in the beam apparatus. The animals are permitted to grasp the string by their forepaws 
and are released. A rating system from 0 to 5 is used during the single 60-sec trial to assess 
each animals’ performance in this task: 0 = unable to remain on the string; 1 = hangs only by 
fore- or hindpaws; 2 = as for 1, but attempts to climb onto string; 3 = sits on string and is able 
to hold balance; 4 = four paws and tail around string with lateral movement; 5 = escape  
(Moran et al. 1995). 
 
Vertical Grip Hanging Task 
Animals were tested for neuromuscular abnormalities (balance and muscle strength) by 
suspending them from wire bars (40 x 20 cm area with 1mm wires 1 cm apart). Latency to fall 
within 60 s was measured after a mouse was placed on the bars and turned upside down 
(height 30 cm) (Erbel-Sieler et al. 2004).  
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Rotarod  
Motor learning and coordination were tested by the use of an accelerating rotarod (TSE-
Systems, Germany). The rotating rod had an axis diameter of 3.5 cm and a black rubber 
surface. Each mouse was given six daily trials for two consecutive days. The mice were 
placed on top of the beam facing away from the experimenters view. They had to move 
forward on the drum (which rotates with increasing speed around the vertical axis), being 
forced to continuously adjust their timing of movements. At the beginning of each trial, mice 
were placed on the inactive drum, which was accelerated to a speed of 48 rpm over a trial 
period of 360 s. The time until the animal fell off the rod was recorded with a cut-off after 
360 s (Dere et al. 2003). Analysis was carried out using a two-way ANOVA (genotype x 
training day), followed by Bonferroni post hoc tests. 
 
Forced Swimming Test 
The forced swimming test is performed identical to a probe test in the Morris Water Maze  
(Spittaels et al. 1999). In brief, a pool with a diameter of 110 cm is filled with opaque water to 
a height of 20 cm and is kept at 22 °C. The mice were placed in the middle of the pool for one 
60 sec single trial and total swimming distance and swimming speed were measured using a 
computer automated tracking system (VideoMot2, TSE-Systems).  
 
Open Field 
The open field test was used to asses both exploratory behavior and locomotor activity. The 
mice were tested using an open field box made of grey plastic with 50 x 50 cm surface area 
and 38 cm-high walls. Monitoring was done by an automated tracking system equipped with a 
rearing indicator consisting of 32 infrared sensors to detect vertical activity (VideoMot2, 
TSE-Systems, Germany). The behavioral parameters registered during 5 min sessions were (i) 
running speed and total traveled distance (ii) the ratio of time spent in the central part (20 x 
20 cm) versus total time (iii) rearing episodes: the number of times an animal stood upon its 
hind legs with forelegs in the air or against the wall (measure of vertical activity) (Dere et al. 
2003). 
 
 T-maze continuous alternation task (T-CAT) 
A T-maze was used according to the measures provided by Gerlai (Gerlai 1998). The 
apparatus was made of black plastic material with a black floor and guillotine doors. Testing 
of the mice consisted of one single session, which started with 1 forced-choice trial, followed 
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by 14 free-choice trials. (i) Forced-choice trial: in the first trial, one of the two goal arms is 
blocked by lowering the guillotine door. After the mouse is released from the start arm, it will 
explore the maze, enter the open arm and return to the start position. As soon as the mouse 
returned to the start arm, the guillotine door was lowered and the animal was confined for 5 s. 
(ii) Free-choice trials: After opening the door of the start arm, the animal is free to choose 
between both goal arms, as all guillotine doors are open. Once the mouse entered a goal arm, 
the other goal arm is closed. When the mouse returned to the start arm, the next free-choice 
trial started after 5 s confinement in the start arm. A test session was terminated after 30 min 
or after 14 free-choice trials were carried out. Animals that performed less than 8 trials within 
the given time frame were excluded from the analysis, which however was not the case. The 
animals were never handled during the task and the experimenter was not aware of the 
genotype of the tested animals.  
 
Y-Maze 
Spontaneous alternation rates were assessed using a triangular Y-shaped maze constructed 
from black plastic material with arm sizes of 30 cm × 8 cm. During 20 min test sessions, each 
mouse was randomly placed in one arm and allowed to move freely through the maze 
(Frenois et al., 2002). Alternation was defined as successive entries into the three arms in 
overlapping triplet sets. An entry was defined to be successive as soon as a mouse enters an 
arm with all four paws.The percent alternation was calculated as the ratio of actual to possible 
alternations. In order to diminish odor cues, the maze was cleaned with a solution containing 
30% ethanol, 60% water and 10% odorless soap. 
 
Cross-Maze 
Spontaneous alternation rates were assessed using a cross-maze (28) constructed from black 
plastic material (arm sizes: 30.0 cm length, 8.0 cm width, wall height 15.0 cm). Adjacent arms 
were in a 90° position. The 4 arms extended from a central space measuring 8.0 cm in square. 
Thus, the animals visited the arms via a central space. During 20.0 min test sessions, each 
mouse was randomly placed in one arm and allowed to traverse freely through the maze. 
Individual arms were signed 1 – 4. An alternation was defined as entry into four different 
arms on consecutive entries on overlapping quadruple sets (for example 2,3,4,1 or 4,2,3,1 but 
not 1,2,3,2). An entry was defined to be successive as soon as a mouse enters an arm with all 
four paws. The percent alternation was calculated as the ratio of actual to overall performed 
alternations during the period of observation. In order to diminish odor cues, the maze was 
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cleaned with a solution containing 30% ethanol, 60% water and 10% odorless soap after each 
trial.  
 
3.16 STEREOLOGICAL QUANTIFICATION OF TOTAL NUMBERS 
OF NEURONS  
Mice were anaesthetized and transcardially perfused as previously described (Schmitz et al., 
2004). The brains were carefully removed from the skull, post-fixed for 2 hours and 
dissected. The left brain halves were cryoprotected in 30% sucrose, quickly frozen and cut 
frontally into series of 30 µm thick sections. Every tenth section was systematically sampled, 
stained with cresyl violet and used for stereological analysis of the hippocampal volume and 
the number of CA1 neurons. The hippocampal cell layer CA1 was delineated on cresyl 
violet-stained sections. Using a stereology workstation (StereoInvestigator; 
MicroBrightField, Williston, VT, USA) and a 100x oil lens, all neurons whose nucleus top 
came into focus were counted using the Optical Fractionator. In addition, volumes of the 
investigated brain regions were calculated from the delineated areas with Cavalieri's 
principle.  
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3.17 HISTOLOGICAL STAININGS 
Cresylviolet staining 
- necessary solutions: 
1A: stock solution 1M sodium acetate  
1B: working solution: 40 mL of 1A + 9.6 mL acetic acid (100%) adjusted to a total 
volume of 1 L. 
2: cresyl violet is supplemented to 1 L of 1B and stirred for 30 min. Solution is stirred 
overnight at room temperature. Before use the solution was filtered. 
3A: stock solution: 2% triton x-100 (20 mL are added to 980 mL mQ-water and stirred for 
1 h at room temperature) 
3B: working solution: 2.5 mL 3A + 50 mL mQ-water + 150 mL ethanol (100%) 
- staining protocol: 
 
1. cryo-sections were mounted on microscope slides and are allowed to dry on air for at 
least 2 h. 
2. 20 min in 1B (2 cuvettes) 
3. 20 min in 3B 
4. 20 min in 1B (2 cuvettes) 
5. 2 x 7 min in 2 (2 cuvettes) 
6. 3 x 1 min in buffer 1B (3 cuvettes) 
7. 3 min in 100% ethanol 
8. 2 x 5 min xyleen 
9. embedding in DEPEX or other suitable mounting medium 
 
Hematoxylin staining 
The H&E staining is a common staining in diagnostic histopathology 
Hematoxylin stains nuclear blue, whereas the matrix of hyaline cartilage, myxomatous and 
mucoid material appears pale blue. 
Solution: 
- Hematoxylin (Mayers hemalaun solution) 
 
1. sections were deparaffinized in xylene and rehydrated in a descending graded alcohol 
row 
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2. washing in aqua dest. (2 min) 
3. incubation in hematoxylin (5 min) 
4. rinse in aque dest. (30 s while moving the slide rack) 
5. rinse in tap water (5 min) 
6. dehydradation in   100% ethanol (5 min) 
100% ethanol (5 min) 
Xylene (2x 10 min) 
7. embedding with a quick hardening mounting medium 
3.18 PLASMA CHOLESTEROL MEASUREMENT USING GAS 
CHROMATOGRAPHY 
For extraction of plasma cholesterol 50 µL of plasma were mixed with 1 mL 1 N ethanolic 
NaOH, stirred for 1 h at 50 °C and 1 mL H2O was added. The aqueous phase was extracted 
twice with 3 mL cyclohexan. Samples were centrifuged for 20 min at 6000 rpm and room 
temperature. The unified organic phases were evaporated in a stream of N2 at 65 °C. For sterol 
analysis 50 µg 5α-cholestane (Serva) and 1 µg epicoprostanol (sigma) were added as internal 
standards. Samples were evaporated under nitrogen at 65 °C, dissolved in n-decan and 
transferred into a micro-vial for gas-liquid chromatography-flame ionization detection (GC-
FID) analysis of cholesterols. Sterols were derivatized to trimethylsilyl- (TMSi) ethers by 
addition of 20 µL of TMSi-reagent (pyridine:hexamethyldisalazane-trimethylchlorosilane; 
9:3:1, by volume; all reagents were supplied by Merck) into each microvial  and incubated for 
1 h at 60 °C. 
 
To quantify cholesterol in plasma samples, cholesterol and 5α-cholestane-TMSi ethers were 
separated on a cross-linked methyl silicone DB-XLB 122-1232 fused silica capillary column 
(J and W, Folsom) (30 m x 0.25 mm i.d. x 0.25 µm film thickness) in a HP 6890 series gas 
chromatograph (Hewlett Packard). The oven temperature was initially kept at 150 °C for 
3 min, then increased by 30 °C * min-1 to a final temperature of 290 °C. The concentration of 
cholesterol was calculated by one-point calibration using 5α-cholestane as a standard. The 
peak area of cholesterol is divided by the peak area of 5α-cholestane and multiplied by the 
amount of 5α-cholestane added to the sample (50 µg). This calculation method was validated 
against standard curves for cholesterol and showed a high validity. The identity of cholesterol 
was proven by comparison with the mass spectrum of authentic cholesterol as a standard 
(Sigma). 
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4 RESULTS 
 
4.1 DEFICITS IN WORKING MEMORY AND MOTOR PERFORMANCE 
DECLINE IN THE APP/PS1KI MOUSE MODEL FOR 
ALZHEIMER`S DISEASE ARE PARALLELLED BY EXTENSIVE 
NEURON LOSS AND HIPPOCAMPAL SHRINKAGE 
 
4.1.1 PHENOTYPICAL CHARACTERIZATION 
 
APP/PS1KI mutant mice did not show any apparent abnormalities until 6 months of age 
(ANOVA, P < 0.0001). At this time point, a progressive and significant decrease in the body 
weight compared to their PS1KI littermates is apparent (P < 0.05), which becomes highly 
significant at the age of 9 and 12 months (P < 0.01 and P < 0.001 respectively, Fig. 10, B). 
Furthermore, most of the APP/PS1ki mice start to develop a marked and rigid thoracolumbar 
kyphosis, which is a type of spinal deformity with an increased spine curvature starting at the 
age of approximately 6 months (Fig. 10, A). X-ray analyzes of PS1KI and APP/PS1KI 
littermates revealed no evidence of abnormal vertebral anatomy or bony deformity, but clearly 
demonstrated a thoracolumbar kyphosis in 12 month-old APP/PS1KI mice (Fig. 10, C - F).  
A characteristic clasping phenotype has been previously shown in aged APP/PS1KI mice, 
which means that they show an unusual simultaneous retraction of both fore- and hindlimbs. 
(Wirths et al. 2006) Quantitative measurement of this behavior by suspending the animals by 
their tail and evaluating the clasping score, revealed a significant increase in the foot-clasping 
time already at 6 months of age in the APP/PS1KI mice (P < 0.001), with no differences in 
young animals at the age of 2 months (ANOVA, P < 0.0001; Fig. 10, G). 
In addition, APP/PS1KI mice showed evidence for an abnormal gait. Measuring the average 
stride length in a foot printing test showed no differences in young animals at the age of 2 
months (ANOVA, P < 0.0001). However, analysis of 6 and 9 month-old animals revealed a 
significantly reduced stride length in the APP/PS1KI mice (P < 0.01 and P < 0.001 
respectively, Fig. 10, H - I).  
Paraphenylene diamine stained gastrocnemic muscle sections were analyzed by light 
microscopy. There was no apparent neurogenic muscle fiber atrophy; no spheroids were 
detected in the distal preterminal nerve fiber branches of any of the mouse lines investigated 
(not shown). 
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Fig. 10: APP/PS1KI mice show an age-dependent development of a thoracolumbar kyphosis (A). 
Additionally they have a reduced body weight compared to their age-matched PS1ki littermates (B). X-
ray examination further highlights the thoracolumbar kyphosis, which becomes very robust in 12 month-
old APP/PS1KI animals (C – F). Quantification of the clasping phenotype revealed highly significant 
differences between APP/PS1KI and PS1KI littermates already at 6 months of age (G). Representative 
footprinting pattern of 6 month-old APP/PS1KI and PS1KI mice (H)(experiment H was conducted by Dr. 
Stephanie Schaefer). Quantitative analysis revealed a significantly reduced stride length already at 6 
months of age in the APP/PS1KI mice (I).  
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4.1.2 APP/PS1KI MICE ARE STRONGLY IMPAIRED IN SENSORY-
MOTOR TASKS 
 
For a more detailed characterization of the abovementioned clasping and rearing phenotypes, 
different sensory-motor tasks were performed using APP/PS1KI and PS1KI mice at the age of 
2, 6, 9 and 12 months. The balance beam task analyzes the ability of mice to remain on a thin 
wooden dowel. Whereas PS1KI mice, as well as young (2 month-old) APP/PS1KI mice were 
able to stay on the dowel and often walked freely around it without any disturbance, aged 
APP/PS1KI mice showed a significant impairment in this task starting at the age of 6 months 
(P < 0.05). This phenotype was even more pronounced at 9 and 12 months of age (both P < 
0.001; Fig. 11, A). A decreased latency to fall was detected between 6 and 12 months of age 
(P < 0.05) and 9 and 12 months of age in the PS1KI mice (P < 0.05), which might be 
attributed to the strong increase in body weight in the aged PS1KI mice (Kruskal-Wallis-Test, 
P < 0.0001; Fig. 10, B). 
The string suspension paradigm is a task which measures the ability of mice to hold on to a 
wire using their forepaws. APP/PS1KI mice showed a significantly poorer performance than 
the PS1ki mice at 6, 9 and 12 months of age ( all P < 0.001, Fig. 11, B), whereas young mice 
at 2 months of age did not show any impairment (P > 0.299). No differences were detected 
during aging in the PS1KI mice (ANOVA, P < 0.0001).  
The vertical grip hanging task is a measure for neuromuscular abnormalities and tests the 
ability of mice to hang upside down from wire bars. This task also revealed a significantly 
decreased latency to fall in the APP/PS1KI mice already at 6 months of age (P < 0.05), which 
persisted at 9 months (P < 0.05) and becomes highly significant at 12 months of age (P < 
0.001, Fig. 11, C). There were no difference in young APP/PS1KI mice (P = 0.309) or in 
PS1KI mice during aging (ANOVA, P < 0.0001). 
The rotarod task is another accepted measure of impaired motor performance in mice. 
Abnormal motor function was revealed already at 6 months of age in this experimental 
paradigm. A genotype x training day ANOVA was calculated for the 2 month-old animals 
and revealed a significantly effect of the training day (F(4, 45) = 13.36, P < 0.0001), as well as a 
tendency towards a genotype effect, which was, however, not significant at that time point 
(F(1, 45) = 3.84, P = 0.056). At 6 months of age, a significant effect of genotype (F(1, 55) = 
17.25, P < 0.0001) and training day (F(4, 55) = 4.78, P = 0.022) was detected. Analysis of data 
presented in Fig. 11, D revealed that APP/PS1KI and PS1KI mice at 2 months of age showed 
a quite similar improvement during motor training. Six-month-old PS1KI mice showed on 
average a prolonged latency to fall than the age-matched APP/PS1KI mice, however, both 
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groups improved their latency to fall over the 5 days training period (Fig. 11, E). Combining 
the rotarod data of the 2 and 6 month-old groups reveals a significant effect of the genotype 
(F(3,100) = 14.80, P < 0.0001), as well as a significant effect of the training day (F(4, 100) = 
17.39, P < 0.0001) 
 
 
Fig. 11: Aged APP/PS1KI mice show highly significant impairment in the balance beam task (A), the 
string suspension task (B), as well as the grip hanging task (C) starting at the age of 6 months. Analysis of 
rotarod performance revealed no genotype effect at 2 months of age (D) but showed a significant genotype 
effect in 6 month-old APP/PS1KI mice (E). 
 
 
4.1.3 FORCED SWIMMING TEST 
 
Analysis of swimming distance and speed in the forced swimming test revealed that both 
parameters were significantly reduced in aged APP/PS1KI mice (ANOVA, P < 0.0001), 
without significant differences in young APP/PS1KI mice at 2 months of age (P = 0.82). 
Regarding swimming distance, impairment was detectable at 6 months (P < 0.001), becoming 
even more severe at 9 and 12 months of age (both P < 0.001; Fig. 12, A). The same held true 
  
 
 Page 62/137 
for the swimming speed, which was also significantly reduced in APP/PS1KI mice older than 
2 months of age (all data, P < 0.001; Fig. 12, B). Additionally, some of the aged APP/PS1KI 
mice displayed alterations in their swimming behavior, often showing circulating and 
tumbling agitations in contrast to their PS1KI littermates, which always showed a straight 
way of swimming in this task (Fig. 12; C – D). 
 
 
Fig. 12: Forced Swimming test. APP/PS1KI mice are strongly impaired in the forced swimming test 
starting at the age of 6 months. This becomes evident by a significantly reduced swimming distance (A), as 
well as a reduced swimming speed during the 60 sec single trial (B). Aged (12 months) PS1KI mice show a 
normal swimming pattern (C), whereas APP/PS1KI mice show a characteristic tumbling and circulating 
swimming behavior (D). 
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4.1.4 LOCOMOTOR AND EXPLORATORY BEHAVIOUR 
 
The exploratory and spontaneous locomotor activity of APP/PS1KI mice was compared to 
PS1KI mice at the age of 2 and 9 months in the open field paradigm (ANOVA, P < 0.0001). 
No significant differences were observed in the distance traveled during the 5 min trial 
between APP/PS1KI and PS1KI mice at 
either age (P > 0.05; Fig. 13, A). The 
mean movement speed was also 
unchanged between APP/PS1KI and 
PS1KI mice (P > 0.05, not shown). The 
ratio of distance traveled in the center of 
the arena versus the total distance can be 
used as a measure of anxiety-related 
behavior (Paylor et al. 1998). No 
differences in the center/total distance 
ratio could be detected between 
APP/PS1KI and PS1KI at either age 
(ANOVA, P < 0.001; t-test both P > 
0.05 (Fig. 13, B)). Interestingly, the 
9 month-old APP/PS1KI mice showed a 
dramatic reduction in the rearing 
frequency, pointing again to an impaired 
motor behavior (P < 0.001; Fig. 13, C). 
 
 
 
 
 
 
 
Fig. 13: Open field. There is no significant 
difference in the exploratory behavior 
between APP/PS1KI and PS1KI mice at the 
analyzed time points. Neither the total 
traveled distance (A) nor the center/total time 
ratio (B) was altered between both groups at 2 
and 9 months of age. However, APP/PS1KI 
mice at 9 months of age showed a significantly 
reduced frequency of rearing events, pointing 
to impaired motor performance (C). 
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4.1.5 AGE-DEPENDENT WORKING MEMORY IMPAIRMENT IN 
APP/PS1KI MICE 
 
Two different paradigms were used to assess whether APP/PS1KI mice are impaired regarded 
to working memory in comparison with their PS1KI littermates. In the Y-maze, no difference 
between the percentages of alternation was detected in 2-month-old APP/PS1KI mice 
(ANOVA, P = 0.0037). However, at 6 months of age APP/PS1KI mice showed a significantly 
reduced alternation percentage (P < 0.05), 
indicating impaired working memory (Fig. 14, A). 
This deficit became even worse at the age of 12 
months (P < 0.01). The observed deficiency was 
obviously not due to a lack of explorative 
behavior, as APP/PS1KI mice at 6 months of age 
showed an even higher frequency of total arm 
entries within the given time frame (P < 0.05; Fig. 
14, B).  
The T-maze continuous alternation task (T-CAT) 
revealed similar results (ANOVA, P = 0.0003). 
Whereas no differences were obvious at 2 months 
of age, a significantly reduced alternation rate was 
observed in 6 and 12 month-old APP/PS1KI mice 
(both P < 0.01). At these time points the 
APP/PS1KI mice alternated even below chance 
level (Fig. 14, C). Mean session duration to 
perform the free-choice trials was not different 
between APP/PS1KI and PS1KI mice at each time 
point analyzed (not shown). 
Fig. 14: Working memory using Y-maze and T-maze 
continuous alternation task (T-CAT). Analysis of 
spontaneous alternation in the Y-maze revealed 
significantly reduced alternation frequencies in the 
APP/PS1KI mice at 6 and 12 months with no difference 
at 2 months of age (A). This is not due to a lack of 
explorative behavior, as APP/PS1KI mice at this age 
showed a higher frequency of total arm entries (B). The 
T-CAT also revealed a significantly reduced alternation 
behavior at the age of 6 and 12 months in the 
APP/PS1KI mice, with no disturbance in 2 month-old 
mice (C). 
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Fig. 15: Working memory test using cross-maze task. Analysis of spontaneous alternation in the cross-
maze revealed significantly reduced alternation frequencies in the APP/PS1KI mice at 6 and 12 months 
with no difference at 2 months of age (N=6-14, unpaired t-test (two-tailed), **: 0.001<p<0.01; ***: 
p<0.001, data shown as mean ± s.e.m.). 
 
The finding of strongly impaired working memory performance shown in Y-maze and T-
maze task is firmly underlined by the results from the cross-maze-task (Fig. 15). The cross-
maze, built up from four arms arranged in rectangular angles instead of three arms with angles 
of 120°, differs from the Y-maze merely by the shape of the maze. Because the higher number 
of arms, this task places higher demands to mice in exploring the maze`s arms in an optimal 
alternating order. Therefore, the results from the crossmaze are very similar to the Y-maze, 
but show an even higher level of statistical significance.  While no difference in working 
memory performance was observable at two months of age between PS1KI and APP/PS1KI 
mice, at six months of age the latter are significantly impaired in this respect (p=0.0001). At 
12 months of age working memory performance of APP/PS1KI mice was also strikingly 
worse compared to age-matched PS1KI mice (p=0.0021). The increase in working memory 
performance comparing twelve-month-old APP/PS1KI mice to six-month-old ones was 
statistically not significant (p=0.1607).  
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4.1.6 CA1 NEURON LOSS AND HIPPOCAMPAL ATROPHY 
 
Neuronal loss was quantitatively assessed by design-based stereology. I found a 33% loss of 
pyramidal cells within the pyramidal layer of CA1 in the hippocampus in 6-month-old 
APP/PS1KI mice compared to 6-month-old PS1KI littermate control mice (P = 0.003; Fig. 
16, A). Previously it has been shown that 2-month-old APP/PS1KI mice showed a normal 
number of CA1 neurons and a 50% reduction at 10 months of age (Casas et al., 2004). In 
addition, 6-month-old APP/PS1KI mice exhibited a decreased volume of the CA1 pyramidal 
cell layer of 30% (P = 0.022; Fig. 16, B), and a total hippocampal atrophy of 18% (P = 
0.019; Fig. 16, C).  
 
Fig. 16: (A) Stereological cell counting of CA1 neurons of 6-month-old APP/PS1KI (n = 7) and PS1KI (n = 
6) mice. Compared to age-matched PS1KI mice, six month old APP/PS1KI mice show a neuron loss in 
CA1/2 region of the hippocampus of 33%.  (B) A significant difference in the volume of the CA1 
pyramidal layer was detected at 6 months, corresponding to a reduction of 22% (n = 6 - 7 per group). (C) 
This results in an overall hippocampus volume reduction of 18%. Values are given as means ± s.e.m. **P 
< 0.01; *P < 0.05, unpaired t-test.  
 
At 12 months of age, APP/PS1KI mice show a further slightly decline in neuron numbers and 
volume figures of CA1 region and total hippocampus as well, however no significant 
differences compared to six month old APP/PS1KI mice were detected. In detail, neuron 
numbers of APP/PS1KI mice showed a decline of 42% (P = 0.0003) at 12 months of age, 
while CA1 and hippocampal volumes exhibited a loss of 25% (P = 0.016) or 22% (P 
= 0.013), respektively (Fig. 17 A-C).  
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Fig. 17: (A) Stereological cell counting of CA1 neurons of 12-month-old APP/PS1KI (n = 7) and PS1KI (n 
= 8) mice. Compared to age-matched PS1KI mice, six month old APP/PS1KI mice show a neuron loss in 
CA1/2 region of the hippocampus of 42%. (B) A significant difference in the volume of the CA1 pyramidal 
layer was detected at 6 months, corresponding to a reduction of 25% (n = 7 - 8 per group). (C) This results 
in an overall hippocampus volume reduction of 22%. Values are given as means ± s.e.m. ***P < 0.001; *P 
< 0.05.  
 
4.2 PATHOLOGY-DEPENDENT DEVELOPMENT OF INFLAMMATION 
IN AN APP/PS1KI MOUSE MODEL OF ALZHEIMER`S DISEASE 
 
Besides rare exceptions no significant upregulation in expression of any of the genes of 
interest could be detected between 2-month-old APP/PS1KI and PS1KI mice. However, I 
observed a significant upregulation of GFAP and a statistical trend pointing to an increased 
expression of toll like receptor 2 (P=0.08). Therefore APP/PS1KI mice appear not to be 
inflicted by severe inflammation in the brain, because at this early timepoint of the AD related 
pathological process is still in its very beginning. This fits well to the behavioural phenotype 
of these mice at two months of age, where no deficits in working memory performance, signs 
of axonal degeneration or motor disturbances are present (Wirths et al. 2007; Wirths et al. 
2006). Interestingly, expression of calcium homeostasis related protein S100A6 was found to 
be significantly downregulated 0.5-fold. Osteopontin showed only a trend of deterioration to 
an extent of (0.5x; P= 0.08) compared to two month old PS1KI mice. 
 
In contrast, at six months of age, where pathology of AD is already extensively present, I 
observed significant upregulation in a broad set of inflammation markers. Expression of 
GFAP mRNA revealed a strong 9-fold increase compared to age-matched PS1KI controls, 
indicating a severe astrogliosis in brains of APP/PS1KI mice. Occurence of astrogliosis was 
also underlined by overexpression of S100A6 (2.6x, P=0.003) that is often used as a marker 
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for activated astrocytes. Proteins characteristic for activated microglia cells like Macrophage 
scavenger 2 (7.8x, P=0.005) and toll like receptor family – I measured Tlr2 (6.1x, P=0.001), 
Tlr4 (1.9x, P=0.016), Tlr7 (3.1, P<0.001) and Tlr9 (2.3x, P=0.004), revealed all prominently 
upregulated expression patters. I detected also an increase in the expression of microglia 
associated cytokines like CD11β (2.4x, P=0.002), F4/80 (3.8x, P<0.001), interleukin-1β 
(1.8x, however by a P-value of 0.194 not significant). Interestingly, the expression of 
interleukin-6 (1.0x, P=0.912) and interleukin-10 (0.8x, P=0.336) remained unchanged. Tumor 
necrosis factor (TNF-α) was not upregulated compared to PS1KI mice at 6 months of age, 
while transforming growth factor (TGF-β) revealed a massively increased 2.7-fold expression 
(P<0.001) at this time point. The expression of cell surface glycoprotein major 
histocompatibilty complex (MHC-II) remained unchanged, although a tendency of age 
dependent diminished expression may be assumed from the data. Macrophage colony 
stimulating factor`s (MCSF-R) expression was elevated 2.6-fold (P<0.001). The same was 
valid for the family of Metallothioneins (Mt1 (2.0x, P=0.002), Mt2 (2.5x, P=0.004), Mt3 
(1.5x, P=0.005), for the proapoptotic factor FAS (1.8x, P=0.004) and for osteopontin (2.7x, 
P=0.001). A strong upregulation of mRNA was also found for iron regulatory proteins 
transferrin (2.4x, P=0.001) and ferritin light chain (Ftl, 1.8x; P=0.001).  
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Fig. 18: Gene expression for various inflammation-associated genes are shown as a ratio of mRNA levels 
in APP/PS1KI mice compared to age-matched PS1KI control animals. Levels of significance refer to the 
expression ratio of APP/PS1KI mice to PS1KI mice at same age: ***P < 0.001; **P < 0.01; *P < 0.05. For 
real-time RT-PCR analysis I used male animals of two (4 PS1KI, 4 APP/PS1KI), six (4 PS1KI; 5 
APP/PS1KI and ten months of age (4 PS1KI; 4 APP/PS1KI). 
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Fig. 19: A) Gene expression for various genes of antioxidant or other neuroprotective relevance is shown 
as a ratio of mRNA levels in APP/PS1KI mice compared to age-matched PS1KI control animals. Levels of 
significance refer to the expression ratio of APP/PS1KI mice to PS1KI mice at same age: ***P < 0.001; 
**P < 0.01; *P < 0.05. B) Expression of reference genes used in statistical calculations is shown as a ratio 
of mRNA levels in APP/PS1KI mice compared to age-matched PS1KI control animals. The expression of 
all three housekeeping genes that were used to form an housekeeping index as a basis for gene expression 
calculations by use of REST software remained highly stable and does not differ between APP/PS1KI and 
PS1KI mice at any timepoint. For real-time RT-PCR analysis I used male animals of two (4 PS1KI, 4 
APP/PS1KI), six (4 PS1KI; 5 APP/PS1KI and ten months of age (4 PS1KI; 4 APP/PS1KI).  
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Immunohistochemically analysis of exemplary chosen proteins gave evidence for 
accumulation of markers for activated astrocytes like GFAP, S100A6, microglia inflammation 
marker Iba1 and for iron metabolism implied transferrin on the protein level at six months of 
age (fig. 20 and 21).  
 
 
 
 
Fig. 20: Immunohistochemical stainings were used to verify the increased expression of inflammatory on 
the protein level. Representative stainings against GFAP in the cortex (A, B), against the microglia 
marker Iba1 in the cortex (C, D), as well as against S100A6 in the hippocampus (E, F) are shown at six 
months of age in PS1KI (A, C, E) and APP/PS1KI (B, D, F) mice. Scale bars: 100 µm (A, B); 50 µm (C, D); 
200 µm (E, F).   
 
 
GFAP was significantly increased at two (P=0.0011; t=8.415, df=4) and six (P=0.0017; 
t=7.527, df=4) months of age between APP/PS1KI and PS1KI mice, indicating massive 
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astrogliosis. Besides, GFAP load was also significantly higher in six-month-old APP/PS1KI 
mice compared to two-month-old mice of equal genotype (P=0.0041; t=5.911, df=4). 
Transferrin was significantly increased comparing six-month-old APP/PS1KI mice to six-
month-old PS1KI control (P=0.0136; t=4.208, df=4) and two-month-old APP/PS1KI mice 
(P=0.0049; t=5.633, df=4) as well. 
 
 
Fig. 21: Exemplary quantitative western blot analysis of GFAP and transferrin normalized to beta-actin 
as a reference gene. GFAP was significantly increased at two (P=0.0011; t=8.415, df=4) and six (P=0.0017; 
t=7.527, df=4) months of age between APP/PS1KI (n=3) and PS1KI (n=3) mice, indicating massive 
astrogliosis. Besides, GFAP load was also significantly higher in six-month-old APP/PS1KI mice 
compared to two-month-old mice of equal genotype (P=0.0041; t=5.911, df=4). Transferrin was 
significantly increased comparing six-month-old APP/PS1KI (n=3) mice to six-month-old PS1KI (n=3) 
control (P=0.0136; t=4.208, df=4) and two-month-old APP/PS1KI mice (P=0.0049; t=5.633, df=4) as well. 
Levels of statistical significance (unpaired t-test) were given as **P < 0.01; *P < 0.05. Data are plotted +/- 
SE. 
 
 
At 10 months of age, expression of all observed genes remained unchanged in means of 
statistical significance or showed only a slight increase in their mean expression. No 
significant decrease in expression of any gene was detected by real time RT-PCR of 
APP/PS1KI mice compared to age-matched PS1KI control mice. In most cases the difference 
in mRNA expression seemed to be more incisive comparing 2 and 6 month old animals than 
between 6 and 10 months of age. This indicates that 6 months represent a critical time point in 
this animal model.  
 
In detail, I observed upregulation of cytokines in 10 m old APP/PS1KI animals compared to 
PS1KI animals of same age as follows: Tlr2 mRNA expression was 7.4-fold elevated 
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(P<0.0001), Tlr4 1.9x (P=0.016), Tlr7 3.8x (P=0.004) and Tlr9 3.9x (P=0.004). CD11/B 
mRNA levels were found to be 3.2-fold higher in APP/PS1KI animals compared to control 
group, IL1β 2.3x – however with an only trend indicating p-value of 0.073. Interleukin-6 and 
interleukin-10 again were detected to remain unchanged. 
 
Tumor necrosis factor TNF-α by mean appeared to be upregulated in 10m old APP/PS1KI 
mice relative to age-matched controls, however there was no statistically significant 
difference (P=0.205). Messenger RNA-levels of MHC-II seemed to be diminished at 10 m of 
age, however no statistical significance could be found here neither (P=0.149). 
 
Transforming growth factor TGF-β showed a 3.5x upregulation in mRNA expression at 10 
months of age (P=0.004). The same was found for MCSF-R (2.6x, P=0.004). 
 
Levels of metallothionein mRNA in brains of 10 m old mice remained stable or showed only 
minor changes in relation to 6 month old mice compared to their age-matched PS1KI 
littermates (MT1: 2.3x, P=0.015; MT2: 2.2x, P=0.028). Interestingly, according to MT3 
mRNA expression, statistical significance between APP/PS1KI and PS1KI mice was no 
longer evident at 10 months of age, though mean expression of this gene was only slightly 
decreased at this time point (1.3x, P= 0.804 at 10 months instead of 1.5x, P=0.005 at 
6 months. In 10-month-old APP/PS1KI mice Transferrin (2.9x, P<0.001), S100A6 (3.6x, 
P=0.016), osteopontin (3.3x, P<0.001) and GFAP (12.9x, P=0.004) mRNA also met strong 
upregulations. 
 
4.3 CHOLESTEROL METABOLISM IN APP/PS1KI MICE 
  
I measured the plasma cholesterol levels in wildtype, PS1KI, APPSL and APP/PS1KI mice at 
two and six months of age.  Cholesterol levels mice were determined by GC. There was no 
detectable difference in plasma cholesterol between APP single transgenic (2 m, 80.16 ± 5.7 
mg/dL; 6 m, 78.88 ± 4.8 mg/dL) and wildtype control mice (2 m, 86.85 ± 5.3 mg/dL; 6m, 
83.32 ± 4.1 mg/dL). Furthermore, the levels of young wildtype mice did not differ from the 
levels of the 3-months group in the first set of mice, verifying that both enzymatic as well GC 
determintation of plasma cholesterol gives comparable results. PS1 knock-in mice revealed 
also no significant change between 2 (125.4 ± 4.7 mg/dL) and 6 months (121.5 ± 10.0 
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mg/dL), whereas APP/PS1KI mice showed a significant decrease between 2 (116.6 ± 5.6 
mg/dL) and 6 months (92.13 ± 5.5 mg/dL) (P = 0.013) (Fig. 22). Both PS1KI and 
APP/PS1KI mice have higher basal cholesterol levels than APP single transgenic or wildtype 
mice. This is due to a different genetic background. Whereas wildtype and APP single 
transgenic mice are on C57BL/6-background, the knock-in lines have C57BL/6 50% - CBA 
25% - 129SV 25%  (Casas et al. 2004).  
 
Fig. 22:  Measurement of plasma cholesterol concentrations in wildtype (2m: N=7, 6m: N=6), PS1KI (2m: 
N=6, 6m: N=5), APP751SL (2m: N=5, 6m: N=5)  and APP751SLxPS1KI mice (2m: N=6, 6m: N=5), *<0.05, 
Mann-Whitney t-test.  
 
4.4 24-(S)-HYDROXY-CHOLESTEROL AS A PREDICTIVE 
BIOMARKER IN ALZHEIMER`S DISEASE? 
 
In this study I measured the levels of total cholesterol and 24(S)-hydroxycholesterol in plasma 
of wildtype, APP751SL, PS1KI transgenic mice and in the APP751SLxPS1KI species. Only 
animals of female gender have been studied, because female mice show an accelerated 
progression of the disesase compared to male mice and proved to show a significant loss of 
hippocampal CA1 neurons of already 33% at 6 months-of-age. Mean values ± SD of the ratio 
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between 24(S)-hydroxycholesterol to cholesterol in plasma at two months respectively six 
months-of-age (values in brackets) were the following (see Fig. 23):  
wildtype = 38.6 ± 9.5 (55.4 ± 40.7), PS1KI = 62.1 ±11.7 (59.4 ± 8.1), APP751SL = 41.2 
± 15.7 (43.5 ± 16.1) and APP751SLxPS1KI =50.4 ± 12.9 (48.7 ± 3.5). Levels of significance 
of cholesterol corrected 24(S)-hydroxycholesterol levels resulted in p = 0.53 for wildtype, 
p = 0.79 for PS1KI, p = 0.84 for APP751SL and p = 0.93 for APP751SLxPS1KI genotype.  
 
 
Fig. 23: Ratio of 24(S)-hydroxycholesterol to total cholesterol in plasma of wildtype (2m: N=7, 6m: N=6), 
PS1KI (2m: N=6, 6m: N=5), APP751SL (2m: N=5, 6m: N=5)  and APP751SLxPS1KI mice PS1KI (2m: 
N=6, 6m: N=5)  (f = female). The ratios were measured at the age of two (2M) and six months (6M). There 
was no significant difference in the ratio of 24(S)-hydroxycholesterol to total cholesterol comparing any 
group at any timepoint. 
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4.5 IN VIVO FORMATION OF PYROGLUTAMATE Aβ in APP/PS1KI, 
TBA1 and TBA2 MICE 
 
4.5.1 DOMINANT AGGREGATION OF β-AMYLOID STARTING WITH 
PYROGLUTAMATE AT POSITION 3 IN THE APP/PS1KI MOUSE 
MODEL  
 
It was previously shown that approximately 85% of all Aβ peptides in the APP/PS1KI mouse 
brain are comprised of peptides ending with residue 42 at the C-terminus (Casas et al. 2004), 
and in addition that a variety of different N-modified Aβ peptides accumulate in this model 
(Casas et al. 2004; Wirths et al. 2006). Accordingly, the immunohistochemical staining 
pattern of N-modified Aβ peptides in the hippocampus has been studied in the present study 
in greater detail. Strong immunoreactivity was detected already at 2 months of age in 
hippocampal CA1 neurons in APP/PS1KI mice with an antibody directed against AβN1(D), 
detecting only Aβ peptides starting at position 1 (Fig. 24 A, B). PS1KI control animals were 
constantly negative (not shown). Interestingly there is some heterogeneity among the 
intraneuronal Aβ peptides, which could be demonstrated by strong immunoreactivity with 
antibodies against racemized aspartate at position 1 (AβN1(rD)) (Fig. 24 D, E), and cyclized 
glutamate (pyroglutamate) at position 3 (AβN3(pE)) (Fig. 24 G, H). Quantification of N-
modified Aβ peptides in CA1 neurons revealed that all 3 different peptides showed a strong 
intraneuronal accumulation between 2 and 6 months of age, however, with varying degrees. 
The amount increased as follows: AβN1(D) by 301%, AβN1(rD) by 297%, and AβN3(pE) by 
435%. In addition the total Aβ load of N-modified Aβ peptides was assessed in the 
hippocampus of 2- and 6-month-old APP/PS1KI mice. The amount showed an age-
dependent increase for AβN1(D) by 529%, for AβN1(rD) by 486%, and for AβN3(pE) by 1076%. 
As previously published, the spatial pattern of plaque deposition did not correlate with the 
observed CA1 neuron loss (Fig. 24). 
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Fig. 24: Representative hippocampal sections of 6-month-old APP/PS1KI mice treated with antibodies 
against N-modified Aβ forms including peptides starting with L-aspartate AβN1(D) (A, B), racemized 
aspartate AβN1(rD) (D, E), and AβN3(pE) against pyroglutamate at position 3 (G, H). Quantitative 
analysis revealed a significant increase of all Aβ peptides in CA1 pyramidal neurons and in total 
hippocampus (C, F, I) at 6 months compared with 2-month-old APP/PS1KI mice (n = 5 per group). Values 
are given as means ± s.e.m., (C, F, I); ***P < 0.001; **P < 0.01; *P < 0.05, unpaired t-test. Scale bars: 200 
µm (hippocampus: A, D, G) and 33 µm (CA1: B, E, H).  
 
Quantification of total brain Aβx-42 and AβN3(pE) peptides using specific ELISAs revealed a 
related finding. Total Aβx-42 peptides were found already in a considerable amount at 
2 months of age (35191 ± 446 pg/mg w.w) and increased significantly up to the age of 
6 months 58063 ± 7014 pg/mg w.w.; P < 0.05; + 65%). Quantification of the N-modified 
peptide AβN3(pE) disclosed a much more dramatic increase in the APP/PS1KI mice between 
2- (2.12 ± 0.01 pg/mg w.w.) and 6-month-old animals (91.32 ± 13.08 pg/mg w.w.; P = 
0.0022; + 4200%) (Fig. 25, A – B), thereby corroborating the results of the 
immunohistochemical quantification in the CA1 granular cell layer and hippocampus.  
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Fig. 25: ELISA analysis of (A) Aβ(x-42) and (B) AβN3(pE) in the brain of APP/PS1KI (2m: N=3, 6m: N=4) 
and PS1KI PS1KI (2m: N=3, 6m: N=3) mice at 2 and 6 months of age. Values are given as means ± s.e.m., 
***P < 0.001, unpaired t-test. 
 
 
4.5.2 Target Gene expression in heterozygous and homozygous 
trangenic mice with Ubiquitous Overexpression of 
Glutaminyl-Cyclase (QC) 
 
The mQC mouse model was designed for analyzing the impact of glutaminyl cyclase on the 
neuropathological development of transgenic mice models for Alzheimer`s disease. 
Therefore, mQC transgenic mice were prepared for later crossing with different Alzheimer`s 
disease mouse models, that have been overexpressing the direct substrates of QC AβN3E-42 and 
AβN3Q-42. 
 
Purpose of the project was to verify the overexpression of mQC in mQC-transgenic mice by 
determination of the activity and the expression of the enzyme glutaminyl cyclase in 
heterozygous and homozygous genotypes of this mouse model. Ubiquitous expression is 
driven in the mQC-model by the chicken-beta-actin CAG promoter and mice were bred on a 
C57BL6 background. Generation of transgenic mice was performed at Genoway Germany 
GmbH, Hamburg. 
 
Activity of glutaminyl cyclase was determined in EDTA-plasma in an HPLC based assay (see 
materials and methods chapter 3.7). I analyzed animals homozygous and heterozygous for 
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mQC and used wildtype C57BL6 animals as a control group that showed only endogenous 
mQC activity. I analyzed the activity of glutaminyl cyclase EDTA-plasma of two month old 
female (N = 1) and male (N = 2) homozygous transgenic animals and two wildtype controls 
with an equal genetic background. All homozygous animals were sacrificed at 2 months of 
age. In addition 2 m old female heterozygous (N = 2) and wildtype (N = 2) mice were 
analyzed. Besides the analysis of mQC-activity, the expression of QC-mRNA in kidney and 
brain was examined by real-time RT-PCR. 
 
4.5.2.1 QC-ACTIVITY IN EDTA-PLASMA AND TISSUE 
HOMOGENATES 
 
The aim of the study was to verify the ubiquitous overexpression of the mQC cDNA in the 
transgenic mQC-mouse-model (heterozygous (He) and homozygous (Ho) transgenic 
animals).  The results proof an overexpression of the target gene in both homozygous and 
heterozygous transgenic mice compared to wiltype mice that express mQC only at 
endogenous levels.   
 
Determination of mQC activity was assessed in a HPLC based assay in EDTA-Plasma, while 
in tissue homogenates this assay could not be applied probably due to the high lipid content in 
tissue that interfere with the sample preparation. 
 
In EDTA-Plasma, 2-month-old heterozygous female mQC mice displayed a 21-fold higher 
specific QC activity compared with wildtype littermates, while homozygous 2-month-old 
mice even displayed a 37-fold increased mQC activity in EDTA-plasma. Males were 
generally seen to show 2 – 3-fold higher levels of mQC-activity compared to females in 
EDTA plasma. The expected double increase between homozygous and heterozygous 2 m old 
animals was – in contradiction to female mice - not observed in male mice, where 
homozygous and heterozygous mice turned out to display similar levels of mQC activity. 
Small group sizes may show their impact here. Though, homozygous and heterozygous mQC-
mice proved to own a highly increased QC-activity in EDTA-plasma, giving clear evidence 
for expression of the transgen in these mice. 
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Fig. 26: Activity of glutaminyl cyclase activity in EDTA-plasma of homozygous (Ho), hemizygous (He) 
mice transgenic for QC and wildtype as reference species (WT).  All mice were bred on a pure C57BL6 
background. 
 
4.5.2.2 EVALUATION OF QC-TRANSCRIPT LEVELS USING REAL-
TIME RT-PCR 
 
In brain and kidney, QC mRNA concentrations were strongly increased compared to control 
group (Fig. 27, 28). Compared to female wildtype animals of 2 months of age, age-matched 
heterozygous mQC-transgenic mice showed a 4.4-fold increase in mQC expression, while 
heterozygous male mice revealed even higher expression of mQC with a 7.7-fold mRNA 
level. Homozygous male mQC-mice of 2 months of age showed a 11.3-fold overexpression of 
mQC-mRNA, which is a 1.47-fold increase compared to heterozygous male animals. 
Homozygous females were determined to have a 6.3-fold higher mQC-mRNA expression 
compared to wildtype female animals, which is a 1.43-fold increase compared to 
heterozygous female animals. Therefore, gender-matched expression ratios between 
homozygous and heterozygous animals showed to be highly stable. Homozygous animals 
seem to have an estimated 40% increase in mQC mRNA-expression compared to 
heterozygous mice. 
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Fig. 27: Analysis of expression of glutaminyl cyclase in brain of homozygous, heterozygous mQC-
transgenic and wildtype mice. Group sizes are shown in brackets behind bar denotations. Data are 
corrected with expression of HRPT as a housekeeping gene. 
 
Conclusively, expression analysis in the brain clearly proves overexpression of mQC in 
mQC-transgenic mice. 
 
4.5.2.3 QC-EXPRESSION IN THE KIDNEY 
 
In the kidney expression of heterozygous female mQC-transgenic mice relative to wildtype 
animals was observed to be 326-fold increased, while this ratio was determined to be only 94-
fold increased in heterozygous male mice. Mice homozygous for mQC revealed to have 
generally higher levels of mQC-expression than gender-matched heterozygous littermates. 
Though no stable ratio of expression was found between gender-matched homozygous and 
heterozygous mQC-mice, as has been described for the brain mRNA expression. 
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Fig. 28: Analysis of expression of glutaminyl cyclase in kidney of homozygous and heterozygous mQC 
transgenic and wildtype mice. Group sizes are shown in brackets behind bar denotations. Data are 
corrected with expression of HRPT as a housekeeping gene. 
 
Homozygous female mQC-mice showed a 375-fold increase in mQC mRNA expression, 
while male littermates revealed only a 284-fold increase. This was nearly three times as high 
as expression determined in heterozygous males. Comparison of expression between 
homozygous and heterozygous females revealed only a minor increase in mQC expression in 
homozygous animals. 
 
 
4.5.3 IN VIVO FORMATION OF PYROGLUAMATE Aβ IN TBA1 AND 
TBA2 MICE 
 
In addition to Aβ starting with aspartate at position 1 (Aβ1D), the majority of amyloid Aβ 
peptides in Alzheimer’s disease (AD) brain exhibit a large heterogeneity at their N-terminus. 
The dominant species starts at position 3 with pyroglutamate (Aβ3(pE)), which can be 
converted enzymatically using either N-terminal glutamate (Aβ3E) or glutamine (Aβ3Q) as 
substrate (Fig. 7). Two novel mouse models that express Aβ3-42 peptides under the control of 
the Thy-1 promoter were generated. The TBA1 line expresses Aβ with N-terminal glutamate 
(Aβ3E-42), whereas the TBA2 line expresses Aβ with N-terminal glutamine (Aβ3Q-42). Both 
transgenic Aβ peptides were expressed as fusion proteins with the pre-pro-sequence of 
murine thyrotropin-releasing hormone (mTRH) (Fig. 29b), for transport via the secretory 
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pathway (Cynis et al. 2006). The mRNA expression levels of the transgenic constructs in the 
brain of TBA1 and TBA2 mice were similar (Table 9).  
 
Mouse line Expression level compared to TBA1 Standard error p-value 
TBA1-QC 0.958 0.775 – 1.162 0.760 
TBA2 1.503 0.913 – 1.423 0.054 
Table 9: mRNA expression ratio of the transgenic construct in TBA1 mice (n = 4) compared with double-
transgenic TBA1-QC (n = 3) and TBA2 mice (n = 4). The results of the expression ratio of the transcripts 
were tested for significance by a Pair Wise Fixed Reallocation Randomisation Test, and did not show a 
significant difference between the different mouse lines. The results were normalized to β-Actin mRNA 
levels. 
 
Protein quantification of Aβx-42 and Aβ3(pE) levels in brain lysates of wildtype (WT), murine 
glutaminyl cyclase transgenic (QC), TBA1, TBA1-QC double-transgenic, and TBA2 mice 
revealed significant differences (Fig. 29 c-e). While WT and QC transgenic mice generated 
low amounts of murine Aβx-42 (WT, 1.29 ± 0.91; QC, 1.36 ± 0.61 pg/mg w.w.), TBA1 mice 
elicited 32.57 ± 2.27 pg/mg w.w. Aβx-42, which was significantly more compared to WT mice 
(P < 0.0001). A trend of increased Aβx-42 was detected in TBA1-QC double-transgenic mice 
with 53.29 ± 10.13 pg/mg w.w., which, however, did not reach statistical significance in 
comparison to TBA1 single-transgenic mice (P = 0.06). TBA2 showed a 12-fold elevation of 
Aβx-42 (410.2 ± 21.52 pg/mg w.w) compared to TBA1 (P < 0.0001) and to TBA1-QC double-
transgenic mice (P < 0.0001) (Fig. 29 c). In WT and QC mice Aβ3(pE) was undetectable by 
ELISA (Fig. 29 d). However, there was a significant difference between TBA1 (1.89 ± 0.16 
pg/mg w.w.), and TBA1-QC double-transgenic mice (2.34 ± 0.14 pg/mg w.w.). The TBA1-
QC double-transgenic mice elicited a 1.2-fold increased amount of Aβ3(pE) (P < 0.05). This 
finding indicates that QC catalyzes N-terminal glutamate to pyroglutamate formation in vivo. 
The TBA2 mice showed significantly higher Aβ3(pE) levels (53.23 ± 4.59 pg/mg w.w) than 
TBA1 (28-fold more; P < 0.0001). The ratios of Aβ3(pE) to total Aβx-42 revealed similar 
results. TBA1 mice had a ratio of 0.06 ± 0.005 compared to TBA1-QC double-transgenic 
mice with 0.05 ± 0.005 (P = 0.25). TBA2 mice showed a increased ratio of 0.11 ± 0.015 (P < 
0.0001) (Fig 29 e).  
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Fig. 29: Constructs to generate the transgenic mice and expression profile in brain at 2 months of age. (a). 
Aβ1-42 starts at position 1 with aspartate (D), Aβ3E-42 at position 3 with glutamate (E), and Aβ3Q-42 with 
glutamine (Q). Both N-truncated Aβ3E-42 and Aβ3Q-42 peptides can be converted by QC activity to generate 
Aβ3(pE)-42 (Fig. 7). (b) Schematic drawing of the transgenic vectors. TBA1 and TBA2 transgenic mice 
express either Aβ3(E)-42 or Aβ3(Q)-42 under the control of the Thy1 promoter and are fused to the signal 
peptide of TRH. QC transgenic mice express the murine QC minigene (mQpct) under the control of the 
CAG promoter. ELISA analysis of (c -e) ELISA measurements of Aβx-42 and Aβ3(pE) in brain hemisphere 
lysates of WT (N=6), QC (N=6), TBA1 (N=9), TBA1/QC (N=9), and TBA2 (N=4) mice. (c) Significant 
increase in Aβx-42 levels was found in TBA1 mice, compared to WT controls (P <0.0001). TBA2 showed the 
highest levels of Aβx-42 compared to TBA1 (P < 0.0001, unpaired t-test) and TBA1-QC double-transgenic 
mice (P < 0.0001, unpaired t-test). (d) TBA1-QC double-transgenic mice had increased levels compared to 
TBA1 expression alone. TBA2 mice showed the highest levels of Aβ3(pE) compared to TBA1 (P < 0.0001, 
unpaired t-test) and TBA1-QC double-transgenic (P < 0.0001, unpaired t-test) mice. (e) The same was true 
for the ratios of Aβ3(pE) to total Aβx-42. All mice were 2 months of age. Values are given as means ± s.e.m., 
*P < 0.05. ***P < 0.001. 
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The TBA2 transgenic mice revealed obvious macroscopic abnormalities, including growth 
retardation, cerebellar atrophy, premature death (Fig. 31), and a striking neurological 
phenotype characterized by loss of motor coordination and ataxia (video material, data not 
shown). The body weight at 2 months of age was significantly reduced in TBA2 mice 
(females, 12.20 ± 0.95 g; males, 17.60 ± 0.51 g), compared to WT control littermates 
(females, 19.90 ± 0.40 g; males, 24.43 ± 1.23 g; both significance: P < 0.001).  
Only one TBA2 founder mouse was fertile and was studied in more detail (named TBA2 
line). The offspring showed a strong transgene Aβ expression in CA1 at 2 months of age, 
however, the accumulation of Aβ3(pE) was low (Fig. 32 b). It is suggestive that accumulation 
of Aβ3(pE) is age-dependent, because it was found to be present at 6 months of age in another 
infertile founder after pronuclear injection of the TBA2 construct. This infertile TBA2 
founder revealed a dramatic loss of neurons in the CA1 layer, which correlated well with 
abundant deposition with Aβ3(pE) (Fig. 30 a-c).  
 
Fig. 30: Immunohistochemical staining of the hippocampus of the infertile TBA2 founder mouse, which 
died at 6 months of age. (a) Haematoxylin staining demonstrating thinning of the CA1 pyramidal cell 
layer (arrows). (b) Immunostaining with 4G8 revealed strong Aβ accumulation in the CA1 pyramidal 
layer of the hippocampus. (c) The same staining pattern was observed with an antibody against Aβ3(pE). 
Scale bar: a-c, 200 µm. 
 
 
It may be hypothesized that the lack to detect Aβ3(pE) associated neurodegeneration in CA1 
neurons in the fertile TBA2 line is due to the premature death phenotype at approximately 3 
months of age.  
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Fig. 31: Characterization of TBA2 transgenic mice. (a, b) Picture of wildtype (WT) and TBA2 mice 
showing that TBA2 mice are generally smaller and that they display a crooked posture (b). (c) 
Macroscopic inspection of TBA2 brains revealed that an atrophic cerebellum as compared to age-matched 
WT littermates (2 months-old mice). (d) Both female (N=4) and male (N=4) TBA2 mice showed a reduced 
body weight compared to their age-matched WT littermates (2 months-old mice, N: 3 female, 4 males)) 
(unpaired t-test). (e) TBA2 (N=9) mice displayed a significantly reduced survival rate compared to WT 
littermates (N=6) (P = 0.0002; Logrank Test). Values are given as means ± s.e.m., ***P < 0.001. 
 
The neurological phenotype of the TBA2 line resembles that of mouse models with Purkinje 
cell degeneration (for example(Burright et al. 1995) ). Consistently, TBA2 brain sections 
showed strong immunoreactivity using antibody 4G8 against Aβ (epitope 17-24) 
predominantly in CA1 pyramidal neurons and in Purkinje cells (Fig. 32). Neurons in other 
brain areas were also positive, but the immunoreactivity was less abundant. Diffuse plaques 
were observed in cortex, hippocampus, cerebellum, thalamus and other subcortical areas, but 
were less prominent compared to intraneuronal staining (not shown). While low number of 
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plaques was detected in the cerebellar molecular, piriform and granular layers, most Aβ 
immunoreactivity was found associated with Purkinje cells (Fig. 32 e, f). Many, but not all, 
Purkinje cells were positive for AβN3(pE) (Fig. 32 f, g). Neuropathological analysis of TBA2 
mice demonstrated neurodegeneration of Purkinje cells by several observations: (i) The 
Purkinje cells were positive for ubiquitin, a marker for protein degradation (Fig. 32 l). (ii) 
Abundant micro- and astrogliosis was observed in the cerebellar molecular layer (Fig. 32 h-
k). (iii) Loss of calbindin-positive Purkinje cells. Interestingly, extracellular Aβ deposition 
was observed, which was associated with the site of Purkinje cell loss (Fig. 32 m, n). The 
neuropathological observations correlate well with the age-dependent neurological and 
cerebellar atrophy deficits in the TBA2 model (Fig. 31 c). No staining was observable using 
antibodies against hyperphosphorylated Tau (AT8 and PS199) or activated caspase-3 (a 
marker for apoptosis).  
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Fig. 32: Immunohistochemical staining of TBA2 mouse brain (2 month-old mice). (a) Immunostaining 
with 4G8 revealed strong Aβ accumulation in the CA1 pyramidal layer of the hippocampus (inset shows a 
hippocampus overview at low magnification). Limited staining was detected with an antibody against 
Aβ3(pE) (b). (c) Intra (arrowhead) - and extracellular Aβ (asterisk) in the thalamus shown by 4G8 staining. 
(d - e) Aβ staining (4G8) in the cerebellum is almost completely restricted to the Purkinje cell layer. (f – g) 
Most Purkinje cells accumulated pyroglutamate-Aβ as shown by an antibody against Aβ3(pE). (h) GFAP 
staining of a TBA2 mouse revealed prominent Bergmann glia immunoreactivity, whereas wildtype 
animals (i) were consistently negative. The microglia marker Iba1 revealed microglia clusters surrounding 
Purkinje cells and in white matter tracts in TBA2 mice (j) but not in wildtype littermates (k). (l) 
Immunostaining of Purkinje cells with 4G8 (red) and anti-ubiquitin (green) antibodies. Note abundant 
ubiquitin immunoreactivity in 4G8-positive Purkinje cells. (m, n) Double-immunostaining of Purkinje 
cells using antibodies against calbindin (green) and 4G8 (inset shows high magnification of a 4G8- and 
calbindin-positive Purkinje cell). Note absent calbindin (asterisk) and extracellular Aβ staining indicating 
Pukinje cell loss. Only 4G8-positive remnants can be seen. Scale bars: a, e, f, h-k 100 µm; b, c, l-n 50 µm; d 
500 µm; g, inset l, m 20 µm (Stainings done by Dr. Oliver Wirths). 
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5 DISCUSSION 
5.1 DEFICITS IN WORKING MEMORY AND MOTOR PERFORMANCE 
DECLINE IN THE APP/PS1KI MOUSE MODEL FOR 
ALZHEIMER`S DISEASE ARE PARALLELLED BY EXTENSIVE 
NEURON LOSS AND HIPPOCAMPAL SHRINKAGE 
 
The objective of the present study was the characterization of a behavioral correlate to a 
previously described age-dependent axonal degeneration and hippocampal neuron loss in a 
mouse model expressing human mutant APP on a homozygous PS1 knock-in background 
(Casas et al. 2004; Wirths et al. 2006), which has not been previously behaviorally 
characterized. It has been shown in this work that APP/PS1KI, in contrast to PS1KI mice, 
display a severe progressive neurological phenotype characterized by wasting, growth 
retardation, gait disturbances and the development of a thoracolumbar kyphosis, which is a 
special type of spinal deformity characterized by an increased curvature of the thoracic spine. 
This phenotype probably results of progressive motor dysfunction due to age-dependent 
axonal degeneration in the spinal cord. A similar phenotype has also been described in mice 
lacking the huntingtin interacting protein 1 (HIP1) (Metzler et al. 2003) or in mice with a 
mutant methyl-CpG binding protein 2 (MECP2) gene, which represent a model system for 
Rett syndrome, a neurodevelopmental disorder characterized by the loss of language and 
motor skills during early childhood (Shahbazian et al. 2002). Additionally, it was 
demonstrated that APP/PS1KI mice develop an age-dependent decline in working memory as 
tested by Y-maze, cross-maze and T-CAT, starting at the age of 6 months. The ability to 
successfully perform these tests was not affected by the motor deficits at the same age, as 
shown by higher frequencies of arm entries in APP/PS1KI mice in the Y-maze, and 
unchanged mean session duration in the T-CAT free-choice trials. The higher frequency of 
arm entries in the 6 month-old APP/PS1KI mice might be attributed to a higher general 
activity, which has been previously reported in a different APP-transgenic mouse line 
(Ambree et al. 2006). 
 
Working memory assesses recent memory related to the optimal foraging strategy in the wild 
(Dember & Fowler 1958), depends on the integrity of prefrontal and hippocampal systems 
(Divac 1975) and has previously been shown to be impaired in another AD mouse model 
(Lovasic et al. 2005). The decline in working memory coincides with the previously reported 
onset of CA1 neuron loss at the age of 6 months in this mouse model (Casas et al. 2004). 
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APP/PS1KI mice at 6 months of age showed a significantly reduced alternation performance 
in the Y-maze and cross-maze compared to their age-matched PS1KI littermates. This result 
differs from spatial working memory measures in other AD mouse models, where no 
impairment was detected (Lalonde et al. 2004; Savonenko et al. 2003). As this task does not 
place a high demand on hippocampus-dependent learning and memory, it is perspicuous that 
only mice with severe hippocampal deficits show impairment in this task. The T-CAT has 
been shown previously to be a valuable tool to measure hippocampal dysfunction (Gerlai 
1998). In this spontaneous alternation task, APP/PS1KI mice performed significantly worse 
than their PS1KI littermates at the age of 6 months, with alternation rates below chance level. 
Two month-old APP/PS1KI mice were not different in both working memory tests, pointing 
to an age-dependent process, as expected. All working memory tasks show a strong decline in 
the measured performance in APP/PS1KI mice between two and six months of age, while 
from six months on to the age of twelve months only minor changes in working memory 
performance were detected. This can be explained by the fact, that around 80% of total neuron 
loss observed in APP/PS1KI mice hippocampal CA1 region occurs up to six months of age, 
while only 20% take place between six and twelve months. 
 
A variety of Alzheimer’s disease mouse models with the development of motor impairment 
and spinal pathology have been previously described; however, most of them express human 
Tau protein and none of them harbors amyloid pathology (Lewis et al. 2000; Spittaels et al. 
1999; Terwel et al. 2005). An abnormal paw-clasping reflex has been described in different 
APP/PS1 mice (Wirths et al. 2006; Wirths et al. 2006), and in mice transgenic for human 
four-repeat tau (Probst et al. 2000) or human apolipoprotein E4 transgenic mice (Tesseur et 
al. 2000), which all displayed marked signs of axonal degeneration. Detailed quantification of 
this clasping phenotype revealed that it is highly significant in APP/PS1KI mice already at 
6 months of age, accompanied by a reduced average stride length becoming significant at the 
same time point.  
 
Deficiencies in motor performance, including gait disturbances and postural deficits have 
been reported in AD patients, raising the question whether underlying axonal alterations 
contribute to this particular feature of the disease (O'Keeffe et al. 1996; Pettersson et al. 2002; 
Scarmeas et al. 2004). It has further been shown that motor signs have a predictive value in 
AD, as e.g. postural-gait abnormalities carry an increased risk for institutionalization and 
mortality (Scarmeas et al. 2005). A tremendous decrease of motor abilities was observed 
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during aging in the APP/PS1KI mice. Highly significant deficits in the balance beam, string 
suspension and vertical grip hanging tasks were detected as early as 6 months of age. These 
mice further showed a reduced latency to fall in the rotarod task, compared to age-matched 
PS1KI mice. However, a clear improvement was noted during training for both groups, 
leading to the assumption that the execution of motor behavior rather than motor learning 
abilities is impaired in APP/PS1KI mice. A similar finding has been reported in 12 month-old 
APPswe/PS1M146L transgenic mice (Ewers et al. 2006). The rotarod task has been shown to be a 
sensitive indicator of cerebellar lesions in mouse mutants (Lalonde & Strazielle 2001). 
However, due to the used Thy1.2-promotor construct, APP expression in this brain region is 
very restricted. Therefore, axonal deficits, loss of connecting neurons with the cerebellum 
and/or impairment of other brain regions like the motor cortex and basal ganglia might result 
in the described motor phenotype. As the PS1KI mice were used as a control group, it is of 
particular interest that no impairment in motor coordination tasks has been recently reported 
in a different homozygous PS1KI (I213T) mouse model (Lalonde & Strazielle 2005). 
 
Analysis of exploration, anxiety and locomotor activity in the open field paradigm revealed 
no age- or genotype-dependent deficits in the total traveled distance or the time spent in the 
inner (exploration) zone at the two analyzed time points. A similar result has been previously 
reported in 7 month-old APPswe + PS1/∆E9 mice (Lalonde et al. 2004) or in 13 month-old 
APPswe mice (Lee et al. 2004), which did not differ from control mice in this task. A strong 
reduction in rearing events was detected in 9 month-old APP/PS1KI mice, which is in line 
with motor deficits revealed in the sensory-motor task battery. Rearing behavior in the open 
field has been reported to reflect exploratory behavior and motor activity (Archer 1973). 
However, considering the unchanged traveled distance in the open field and the increased 
number of arm entries in the Y-maze, the reduced rearing frequency is most likely due to 
impaired motor activity, rather than reduced exploratory drive. 
 
Several APP transgenic models have been demonstrated to show impairments during 
acquisition in the hidden platform version of the Morris water maze, a task which has become 
one of the standard measures of working memory deficits in mice (Hsiao et al. 1996; Janus 
2004; Lalonde et al. 2002). Analysis of swimming parameters revealed a significantly 
reduced swimming distance and speed in APP/PS1KI mice of 6 months of age and older, 
accompanied by alterations in swimming behavior in aged mice (12 months). Therefore, the 
often used Morris water maze task as a test for reference memory impairment was omitted in 
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the APP/PS1KI mouse model. The underlying motor deficits displayed by the forced 
swimming task preclude drawing any conclusions from these experiments. The assessment of 
reference memory using tasks like the Morris water maze therefore has to be always 
combined with an extensive analysis of motor performance in order to avoid misinterpretation 
due to an overlap of motor and cognitive deficiency.  
 
Axonal deficits have been previously published in another APP/PS1 transgenic mouse model 
(Wirths et al. 2006), as well as in APP single transgenic mice already at a young age well 
before other neuropathological lesions were observed (Stokin et al. 2005). Stokin et al 
showed that axonal defects consisted of swellings that accumulated abnormal amounts of 
microtubule-associated and molecular motor proteins, organelles, and vesicles. Impairing 
axonal transport by reducing the dosage of a kinesin molecular motor protein enhanced the 
frequency of axonal defects and increased the level of intraneuronal Aβ peptides and plaque 
deposition. The authors concluded that reductions in microtubule-dependent transport may 
stimulate proteolytic processing of APP, triggering typical AD pathology. In the APP/PS1KI 
model the situation is different. Due to overexpression of APP and expression of mutant 
knocked-in PS1, there is a robust and early intraneuronal accumulation of a variety of N-
modified Aβ peptides (Wirths et al. 2006). It is important to note that 85% of the Aβ peptides 
end at position 42 (Casas et al. 2004). It is to speculate that the two PS1 knock-in mutations 
induce a loss of function in β-secretase cleavage of APP, therefore elevated C99 levels were 
observed in these mice, together with an increase in Aβx-42 levels (Casas et al. 2004). 
Recently, Kumar-Singh et al. have demonstrated that several PS1 mutations significantly 
increased the ratio of Aβ42/Aβ40 in vitro by significantly decreasing Aβ40 with accumulation 
of APP C-terminal fragments, a sign of decreased β-secretase activity (Kumar-Singh et al. 
2006). This suggests that Aβ40 might be protective for neuronal integrity; however, it has been 
recently shown that increased Aβ40 levels lead to congophilic amyloid angiopathy (CAA) and 
microvessel rupture in a transgenic mouse model (Herzig et al. 2004). The two PS1 mutations 
(M233T/L235P) in the APP/PS1KI mouse may therefore also induce a loss of PS1 function 
resulting in reduced Aβ40 levels and an increased Aβ42/Aβ40 ratio. The consequence clearly is 
an increase in intraneuronal Aβ42 levels, which might induce axonal degeneration in brain and 
spinal cord and a robust neuron loss in CA1 of the hippocampus. I have demonstrated that 
both pathological features coincide with the observed changes in body weight, body shape, 
working memory and motor performance. It has been previously shown that plaque load does 
not correlate with neuron loss in another AD transgenic model (Schmitz et al. 2004). 
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Moreover, plaque-independent axonal degeneration has been previously demonstrated 
(Wirths et al. 2006; Wirths et al. 2006) Therefore, intraneuronal Aβx-42 accumulation as an 
early pathological event might promote the observed behavioral deficits.  
 
 
5.2 PATHOLOGY-DEPENDENT DEVELOPMENT OF INFLAMMATION 
IN AN APP/PS1KI MOUSE MODEL OF ALZHEIMER`S DISEASE 
 
APP/PS1KI mice used for this study are characteristic for developing a severe age-depending 
phenotype of Alzheimer disease. This phenotype is prominently present at six months of age 
and features besides massive accumulation of intracellular Aβ and extracellular Aβ plaque 
build-up also a striking neuron loss in hippocampal CA1 region evident already at six months 
of age, motor deficits in accordance with axonopathy as well as a remarkable loss in working 
memory performance proven by results from working memory related tasks like Y-, T-maze 
(Casas et al. 2004; Wirths et al. 2007;Wirths et al. 2002; Wirths et al. 2006). Contrastingly, at 
2 months of age APP/PS1KI mice showed no eye-catching phenotypical difference compared 
to age-matched PS1KI control mice. In terms of immunohistochemical consideration the most 
eminent difference between these two genotypes at 2 months of age is an extensive positive 
immunohistostaining for intracellular Aβ in hippocampal CA1 neurons, which obviously is 
not sufficient to induce any observable phenotype in APP/PS1KI mice at least with the motor 
and memory tests of our choice. A detailed histochemical and behaviour analysis of these 
mice can be looked up in Casas et. al. 2004 and Wirths et al. 2002, 2004, 2006 and 2007 
(Casas et al. 2004; Wirths et al. 2007; Wirths et al. 2002; Wirths et al. 2006). 
 
Going well in line with the unobtrusive behavioural phenotype and the poor histochemical 
findings according to Aβ plaque pathology in young APP/PS1KI animals, glial fibrillary 
acidic protein (GFAP) came out to show the only significantly increased expression on the 
mRNA level at two months of age. In AD brains GFAP is prominently upregulated in the 
vicinity of amyloid plaques. In young APP/PS1KI mice with beginning extracellular plaque 
deposition upregulated GFAP mRNA-synthesis may indicate beginning activation of 
astrocytes as a result of intracellular Aβ formation in CA1 neurons.  
 
No broader indication of early inflammatory processes was detectable, though a wide variety 
of genes involved in several complement inflammation pathways was observed. One 
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explanation could be that the formation of extracellular plaque material is the main trigger for 
inflammatory responses in the brains of this AD mouse model. Extracellular plaque pathology 
increases quickly and dramatically in this APP/PS1KI mouse mode from the second month 
on. Extracellular plaque deposits are abundantly present at six months of age while PS1KI 
control mice are showing no plaque pathology at all at any age. 
 
With this assumption in mind, it is no surprise at all to find a broad range of inflammatory 
genes massively upregulated in their mRNA expression in APP/PS1KI mice compared to 
PS1KI control mice at six months of age. The pattern of upregulation indicates mainly a 
highly intense activation of the glia system in APP/PS1KI mice at six months of age. Glia 
cells are the most common cell type in the human brain and represent a discrete population of 
phagocytes that appear first as colonies of embryonic brain and that migrate during further 
development throughout the CNS (Giulian 1999). Microglia are present in white and gray 
matter as well. The glia system of the brain is subdivided in several cellular subspecies, most 
important of them thought to be implicated in inflammation response are microglia and 
astroglia cells (astrocytes). Microglia are mostly composed of mesodermally derived 
macrophages. Microglia cells are ascribed to hold a putative role for neurons guarding their 
functions in the CNS.  They are believed to act as immunocompetent defense cells taking lead 
in organization of the immune response of the CNS towards inflammation events. In healthy 
brain, microglia exist in general in a quiescent state, that is characterized by low expression of 
surface receptors, minimal secretory activity, and - in case of contact with astroglia or neurons 
- minimal migratory behaviour. Microglia cells switching from the quiescent to the reactive 
state are one of the hallmarks of AD immune pathology (Giulian 1999). Activated microglia 
are known for their capability to uptake extracellular Aβ, what appears to be an attempt to 
remove this excessively spreading protein from the brain (Chen et al. 2006). It is well known, 
that Aβ and neuritic plaques are capable to induce activation of microglia in AD affected CNS 
leading also to clustering of microglia around amyloid plaque deposition sites in the brain 
(Tuppo & Arias 2005). As a consequence of activation, microglia start to secrete a broad 
range of scavenger receptors, cytokines, reactive oxygen species and complement proteins – 
all inflammatory mediators involved in triggering numerous signalling pathways.  
 
In six-month-old APP/PS1KI mice all signs of extensive glia activation were found in 
abundance.  
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Most prominently increased was GFAP, which has been already increased at two months of 
age. GFAP is expressed in astrocytes and APP/PS1KI mice show a well-defined pattern of 
astrogliosis and reactive astrocytes at two and six months of age as can be seen from 
immunohistochemical analysis using GFAP-directed antibody (Fig. 20, 21).  The detected 
increase of GFAP on mRNA and protein level could be caused by higher expression rates of 
GFAP in activated astrocytes or by the increase of the total number of astrocytes in the brain 
due to proliferation as a follow-up process to Aβ-induced inflammation separately or in a 
coactive manner. 
 
Msr2 and analysed members of toll like receptor family (TLR2, TLR4, TLR7, TLR9) did also 
reveal strong upregulation of mRNA levels in APP/PS1KI mice. While scavenger receptors 
have been implicated in the binding process from Aβ to astrocytes and in the clearance of 
fragmented DNA from the brain (Alarcon et al. 2005; Li et al. 2004b), toll-like receptors 
(TLRs) are a group of pattern-recognition receptors in the innate immune system of the brain, 
that have been shown to play a crucial role in activation of the microglia system. In response 
to insults by for example pathogens and damaged host cells, TLRs can induce the activation 
of phagocytes and tissue dendritic cells, that leads to the secretion of cytokines, chemokines 
and other co-stimulatory molecules needed for protective immune responses, efficient 
damaged tissue removal and for the stimulation of adaptive immunity (Tahara et al. 2006). 
Increased TLR signalling is well described to induce a broad range of genes implicated in 
phagocytosis and inflammation. Chen et al. reported promoted cellular uptake of Aβ in 
primary murine microglial cells from newborn C57BL/6 mice and murine microglial cell line 
N9 by activation of TLR2 (Chen et al. 2006). This is in well compliance with the intense 
upregulation especially of TLR2 in six-month-old APP/PS1KI mice compared to PS1KI 
littermate controls. Furthermore, Tahara et al. were able to show, that activation of microglia 
(BV-2 cell) with specific ligands for TLR2, TLR4 or TLR9 markedly boosts the uptake and 
ingestion of Aβ in vitro (Tahara et al. 2006). 
  
Secondly, I observed expression patterns of a variety of cytokine genes. Cytokines are 
inflammatory mediators produced by activated microglia, that trigger and contribute to the so 
called “cytokine cycle”. They represent as well as their nearby but nevertheless distinct 
relatives from the family of chemokines intercellular and intracellular signalling factors. A 
number of cytokines and chemokines as well has been found to be upregulated in AD 
compared to non demented (ND) individuals. This holds especially true for the major 
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proinflammatory mediators IL-1β, IL-6, and TNFα, which can induce cytotoxic or cytopathic 
effects in the CNS (Dickson et al. 1993).  
 
Interleukin1-β has been shown to be increased on protein level in homogenates from frontal, 
parietal, temporal cortex, hypothalamus, thalamus and hippocampus in humans with AD 
compared to controls (Cacabelos et al. 1994). Microglia-derived IL-1β is described as a 
potent immunomodulating cytokine that triggers various inflammatory mediators in astrocytes 
and neurons (Mrak et al. 1995). IL-1β is directly localized to plaque-associated microglia and 
appears to be directly involved in AD pathophysiological alterations (Griffin et al. 1989). 
However, in APP/PS1KI mice no statistical significant increased expression of IL-1β could be 
found at any timepoint. Though, it is to mention, that at ten months of age there is a statistical 
trend, indicating a tendency to increased IL-1β mRNA-levels in comparison to age-matched 
PS1KI mice. 
 
Surprisingly, also the expression of the proinflammatory cytokine IL-6 remained unchanged, 
although increased protein levels have beein found in human AD brains (Hampel et al. 2005). 
IL-6 is a pleiotropic cytokine that mediates immune response and inflammatory reactions 
affecting CNS cell growth and differentiation (Akiyama et al. 2000). During development, 
IL-6 is expressed in the nervous system ubiquitously. Microglia, astroglia, neurons, and 
endothelial cells are described as capable to synthesize IL-6 (Frei et al. 1989; Hampel et al. 
2005; Marz et al. 1998). 
 
TNF-α as a further proinflammatory cytokine secreted by activated macrophages and 
microglia is believed to promote cell survival and death in the CNS. An increase of TNF-α 
was immunohistochemically shown in the vicinity to senile plaques, implying its participation 
in Aβ-induced inflammation (Akiyama et al. 2000; Tuppo & Arias 2005; Zhao et al. 2003). 
Recently, though the mechanism remains unsolved, it was shown that TNFα plays a pivotal 
role for the neurotoxicity of Aβ (Zhao et al. 2003). Contradictory, some reports also suggest a 
neuroprotective function of TNF-α by reducing cdk5 induced tau hyperphosphorylation 
(Orellana et al. 2007). 
 
IL-10 is thought to be an anti-inflammatory cytokine capable of suppressing microglia 
activation by the Aβ-component of senile plaques and of protecting dopaminergic neurons 
against inflammation-mediated neurodegeneration (Arimoto et al. 2006; Szczepanik et al. 
  
 
 Page 97/137 
2001). However, despite massive glia activation mRNA-levels of IL-10 kept unchanged 
relative to age-matched controls at 2, 6 and 10 months of age. On the other hand Rota et al. 
recently reported about unchanged levels of IL-10 in sera and CSF of AD patients compared 
to non demented controls (Rota et al. 2006). 
 
A further multifunctional cytokine said to be implied in the progression of AD pathology is 
transforming growth factor beta (TGF-β). TGF-β is produced by glial and neuronal cells as 
well. TGF-β has been described to be upregulated in response to brain injury, stroke and 
under neurodegenerative conditions. Furthermore, TGF-β is thought to possess angiogenic 
properties besides its capability to promote amyloidogenesis. Tarkowski et al. reported 
evidence about increased intrahecal levels of the angiogenic factors vascular endothelian 
growth factor (VEGF) and TGF-β (Tarkowski et al. 2002). Well supplemented from the 
literature, I found a clearly significant increase of TGF-β in APP/PS1KI mice at six and ten 
months as well. In CSF of human AD patients a significant correlation between levels of 
TNF-α and TGF-β has been described and it has been suggested, that TNF-α could be 
responsible to trigger the production of TGF-β at least to a certain extent (Tarkowski et al. 
2002). However, with TNF-α showing just a statistically not significant trend for age-
dependent upregulation in mRNA-expression, I cannot derive clear evidence for this 
connection from our data nor can I exclude it. Also a beneficial function of TGF-β has been 
reported. Wyss-Coray et al. described in a transgenic mouse model overexpressing hAPP and 
TGF-β, that increased expression TGF-β promotes microglial Aβ clearance and reduces 
plaque burden (Wyss-Coray et al. 2001), pointing to a protective role of TGF-β in AD 
pathology. 
 
Interestingly, angiogenesis implicated factors VEGF mRNA expression was slightly 
significant upregulated in APP/PS1KI mice at six months but not any more at ten months of 
age. The perception of angiogenesis is the formation of new blood vessels from existing 
vasculature. Normally, angiogenesis is implicated in embryogenesis, tissue growth, 
development and regeneration, but it also underlies the advancement of cancer and 
inflammation processes (Pogue & Lukiw 2004; Semenza 2003; Zadeh & Guha 2003). 
Hypoxia has been shown to induce higher expression of VEGF, while IL-1β is known to 
being able to substitute for key aspects of hypoxia signalling, including induction of VEGF 
gene expression (Ottino et al. 2004; Pogue & Lukiw 2004). 
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The cytokine receptor MCSF-R (macrophage colony stimulating factor) is expressed in 
macrophages, glia and neurons as well and has been found to be elevated expressed in plaque 
associated and in reactive microglia. It has been previously shown that MCSF-R strongly 
fosters proinflammatory effects of Aβ on cultured microglia cells and is highly capable of 
activating microglia and other macrophage-like cells (Murphy et al. 2000). Increased MCSF-
R expression has been reported in brain microglia of a mouse model for mechanical injury 
and ischemia stroke (Raivich et al. 1998). Moreover, MCSF-R is believed to function as a 
signalling molecule that is implicated in directing activated microglia to sites of insult by 
promoting cell migration and proliferation (Giulian 1999). Our observation of highly 
upregulated expression of MCSF-R in APP/PS1KI mice at six and ten months of age 
featuring massively activated glia cells fits well to the assumed function of this protein. 
 
The cell surface glycoprotein major histocompatibility complex type II (MHC-II) has been 
reported to be upregulated in activated microglia of human AD by numerous reports, 
especially in brain regions of pathological relevance for this disease like e.g. the hippocampus 
(Parachikova et al. 2006; Perlmutter et al. 1992). Surprisingly, no age-dependent increase of 
MHC-II was found in APP/PS1KI mice. Moreover, although not statistically significant, an 
age-dependent decline of MHC-II expression seems to take place in APP/PS1KI mice. This is 
in contrast to the literature, where for example even in normal ageing a continuous 
upregulation of MHC-II is being reported (Akiyama et al. 2000; Perry et al. 1993; Streit & 
Sparks 1997). 
 
F4/80 and CD11/B are also well defined markers for detection of activated microglia. Both 
were found to be highly significant upregulated according to their level of mRNA expression 
in APP/PS1KI mice at six and ten months of age. This can be interpreted as additional 
underlinement of the inflammation pathology of the glia system in these mice. Again, it has to 
be noted, that the increase in gene expression is more incisive comparing six to two month old 
APP/PS1KI mice than ten and six months old animals. 
 
FAS is a gene often brought into discussion about apoptotic neuron cell death in AD and 
represents a part of the death receptor subfamily. FAS has been reported to be associated with 
senile plaques and astrocytes of AD patients (Nishimura et al. 1995) and in tangle bearing and 
non-tangle bearing neurons in the frontal cortex of AD patients. Several downstream enzymes 
of FAS belonging to the caspase family are also implicated in various apoptotic pathways 
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(Yew et al. 2004). In APP/PS1KI mice, FAS was found to show highly significant 
upregulation at six months and ten months as well compared to age-matched controls.  
However, if the upregulation of FAS can be interpreted as an indication for apoptosis induced 
neuron death in APP/PS1KI mice is to be provided with a strong questionmark. TUNEL-
staining in six months old APP/PS1KI mice did not reveal any positive stained neurons (data 
not shown). It has to be mentioned, that the responsibilty of apoptotic processes for neuron 
death in AD and neurodegenerative diseases in general is still a matter of intense debate and 
widely questionmarked by some researchers (Jellinger 2006). 
 
Recently, in AD patients and two different APP/PS1 AD mouse models an prominent 
upregulation of S100A6 protein was reported. S100A6 is an acidic Ca2+/Zn2+ binding protein 
with a 11 kDa molecular weight and is part of the S100 family. 
S100A6 immunoreactivity was shown to be concentrated in astrocytes surrounding classical 
senile plaques with a dense core of Aβ as well as to a minor extent also in diffuse plaques. 
Astrocytes showing a staining for S100A6 were also positive for GFAP and S100B protein 
(Boom et al. 2004). The authors of this study speculate about an implication of S100A6 in the 
regulation of Ca2+ and Zn2+ homeostasis in AD, based on the findings that intracellular Ca2+ 
levels have been shown to arise induced by aggregated Aβ and, secondly, that elevated 
concentrations of Zn2+ have been reported for neocortical areas and Aβ deposits (Boom et al. 
2004). 
 
In APP/PS1KI mice osteopontion (SPP1) was significantly higher expressed at six and ten 
months in comparison to age-matched PS1KI control mice. 
Osteopontin is a secreted phosphoprotein and multifunctional Ca2+ binding cytokine inflicted 
to diverse biological functions, including inflammation, oxidative stress, cell migration and 
antiapoptotic processes (Meller et al. 2005; Wung et al. 2007). In inflammation SPP1 is 
believed to play a role both in acute and chronic inflammation and to be involved in the 
recruitment of macrophages and T-cells (Mazzali et al. 2002). Furthermore osteopontin is of 
importance in cell adhesion, stress-related angiogenesis and macrophage-directed IL-10 
suppression (Akama et al. 1998). Besides their potential to enforce direct damage, reactive 
oxygen species (ROS) have also been shown to change cell signalling pathways, which may 
lead to further deleterious effects. Also, Aß has been shown to increase several markers 
typical for oxidative stress, e.g. superoxide anion production rises in microglia cells treated 
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with Aß. Oxidative stress in general is believed to foster neuronal dystruction in AD brains by 
lipid peroxidation, tyrosine nitrosylation or DNA oxidative damage (Akama et al. 1998). 
 
To get an impression about the AD affected brains response to oxidative stress, I observed the 
expression pattern of the family of metallothioneins displaying some important defense 
proteins against free radicals. The human brain is compared to other organs much more at risk 
to get damaged by free radicals, because its cell membranes are built up to a especially high 
degree by polyunsaturated fatty acids that are especially prone to oxidation by ROS. 
Furthermore the brain itself produces significant amounts of nitric oxide and owns only poor 
to moderate enzyme activities of oxidative stress defense enzymes like catalase, superoxide 
dismutase and glutathione peroxidise (Carrasco et al. 2003). 
 
 There is compelling evidence from the literature, that the members of metallothionein family 
accomplish a neuroprotective mission in the inflammation affected brain by protecting cells 
from oxidative damage (Carrasco et al. 2006; Carrasco et al. 2003; Giralt et al. 2002; Giralt et 
al. 2002; Penkowa et al. 2006). Metallothioneins are small, cystein-rich intracellular proteins, 
that are almost ubiquitously expressed. Metallothioneins are known to possess a high affinity 
for binding Zn2+ and Cu2+. In rodents, the family of metallothioneins subdivides into four 
distinct proteins classified as metallothionein 1 – 4 (MT-1, MT-2, MT-3, MT-4). MT4 is the 
only one not expressed in the brain and therefore has not been in the scope of this study. MT-
1 and MT-2 are expressed coordinatively in CNS and in most tissues as well (Carrasco et al. 
2003), whereas MT-3 is the only family member that is expressed exclusively in the brain. 
Expression of MT-3 takes place predominantly in neurons but is also reported for astrocytes 
under special circumstances. In APP/PS1KI mice, a strong increase of gen expression for 
MT-1, MT-2 and MT-3 was observed at six months of age compared to PS1KI control mice 
while no significant change was found at two months of age. These findings perfectly 
underline the often made presumption that AD affected brains try to counteract the deleterious 
effects of oxidative stress by expression of protective proteins like metallothioneins. 
Interestingly, again at ten months of age no further increase in the expression of 
metallothionein genes could be detected in a direct comparison to the expression level 
observed at six months of age in APP/PSKI mice. 
 
Another main source of oxidative stress in AD is anticipated to be founded in disturbances of 
iron metabolism in the brain. Although iron is essential for cell metabolism, it is also known 
  
 
 Page 101/137 
to display a source of cytotoxicity in case of disturbance of this metabolism (Castellani et al. 
2007; Wung et al. 2007). Recently, osteopontin has been reported to act as a potent 
neuroprotectant against ischemic injury due to stroke (Meller et al. 2005). Wung et al. 
reported recently SPP1 to be 41% increased in AD hippocampal neurons compared to age-
matched ND controls, while no other neuronal cell types were stained. SPP1 expresssion was 
found to be dependent upon Aß load (Wung et al. 2007). The authors suggested that SPP1 
upregulation may be a result of cell-cycle related changes and/or may work as a compensatory 
response to neuronal degeneration in AD affected brain (Wung et al. 2007). 
 
While microglia in general are known to play neurotrophic roles in the healthy brain, in AD 
research the main focus is directed to the potential neurotoxic actions of the glia system. 
Activated microglia and astrocytes are capable to secrete a broad range of pro-inflammatory 
cytokines like interleukin-1ß and neurotoxic substances like free radicals and thereby 
contribute to AD pathology (Hu et al. 1998). For example activated glia cells are suspected to 
be implicated in the formation of reactive oxygen species (ROS) in the brain and therefore 
contribute to the increase of oxidative stress often reported in brains of AD. Furthermore, 
reactive astrocytes are known to produce nitric oxide mediated by cytokine-induction of 
inducible nitric oxide synthase (iNOS) (Moore & O'Banion 2002). 
Egana et al. reported that iron induced oxidative stress can modify tau phosphorylation 
patterns in hippocampal cell cultures from E18.5 rat embryos (Egana et al. 2003). High 
concentrations have been reported in human brain cells, that can be released from dying cells 
to give rise to the production of highly aggressive hydroxyl radicals in a Fenton reaction like 
pathway (Castellani et al. 2007; Mattson 2004). 
 
Transferrin (Trf) and Ferritin light chain (Ftl) mRNA expression were found to be 
significantly upregulated at six and ten months of age in APP/PS1KI mice compared to age-
matched PS1KI controls. With transferrin and ferritin light chain the expression of genes 
whose corresponding proteins are known for their iron binding properties and their 
implication in cell iron metabolism were analyzed. Transferrin is the predominant protein for 
iron transport and essential for surviving. Weekly injections of Trf were reported to be crucial 
to keep Trf-deficient mice alive (Kaplan et al. 1988). Diferric transferrin is taken up by the 
cell via endocytosis dependent on and mediated by expression of the transferrin receptor 
located on the surface of the cells (Koeller et al. 1989). Expression of Trf receptor is known 
to be directly controlled by iron concentrations (Casey et al. 1989). 
  
 
 Page 102/137 
 
Ferritin light chain is another main player in the cellular iron management and is mainly 
considered to function as an intracellular iron storage protein (Connor & Menzies 1995). 
Ferritin light chain has been associated with slow uptake of iron and promotion of iron 
mineralization at the ferritin core (Arosio et al. 1991; Connor & Menzies 1995).  
Upregulation of the expression of iron metabolism enmeshed proteins may be interpreted as 
an attempt of the cell to encounter excess iron and its pernicious follow-up effects in 
oxidative stress cascade in AD pathology affected mouse brain.  
 
In conclusion, our study yields new insights in the APP/PS1KI mouse model of AD and 
provides a detailed analysis of the expression pattern of inflammation associated genes in 
these mice. Furthermore I compared the development of inflammatory processes to the 
progress of AD-like pathology in these mice. The bottom-line is, that inflammation appears to 
be a follow-up event to the development of AD pathology with the formation of extracellular 
plaque deposits standing in the focus of potential inflammation triggering events. AD referred 
pathological process in APP/PS1KI mice is next to its summit already at six months of age. 
Therefore it can be understood, that the most prominent changes in upregulation of 
inflammation connected genes are observed from two to six months, while – in most cases - 
only very modest changes were detected comparing six and ten months old APP/PS1KI mice. 
 
As a result of this work, the APP/PS1KI mouse model may be considered as a suitable model 
to observe the widely discussed potential beneficial effects of anti-inflammatory therapies on 
the progress of AD. The APP/PS1KI model may be especially appropriate for such studies not 
only because of the rich potential read-out on the molecular level as shown in this study, but 
also because its read-out on the behavioural and stereological level, where these mice display 
severe working memory and motoric deficits as well as extensive neuron loss from six months 
of age on. 
 
 
5.3 CHOLESTEROL AS A BIOMARKER IN ALZHEIMER`S DISEASE 
 
I studied plasma cholesterol levels in transgenic mouse models of Alzheimer’s disease and 
control mice and found a significant decrease of plasma cholesterol in the APP transgenic 
animals which were on a homozygous PS1 knock-in background. Total Plasma cholesterol 
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levels remained mostly unchanged in young and aged wildtype, PS1KI and APPSL control 
mice. 
The finding of decreased plasma cholesterol in aged and pathology affected APP/PS1KI mice 
is well in line with numerous epidemiological studies, that report about decreased plasma 
cholesterol levels in AD patients (Kuusisto et al. 1997; Panza et al. 2006; Solfrizzi et al. 
2002). Moreover, data from the Italian Longitudinal Study on Aging (ILSA) (2983 
participants) suggested, that there is no relation between higher plasma cholesterol and an 
increased risk for progression of mild cognitive impairment (MCI) to dementia.  A 
multivariate analysis of this study yielded, that only age was a risk factor for incident MCI, 
while a protective effect was suggested for higher level education and increased serum 
cholesterol (Solfrizzi et al. 2004). 
 
Recently, Mielke et al. reported in a population-based 70-year-old birth cohort followed for 
18 years that increasing levels of plasma total cholesterol at ages of 70, 75, and 79 are related 
to a reduced risk of dementia between ages 79 and 88 (Mielke et al. 2005). However, the 
association of high levels of plasma cholesterol during late-life with a decreased risk of AD is 
in contrast to other reports that suggest high total plasma cholesterol in mid-life to be a risk 
factor for later dementia (Kuusisto et al. 1997). These opposing results may derive from the 
timing of total cholesterol measurement related to age and clinical onset of dementia. One 
hypothesis may be, that in mid-life individuals prone to develop dementia in their later life, 
levels of total plasma cholesterol start to decline several years before onset of the disease. 
Well in line with this hypothesis, a retroperspective study on autopsy cases of over 40 years 
old patients revealed a significant correlation between increased plasma cholesterol levels in 
mid-life period and the presence of amyloid deposition in these patients brain (Pappolla et al. 
2003). 
Our finding of decreased plasma cholesterol in aged APP/PS1KI mice may support the 
hypothesis of decreased plasma cholesterol in late-life as an accompanying factor during 
development of dementia. Because young and normal control mice showed mostly unchanged 
levels of plasma cholesterol, in APP/PS1KI mice decline of plasma cholesterol seems to co-
occur with progression of AD-pathology. 
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5.4 24(S)-HYDROXYCHOLESTEROL AS A BIOMARKER IN 
ALZHEIMER`S DISEASE 
 
I found no significant change in the ratio of 24(S)-hydroxycholesterol from two to six months 
neither for wildtype, APP751SL, PS1KI nor APP751SLxPS1KI mice. For the first three mice 
models these results were anticipated, because all of these three genotypes show no 
significant pathological change like abundant plaque formation or neuron loss at 6 months-of-
age.  
 
If the hypothesis of 24(S)-hydroxycholesterol as a biomarker correlated to AD pathology in 
APP/PS1KI mice should held true, in the APP751SLxPS1KI mice an increased ratio of 24(S)-
hydroxycholesterol to total cholesterol would have been expected. These mice show a 
massive neuron loss and abundant plaque pathology accompanied by extensive 
neuroinflammation already at six months of age. An increased efflux of 24(S)-
hydroxycholesterol from the brain to the plasma has been hypothesized as an early biomarker 
of AD (Lutjohann et al. 2001; Papassotiropoulos et al. 2002). Surprisingly, no increase of the 
ratio of total to 24(S)-hydroxycholesterol was detected in this mouse model comparing six 
and two-month-old animals, though AD pathology is far developed at the latter age.  This 
result seems to us very noteworthy because this mouse model recapitulates the 
neuropathology of AD very well. First signs of Aβ deposition in APP751SL/PS1KI mouse 
brain is seen at 2.5 months of age compared to six months in APPSL mice as previously 
described (Casas et al. 2004). APP751SL/PS1KI mice develop a marked reduction of the 
hippocampal pyramidal cell layer thickness that is particularly prominent in the CA1/2 regin 
at 10 months of age in both males and females. Female APP751SL/PS1KI mice show a 
hippocampal CA1/2 neuron loss of 33% at six months and 41% at 12 months of age, as male 
animals showing no thinned out pyramidal cell layer at six months of age by macroscopic 
analysis. The observed CA1 neuronal loss in APP751SL/PS1KI mice extends homogenously 
throughout the pyramidal cell layer and is not related to the local proximity of extracellular 
Aβ deposits. It is therefore distinct from the neuronal loss observed in most other transgenic 
models, which has been limited to the close vicinity of Aβ deposits. In summary, 
APP751SL/PS1KI mice represent the first transgenic model of AD showing early onset and 
severe neuronal loss. 
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The use of mouse models to study the coherences  between cholesterol metabolism and AD is 
well established (Refolo et al. 2001). In the present model I did not find any evidence for 
24(S)-hydroxycholesterol plasma concentration as an early onset biomarker for AD as 
proposed in other studies (Kolsch et al. 2003; Papassotiropoulos et al. 2002; Schonknecht et 
al. 2002).  
 
It has been described in man that about 90% of 24(S)-hydroxycholesterol is of cerebral origin 
because the 24(S)-hydoxylase enzyme CYP46 is almost exclusively located in the human 
brain (Lutjohann et al. 2002). Feeding mice with deuterated cholesterol showed that only 50% 
of total 24(S)-hydroxycholesterol is of cerebral origin (Lund et al. 1999; Meaney et al. 2000). 
Brain 24(S)-hydroxycholesterol levels were 131 ng/mg protein in 15 days old wildtype mice 
but were undetectable in this tissue in age matched Cyp46-/- animals (Lund et al. 1999). 
However, Cyp46-/- knockout mice showed serum levels of 24(S)-hydroxycholesterol of 
11 ng/mL compared to age-matched wildtype mkice with serum levels of 24(S)-
hydroxychloseterol ranging from 60 to 90 ng/mL (Lund et al. 1999). Moreover, using 
semiquantitative immunoblotting of the cholesterol 24(S)-hydroxylase, it has been shown that 
there was approximately 100 times more 24(S)-hydroxylase protein per gram in brain as 
could be found in liver. The latter is believed to contribute most if not all of the extracerebral 
amount of 24(S)-hydroxycholesterol (Lund et al. 1999). Overall, Cyp46 seems to be the major 
enzyme converting cholesterol into 24(S)-hydroxycholesterol in mouse and man. Recently, 
plasma 24(S)-hydroxycholesterol has been discussed not to be a biomarker for AD. Though, 
rather high levels of this oxysterol may be a modifiable risk factor for AD as are high levels 
of cholesterol (Irizarry 2004). 
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5.5 PYROGLUTAMATE AMYLOID BETA AS A POTENTIAL TRIGGER 
FOR SPORADIC ALZHEIMER`S DISEASE 
 
5.5.1 DOMINANT AGGREGATION OF BETA-AMYLOID STARTING 
WITH PYROGLUTAMATE AT POSITION 3 IN THE APP/PS1KI 
MOUSE MODEL  
 
At the age of 6 months APP/PS1KI mice develop working memory deficits (Wirths et al. 
2007), and abundant axonal degeneration (Wirths et al. 2006). Interestingly, 85% of total 
Aβ in this model consists of Aβ42, which exhibits a large heterogeneity at the N-terminus 
(Casas et al. 2004; Wirths et al. 2006). The amount of AβN3(pE) is ~90 pg/mg w.w. (at 
6 months of age) and is therefore the highest level reported so far in an APP mouse model. 
AβN3(pE) not only aggregates in plaques, but also in CA1 neurons between 2 and 6 months of 
age, supporting a role in intraneuronal toxicity. 
 
Intracellular Aβ deposition has been previously shown in human AD (Gouras et al. 2000) 
and in Down’s syndrome patients (Gyure et al. 2001; Mori et al. 2002). The localization of 
these peptides has been demonstrated to be predominantly in abnormal endosomes (Cataldo 
et al. 2004), multivesicular bodies and within pre- and postsynaptic compartments (Langui et 
al. 2004; Takahashi et al. 2002). Takahashi et al. demonstrated that Aβ42 aggregates into 
oligomers within endosomal vesicles and along microtubules of neuronal processes, both in 
Tg2576 neurons with time in culture, as well as in Tg2576 and human AD brain (Takahashi 
et al. 2004).  
 
Long-standing evidence shows that progressive cerebral deposition of Aβ plays a seminal 
role in the pathogenesis of AD (Selkoe 1991). There is great interest, therefore, in 
understanding the proteolytic processing of APP and its proteases responsible for cleaving at 
the amino- and carboxy-terminus of the Aβ region. Ragged peptides with a major species 
beginning with phenylalanine at position 4 of Aβ have been reported already in 1985 by 
Masters et al. (Masters et al. 1985). This finding has been disputed, because no amino-
terminal sequence could be obtained from cores purified in a sodium dodecyl sulfate-
containing buffer, which mounted in the suggestion that the N-terminus is blocked (Gorevic 
et al. 1986; Selkoe et al. 1986). In 1992, Mori et al. first described the presence of AβN3(pE) 
using mass spectrometry of purified Aβ protein from AD brains, which explaines the 
difficulties in sequencing the amino-terminus (Mori et al. 1992). They reported that only 10-
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15% of the total Aβ isolated by this method begins at position 3 with a AβN3(pE). Later it 
became clear that AβN3(pE) represents a dominant fraction of Aβ peptides in AD and Down’s 
syndrome brain (Guntert et al. 2006; Harigaya et al. 2000; Hosoda et al. 1998; Iwatsubo et 
al. 1996; Kuo et al. 1997; Kuo et al. 2001; Miravalle et al. 2005; Piccini et al. 2005; Piccini 
et al. 2007; Russo et al. 1997; Saido et al. 1995; Saido et al. 1996; Tekirian et al. 1998). 
Amino-terminal deletions in general enhance aggregation of β-amyloid peptides in vitro 
(Pike et al. 1995). The same is true for AβN3(pE), which has a higher aggregation propensity 
(He & Barrow 1999), stabilizes Aβ (Kuo et al. 1998b), and shows an increased toxicity 
compared to full-length Aβ and underlined therefore the potential of Aβ peptides in general 
and in particular of AβN3(pE) for neurotoxicity (Youssef et al. 2007). Other studies reported 
that the toxicity of pyroglutaminated amyloid beta-peptides AβΝ3(pE)-40/42 is similar to that of 
Aβ1-40 and Aβ1-42 (Tekirian et al. 1999), and that the AβN3(pE) is not the major variant in AD 
brain (Lemere et al. 1996). In contrast, Schilling et al. have demonstrated that N3(pE)-
modified peptides display an up to 250-fold acceleration in the initial formation of Aβ 
aggregates (Schilling et al. 2006), and presented in vitro evidence that the cyclization of 
glutamate at position 3 of Aβ is driven enzymatically by glutaminyl cyclase (QC). QC 
inhibition leads to significantly reduced AβN3(pE) formation, showing the importance of QC-
activity during cellular maturation of pE-containing peptides (Cynis et al. 2006).  
 
QC inhibition leads to significantly reduced Aβ3(pE) formation, showing the importance of 
QC-activity during cellular maturation of pyroglutamate-containing peptides (Cynis et al. 
2006). APP transgenic mouse models have been reported to show no (Kuo et al. 2001) or low 
Aβ3(pE) levels (Guntert et al. 2006), in contrast to the APP/PS1KI mouse, which harbours 
considerable amounts of Aβ3(pE) detected by 2D-gel electrophoresis of whole brain lysates 
(Casas et al. 2004).  
 
Recently, Maeda et al. (Maeda 2007) have shown that the localization and abundance of 
[11C]PIB autoradiographic signals were closely associated with those of amino-terminally 
truncated and modified Aβ3(pE) deposition in AD and APP transgenic mouse brains, implying 
that the detectability of amyloid by [11C]PIB-PET is dependent on the accumulation of 
specific Aβ subtypes. In addition, deficiency of the physiological Aβ degrading enzyme, i.e. 
neprilysin (NEP), results in generation of Aβ3(pE), which is metabolically stable and 
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pathologically causative, via conversion of Aβ1-42 to Aβ3E-42 followed by N-terminal 
glutamate cyclization (Iwata 2007). 
 
In conclusion, these data add evidence to the pathological role of AβN3(pE) in AD. An excess 
of accumulation of AβN3(pE), with a high aggregation propensity and increased toxicity, 
therefore may lead to an enhanced intra- and extracellular Aβ aggregation and plaque 
formation.   
 
Fig. 33: Scheme of AβN3(pE) action on neurodegeneration in Alzheimer‘s disease. APP is cleaved by β- and 
γ-secretase function liberating AβN1(D). AβN3(E) is generated by putative mono-, or dipeptidylpeptidases, 
which is further modified by N-terminal enzymatic cyclization of glutamate by glutaminyl cyclase 
generating AβN3(pE). AβN3(pE) is resistant to most aminopeptidases, has a higher stability, aggregation rate 
and toxic profile as compared to other Aβ peptides. It may therefore serve as a seed for other Aβ species 
for intra- and extraneuronal Aβ accumulation. AβN3(pE) accumulation leads to synaptic dysfunction, 
neuron death, and hippocampus atrophy (adapted from (Saido et al., 1995)).  
 
To observe the pathologic impact of  AβN3(pE) peptides separately, the mouse models TBA1, 
TBA2 and mQC-transgenic mice were generated. The results are discussed in the following 
chapters.
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5.5.2 OVEREXPRESSION OF mQC IN mQC-TRANSGENIC MICE 
 
Substantial overexpression of mQC compared to wildtype animals was verified in both 
homozygous and heterozygous mice transgenic for mQC. Overexpression of mRNA levels 
was confirmed for the kidney as a peripheral organ. Most importantly for the usability of this 
mouse model for analyzing the impact of mQC on the neuropathological changes in 
Alzheimer disease mouse models, I found a multiple expression increase of mQC mRNA in 
the brain. By activity measurements in EDTA-plasma it was shown, that higher expression of 
mQC mRNA led to higher concentrations of biological active mQC-enzyme on the peptide 
level. As consequence of this results, I decided to cross heterozygous mQC-mice with 
heterozygous TBA1 mice to analyze the influence of mQC overexpression on the formation 
of Aβ3(pE). 
 
 
5.5.3 IN VIVO FORMATION AND NEUROTOXICITY OF PYRO-
GLUTAMATE Aβ IN TBA1 AND TBA2 MICE 
 
To specifically investigate the neurotoxicity of Aβ3(pE) generation in vivo,  transgenic mice 
that express Aβ3E with the normal glutamate at the N-terminus (TBA1) and mice that express 
Aβ3Q starting at position 3 with glutamine (TBA2) were generated. Due to the replacement of 
N-terminal glutamate by glutamine, the Aβ peptides are more prone to conversion into 
pyroglutamate by QC activity in the TBA2 model (Schilling et al. 2004). The severity of the 
neurological phenotype observed in the TBA2 model, accompanied with the massive neuronal 
loss and premature mortality reflects the enormous toxicity of Aβ3(pE)-42. However, the 
possibility that unprocessed Aβ3Q-42 has been stabilized by Aβ3(pE)-42 accumulation, and also 
contributes to the observed severe pathology cannot be ruled out. Applying a mouse Aβ1-40 
specific ELISA, I did not find elevated mouse Aβ-species in SDS soluble brain extracts (not 
shown), suggesting that mouse Aβ1-40 is not precipitated together with human Aβ variants. In 
conclusion the major peptide in TBA2 brain extracts is Aβx-42, which is likely not 
posttranslationally transformed into Aβ3(pE). In addition, it can not be ruled out that besides 
Aβ3(pE) other N-truncated Aβx-42 variants also aggregate and contribute to the observed 
neurotoxicity in the TBA2 model. On the other hand, Iwata et al. have clearly shown that 
Aβ3(pE)-42 has the longest half live compared to that of all other Aβx-42 peptides starting with 
unmodified aspartate, alanine, glutamate, phenylalanine or with modified aspartate (Iwata 
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2007). In addition, they have demonstrated that deficiency of the Aβ-degrading enzyme 
neprilysin (NEP) results in generation of metabolically stable and pathologically causative 
Aβ3(pE)-42. Therefore, it may be concluded that Aβ3(pE) peptides serve as a seed for Aβ 
accumulation in the TBA2 model. The neurotoxicity of the N-truncated and 
posttranslationally transformed Aβ3(pE)-42 species observed in our TBA2 mouse model is 
corroborated by the pharmacological inhibition of QC activity by the QC inhibitor P150, 
which significantly reduces the level of Aβ3(pE) in vitro (Cynis et al. 2006) and in Tg2576 
mice in vivo (Schilling 2007). These results demonstrate that pharmacological treatment of 
Aβ3(pE) formation and deposition may serve as new therapeutic approach to treat AD-like 
neurodegeneration.  
 
  
 
 Page 111/137 
6 REFERENCES 
 
Akama, K.T., Albanese, C., Pestell, R.G. & Van Eldik, L.J. (1998) Amyloid beta-peptide 
stimulates nitric oxide production in astrocytes through an NFkappaB-dependent 
mechanism. Proc Natl Acad Sci U S A 95 5795-5800. 
Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G.M., Cooper, N.R., 
Eikelenboom, P., Emmerling, M., Fiebich, B.L., Finch, C.E., Frautschy, S., Griffin, 
W.S., Hampel, H., Hull, M., Landreth, G., Lue, L., Mrak, R., Mackenzie, I.R., et al 
(2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21 383-421. 
Alarcon, R., Fuenzalida, C., Santibanez, M. & von Bernhardi, R. (2005) Expression of 
scavenger receptors in glial cells. Comparing the adhesion of astrocytes and microglia 
from neonatal rats to surface-bound beta-amyloid. J Biol Chem 280 30406-30415. . 
Alexander, N.B., Mollo, J.M., Giordani, B., Ashton-Miller, J.A., Schultz, A.B., Grunawalt, 
J.A. & Foster, N.L. (1995) Maintenance of balance, gait patterns, and obstacle 
clearance in Alzheimer's disease. Neurology 45 908-914. 
Ambree, O., Touma, C., Gortz, N., Keyvani, K., Paulus, W., Palme, R. & Sachser, N. (2006) 
Activity changes and marked stereotypic behavior precede Abeta pathology in 
TgCRND8 Alzheimer mice. Neurobiol Aging 27 955-964. 
Archer, J. (1973) Tests for emotionality in rats and mice: a review. Anim Behav 21 205-235. 
Arendash, G.W., Gordon, M.N., Diamond, D.M., Austin, L.A., Hatcher, J.M., Jantzen, P., 
DiCarlo, G., Wilcock, D. & Morgan, D. (2001) Behavioral assessment of Alzheimer's 
transgenic mice following long-term Abeta vaccination: task specificity and 
correlations between Abeta deposition and spatial memory. DNA Cell Biol 20 737-
744. 
Arimoto, T., Choi, D.Y., Lu, X., Liu, M., Nguyen, X.V., Zheng, N., Stewart, C.A., Kim, H.C. 
& Bing, G. (2006) Interleukin-10 protects against inflammation-mediated 
degeneration of dopaminergic neurons in substantia nigra. Neurobiol Aging 10 10. 
Arnaud, L., Robakis, N.K. & Figueiredo-Pereira, M.E. (2006) It may take inflammation, 
phosphorylation and ubiquitination to 'tangle' in Alzheimer's disease. Neurodegener 
Dis 3 313-319.  
Arosio, P., Levi, S., Santambrogio, P., Cozzi, A., Luzzago, A., Cesareni, G. & Albertini, A. 
(1991) Structural and functional studies of human ferritin H and L chains. Curr Stud 
Hematol Blood Transfus 127-131. 
  
 
 Page 112/137 
Askanas, V., Alvarez, R.B. & Engel, W.K. (1993) beta-Amyloid precursor epitopes in muscle 
fibers of inclusion body myositis. Ann Neurol 34 551-560. 
Baddeley, A.D., Bressi, S., Della Sala, S., Logie, R. & Spinnler, H. (1991) The decline of 
working memory in Alzheimer's disease. A longitudinal study. Brain 114 2521-2542. 
Bayer, T.A., Wirths, O., Majtenyi, K., Hartmann, T., Multhaup, G., Beyreuther, K. & Czech, 
C. (2001) Key Factors in Alzheimer's Disease: ß-amyloid Precursor Protein 
Processing, Metabolism and Intraneuronal Transport. Brain Pathology 11 1-11. 
Bjorkhem, I., Andersson, U., Ellis, E., Alvelius, G., Ellegard, L., Diczfalusy, U., Sjovall, J. & 
Einarsson, C. (2001) From brain to bile. Evidence that conjugation and omega-
hydroxylation are important for elimination of 24S-hydroxycholesterol (cerebrosterol) 
in humans. J Biol Chem 276 37004-37010. 
Bjorkhem, I. & Meaney, S. (2004) Brain cholesterol: long secret life behind a barrier. 
Arterioscler Thromb Vasc Biol 24 806-815. 
Blanchard, V., Moussaoui, S., Czech, C., Touchet, N., Bonici, B., Planche, M., Canton, T., 
Jedidi, I., Gohin, M., Wirths, O., Bayer, T.A., Langui, D., Duyckaerts, C., Tremp, G. 
& Pradier, L. (2003) Time sequence of maturation of dystrophic neurites associated 
with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol 184 247-263.  
Blennow, K. (2005) CSF biomarkers for Alzheimer's disease: use in early diagnosis and 
evaluation of drug treatment. Expert Rev Mol Diagn 5 661-672. 
Blennow, K. & Hampel, H. (2003) CSF markers for incipient Alzheimer's disease. Lancet 
Neurol 2 605-613. 
Bobinski, M., de Leon, M.J., Wegiel, J., Desanti, S., Convit, A., Saint Louis, L.A., Rusinek, 
H. & Wisniewski, H.M. (2000) The histological validation of post mortem magnetic 
resonance imaging-determined hippocampal volume in Alzheimer's disease. 
Neuroscience 95 721-725. 
Bodovitz, S. & Klein, W.L. (1996) Cholesterol modulates alpha-secretase cleavage of 
amyloid precursor protein. J Biol Chem 271 4436-4440. 
Boom, A., Pochet, R., Authelet, M., Pradier, L., Borghgraef, P., Van Leuven, F., Heizmann, 
C.W. & Brion, J.P. (2004) Astrocytic calcium/zinc binding protein S100A6 over 
expression in Alzheimer's disease and in PS1/APP transgenic mice models. Biochim 
Biophys Acta 1742 161-168. 
Boutajangout, A., Leroy, K., Touchet, N., Authelet, M., Blanchard, V., Tremp, G., Pradier, L. 
& Brion, J.P. (2002) Increased tau phosphorylation but absence of formation of 
  
 
 Page 113/137 
neurofibrillary tangles in mice double transgenic for human tau and Alzheimer mutant 
(M146L) presenilin-1. Neurosci Lett 318 29-33. 
Bretillon, L., Lutjohann, D., Stahle, L., Widhe, T., Bindl, L., Eggertsen, G., Diczfalusy, U. & 
Bjorkhem, I. (2000) Plasma levels of 24S-hydroxycholesterol reflect the balance 
between cerebral production and hepatic metabolism and are inversely related to body 
surface. J Lipid Res 41 840-845. 
Burright, E.N., Clark, H.B., Servadio, A., Matilla, T., Feddersen, R.M., Yunis, W.S., Duvick, 
L.A., Zoghbi, H.Y. & Orr, H.T. (1995) SCA1 transgenic mice: a model for 
neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82 937-948. 
Busciglio, J., Pelsman, A., Wong, C., Pigino, G., Yuan, M., Mori, H. & Yankner, B.A. (2002) 
Altered metabolism of the amyloid beta precursor protein is associated with 
mitochondrial dysfunction in Down's syndrome. Neuron 33 677-688. 
Cacabelos, R., Alvarez, X.A., Fernandez-Novoa, L., Franco, A., Mangues, R., Pellicer, A. & 
Nishimura, T. (1994) Brain interleukin-1 beta in Alzheimer's disease and vascular 
dementia. Methods Find Exp Clin Pharmacol 16 141-151. 
Calhoun, M.E., Wiederhold, K.H., Abramowski, D., Phinney, A.L., Probst, A., Sturchler-
Pierrat, C., Staufenbiel, M., Sommer, B. & Jucker, M. (1998) Neuron loss in APP 
transgenic mice. Nature 395 755-756. 
Carrasco, J., Adlard, P., Cotman, C., Quintana, A., Penkowa, M., Xu, F., Van Nostrand, W.E. 
& Hidalgo, J. (2006) Metallothionein-I and -III expression in animal models of 
Alzheimer disease. Neuroscience 143 911-922. 
Carrasco, J., Penkowa, M., Giralt, M., Camats, J., Molinero, A., Campbell, I.L., Palmiter, 
R.D. & Hidalgo, J. (2003) Role of metallothionein-III following central nervous 
system damage. Neurobiol Dis 13 22-36. 
Carter, J. & Lippa, C.F. (2001) Beta-amyloid, neuronal death and Alzheimer's disease. Curr 
Mol Med 1 733-737. 
Casas, C., Sergeant, N., Itier, J.M., Blanchard, V., Wirths, O., van der Kolk, N., Vingtdeux, 
V., van de Steeg, E., Ret, G., Canton, T., Drobecq, H., Clark, A., Bonici, B., 
Delacourte, A., Benavides, J., Schmitz, C., Tremp, G., Bayer, T.A., Benoit, P., et al 
(2004a) Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated 
Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol 165 1289-
1300. 
Casey, J.L., Koeller, D.M., Ramin, V.C., Klausner, R.D. & Harford, J.B. (1989) Iron 
regulation of transferrin receptor mRNA levels requires iron-responsive elements and 
  
 
 Page 114/137 
a rapid turnover determinant in the 3' untranslated region of the mRNA. Embo J 8 
3693-3699. 
Castellani, R.J., Moreira, P.I., Liu, G., Dobson, J., Perry, G., Smith, M.A. & Zhu, X. (2007) 
Iron: The Redox-active Center of Oxidative Stress in Alzheimer Disease. Neurochem 
Res 17 17. 
Cataldo, A.M., Petanceska, S., Terio, N.B., Peterhoff, C.M., Durham, R., Mercken, M., 
Mehta, P.D., Buxbaum, J., Haroutunian, V. & Nixon, R.A. (2004) Abeta localization 
in abnormal endosomes: association with earliest Abeta elevations in AD and Down 
syndrome. Neurobiol Aging 25 1263-1272. 
Chen, K., Iribarren, P., Hu, J., Chen, J., Gong, W., Cho, E.H., Lockett, S., Dunlop, N.M. & 
Wang, J.M. (2006) Activation of Toll-like receptor 2 on microglia promotes cell 
uptake of Alzheimer disease-associated amyloid beta peptide. J Biol Chem 281 3651-
3659.   
Chetelat, G., Desgranges, B., de la Sayette, V., Viader, F., Berkouk, K., Landeau, B., Lalevee, 
C., Le Doze, F., Dupuy, B., Hannequin, D., Baron, J.C. & Eustache, F. (2003) 
Dissociating atrophy and hypometabolism impact on episodic memory in mild 
cognitive impairment. Brain 126 1955-1967. 
Chishti, M.A., Yang, D.S., Janus, C., Phinney, A.L., Horne, P., Pearson, J., Strome, R., Zuker, 
N., Loukides, J., French, J., Turner, S., Lozza, G., Grilli, M., Kunicki, S., Morissette, 
C., Paquette, J., Gervais, F., Bergeron, C., Fraser, P.E., et al (2001) Early-onset 
amyloid deposition and cognitive deficits in transgenic mice expressing a double 
mutant form of amyloid precursor protein 695. J Biol Chem 276 21562-21570. 
Coleman, P.D. & Yao, P.J. (2003) Synaptic slaughter in Alzheimer's disease. Neurobiol Aging 
24 1023-1027. 
Connor, J.R. & Menzies, S.L. (1995) Cellular management of iron in the brain. J Neurol Sci 
134 33-44. 
Cummings, J.L., Vinters, H.V., Cole, G.M. & Khachaturian, Z.S. (1998) Alzheimer's disease: 
etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 
51 S2-17; discussion S65-17. 
Cynis, H., Schilling, S., Bodnar, M., Hoffmann, T., Heiser, U., Saido, T.C. & Demuth, H.U. 
(2006) Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian 
cells. Biochim Biophys Acta 1764 1618-1625. 
  
 
 Page 115/137 
Dai, J., Buijs, R.M., Kamphorst, W. & Swaab, D.F. (2002) Impaired axonal transport of 
cortical neurons in Alzheimer's disease is associated with neuropathological changes. 
Brain Res 948 138-144. 
D'Andrea, M.R., Nagele, R.G., Wang, H.Y., Peterson, P.A. & Lee, D.H. (2001) Evidence that 
neurones accumulating amyloid can undergo lysis to form amyloid plaques in 
Alzheimer's disease. Histopathology 38 120-134. 
Dember, W.N. & Fowler, H. (1958) Spontaneous alternation behavior. Psychol Bull 55 412-
428. 
Dere, E., De Souza-Silva, M.A., Frisch, C., Teubner, B., Sohl, G., Willecke, K. & Huston, 
J.P. (2003) Connexin30-deficient mice show increased emotionality and decreased 
rearing activity in the open-field along with neurochemical changes. Eur J Neurosci 
18 629-638. 
Dickson, D.W., Lee, S.C., Mattiace, L.A., Yen, S.H. & Brosnan, C. (1993) Microglia and 
cytokines in neurological disease, with special reference to AIDS and Alzheimer's 
disease. Glia 7 75-83. 
Dietschy, J.M. & Turley, S.D. (2001) Cholesterol metabolism in the brain. Curr Opin Lipidol 
12 105-112. 
Divac, I. (1975) Magnocellular nuclei of the basal forebrain project to neocortex, brain stem, 
and olfactory bulb. Review of some functional correlates. Brain Res 93 385-398. 
Dodart, J.C., Meziane, H., Mathis, C., Bales, K.R., Paul, S.M. & Ungerer, A. (1999) 
Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid 
precursor protein. Behav Neurosci 113 982-990. 
Dudal, S., Krzywkowski, P., Paquette, J., Morissette, C., Lacombe, D., Tremblay, P. & 
Gervais, F. (2004) Inflammation occurs early during the Abeta deposition process in 
TgCRND8 mice. Neurobiol Aging 25 861-871. 
Egana, J.T., Zambrano, C., Nunez, M.T., Gonzalez-Billault, C. & Maccioni, R.B. (2003) Iron-
induced oxidative stress modify tau phosphorylation patterns in hippocampal cell 
cultures. Biometals 16 215-223. 
Erbel-Sieler, C., Dudley, C., Zhou, Y., Wu, X., Estill, S.J., Han, T., Diaz-Arrastia, R., 
Brunskill, E.W., Potter, S.S. & McKnight, S.L. (2004) Behavioral and regulatory 
abnormalities in mice deficient in the NPAS1 and NPAS3 transcription factors. Proc 
Natl Acad Sci U S A 101 13648-13653. 
Eriksen, J.L. & Janus, C.G. (2007) Plaques, tangles, and memory loss in mouse models of 
neurodegeneration. Behav Genet 37 79-100. 
  
 
 Page 116/137 
Ewers, M., Morgan, D.G., Gordon, M.N. & Woodruff-Pak, D.S. (2006) Associative and 
motor learning in 12-month-old transgenic APP+PS1 mice. Neurobiol Aging 27 1118-
1128. 
Frei, K., Malipiero, U.V., Leist, T.P., Zinkernagel, R.M., Schwab, M.E. & Fontana, A. (1989) 
On the cellular source and function of interleukin 6 produced in the central nervous 
system in viral diseases. Eur J Immunol 19 689-694. 
Gandy, S. & Petanceska, S. (2000) Regulation of Alzheimer beta-amyloid precursor 
trafficking and metabolism. Biochim Biophys Acta 1502 44-52. 
George, A.J., Holsinger, R.M., McLean, C.A., Laughton, K.M., Beyreuther, K., Evin, G., 
Masters, C.L. & Li, Q.X. (2004) APP intracellular domain is increased and soluble 
Abeta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model 
of Alzheimer disease. Neurobiol Dis 16 124-132. 
Gerlai, R. (1998) A new continuous alternation task in T-maze detects hippocampal 
dysfunction in mice. A strain comparison and lesion study. Behav Brain Res 95 91-
101. 
Giralt, M., Penkowa, M., Hernandez, J., Molinero, A., Carrasco, J., Lago, N., Camats, J., 
Campbell, I.L. & Hidalgo, J. (2002a) Metallothionein-1+2 deficiency increases brain 
pathology in transgenic mice with astrocyte-targeted expression of interleukin 6. 
Neurobiol Dis 9 319-338. 
Giralt, M., Penkowa, M., Lago, N., Molinero, A. & Hidalgo, J. (2002b) Metallothionein-1+2 
protect the CNS after a focal brain injury. Exp Neurol 173 114-128. 
Giulian, D. (1999) Microglia and the immune pathology of Alzheimer disease. Am J Hum 
Genet 65 13-18. 
Glabe, C. (2001) Intracellular mechanisms of amyloid accumulation and pathogenesis in 
Alzheimer's disease. J Mol Neurosci 17 137-145. 
Goedert, M. & Jakes, R. (1990) Expression of separate isoforms of human tau protein: 
correlation with the tau pattern in brain and effects on tubulin polymerization. Embo J 
9 4225-4230. 
Golde, T.E., Estus, S., Usiak, M., Younkin, L.H. & Younkin, S.G. (1990) Expression of beta 
amyloid protein precursor mRNAs: recognition of a novel alternatively spliced form 
and quantitation in Alzheimer's disease using PCR. Neuron 4 253-267. 
Gomez-Isla, T., Price, J.L., McKeel, D.W., Jr., Morris, J.C., Growdon, J.H. & Hyman, B.T. 
(1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild 
Alzheimer's disease. J Neurosci 16 4491-4500. 
  
 
 Page 117/137 
Gong, J.S., Sawamura, N., Zou, K., Sakai, J., Yanagisawa, K. & Michikawa, M. (2002) 
Amyloid beta-protein affects cholesterol metabolism in cultured neurons: implications 
for pivotal role of cholesterol in the amyloid cascade. J Neurosci Res 70 438-446. 
Gordon, M.N., King, D.L., Diamond, D.M., Jantzen, P.T., Boyett, K.V., Hope, C.E., Hatcher, 
J.M., DiCarlo, G., Gottschall, W.P., Morgan, D. & Arendash, G.W. (2001) Correlation 
between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol 
Aging 22 377-385. 
Gorevic, P.D., Goni, F., Pons-Estel, B., Alvarez, F., Peress, N.S. & Frangione, B. (1986) 
Isolation and partial characterization of neurofibrillary tangles and amyloid plaque 
core in Alzheimer's disease: immunohistological studies. J Neuropathol Exp Neurol 45 
647-664. 
Gouras, G.K., Almeida, C.G. & Takahashi, R.H. (2005) Intraneuronal Abeta accumulation 
and origin of plaques in Alzheimer's disease. Neurobiol Aging 26 1235-1244. 
Gouras, G.K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J.P., 
Haroutunian, V., Buxbaum, J.D., Xu, H., Greengard, P. & Relkin, N.R. (2000) 
Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156 15-20. 
Griffin, W.S., Stanley, L.C., Ling, C., White, L., MacLeod, V., Perrot, L.J., White, C.L., 3rd 
& Araoz, C. (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in 
Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 86 7611-7615. 
Guntert, A., Dobeli, H. & Bohrmann, B. (2006) High sensitivity analysis of amyloid-beta 
peptide composition in amyloid deposits from human and PS2APP mouse brain. 
Neuroscience 143 461-475. Epub 2006 Sep 2027. 
Gyure, K.A., Durham, R., Stewart, W.F., Smialek, J.E. & Troncoso, J.C. (2001) Intraneuronal 
abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch 
Pathol Lab Med 125 489-492. 
Hampel, H., Haslinger, A., Scheloske, M., Padberg, F., Fischer, P., Unger, J., Teipel, S.J., 
Neumann, M., Rosenberg, C., Oshida, R., Hulette, C., Pongratz, D., Ewers, M., 
Kretzschmar, H.A. & Moller, H.J. (2005) Pattern of interleukin-6 receptor complex 
immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's 
disease brain. Eur Arch Psychiatry Clin Neurosci 255 269-278. 
Hampel, H., Mitchell, A., Blennow, K., Frank, R.A., Brettschneider, S., Weller, L. & Moller, 
H.J. (2004) Core biological marker candidates of Alzheimer's disease - perspectives 
for diagnosis, prediction of outcome and reflection of biological activity. J Neural 
Transm 111 247-272.  
  
 
 Page 118/137 
Hardy, J. & Allsop, D. (1991) Amyloid deposition as the central event in the aetiology of 
Alzheimer's disease. Trends Pharmacol Sci 12 383-388. 
Hardy, J. & Selkoe, D.J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and 
problems on the road to therapeutics. Science 297 353-356. 
Harigaya, Y., Saido, T.C., Eckman, C.B., Prada, C.M., Shoji, M. & Younkin, S.G. (2000) 
Amyloid beta protein starting pyroglutamate at position 3 is a major component of the 
amyloid deposits in the Alzheimer's disease brain. Biochem Biophys Res Commun 276 
422-427. 
He, W. & Barrow, C.J. (1999) The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides 
found in senile plaque have greater beta-sheet forming and aggregation propensities in 
vitro than full-length A beta. Biochemistry 38 10871-10877. 
Herzig, M.C., Winkler, D.T., Burgermeister, P., Pfeifer, M., Kohler, E., Schmidt, S.D., 
Danner, S., Abramowski, D., Sturchler-Pierrat, C., Burki, K., van Duinen, S.G., Maat-
Schieman, M.L., Staufenbiel, M., Mathews, P.M. & Jucker, M. (2004) Abeta is 
targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with 
amyloidosis. Nat Neurosci 7 954-960. 
Hiraoka, Y., Ohno, M., Yoshida, K., Okawa, K., Tomimoto, H., Kita, T. & Nishi, E. (2007) 
Enhancement of alpha-secretase cleavage of amyloid precursor protein by a 
metalloendopeptidase nardilysin. J Neurochem 7 7. 
Holcomb, L., Gordon, M.N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., 
Saad, I., Mueller, R., Morgan, D., Sanders, S., Zehr, C., O'Campo, K., Hardy, J., 
Prada, C.M., Eckman, C., Younkin, S., Hsiao, K. & Duff, K. (1998) Accelerated 
Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor 
protein and presenilin 1 transgenes. Nat Med 4 97-100. 
Hosoda, R., Saido, T.C., Otvos, L., Jr., Arai, T., Mann, D.M., Lee, V.M., Trojanowski, J.Q. & 
Iwatsubo, T. (1998) Quantification of modified amyloid beta peptides in Alzheimer 
disease and Down syndrome brains. J Neuropathol Exp Neurol 57 1089-1095. 
Howland, D.S., Trusko, S.P., Savage, M.J., Reaume, A.G., Lang, D.M., Hirsch, J.D., Maeda, 
N., Siman, R., Greenberg, B.D., Scott, R.W. & Flood, D.G. (1998b) Modulation of 
secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by 
cholesterol. J Biol Chem 273 16576-16582. 
Hsia, A.Y., Masliah, E., McConlogue, L., Yu, G.Q., Tatsuno, G., Hu, K., Kholodenko, D., 
Malenka, R.C., Nicoll, R.A. & Mucke, L. (1999a) Plaque-independent disruption of 
  
 
 Page 119/137 
neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A 96 
3228-3233. 
Hsiao, K.K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F. & 
Cole, G. (1996) Correlative memory deficits, Abeta elevation and amyloid plaques in 
transgenic mice. Science 274 99-102. 
Hu, J., Akama, K.T., Krafft, G.A., Chromy, B.A. & Van Eldik, L.J. (1998) Amyloid-beta 
peptide activates cultured astrocytes: morphological alterations, cytokine induction 
and nitric oxide release. Brain Res 785 195-206. 
Hull, M., Berger, M. & Heneka, M. (2006) Disease-modifying therapies in Alzheimer's 
disease: how far have we come? Drugs 66 2075-2093.  
Hye, A., Lynham, S., Thambisetty, M., Causevic, M., Campbell, J., Byers, H.L., Hooper, C., 
Rijsdijk, F., Tabrizi, S.J., Banner, S., Shaw, C.E., Foy, C., Poppe, M., Archer, N., 
Hamilton, G., Powell, J., Brown, R.G., Sham, P., Ward, M., et al (2006) Proteome-
based plasma biomarkers for Alzheimer's disease. Brain 129 3042-3050. 
Irizarry, M.C. (2004) Biomarkers of Alzheimer disease in plasma. NeuroRx 1 226-234. 
Iwata, N.e.a. (2007) N-terminal modification of amyloid-beta peptide, Abeta x-42 , in 
Alzheimer's disease and mouse models. Nature, co-submitted. 
Iwatsubo, T., Saido, T.C., Mann, D.M., Lee, V.M. & Trojanowski, J.Q. (1996) Full-length 
amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 
42(43) deposit in diffuse plaques. Am J Pathol 149 1823-1830. 
Jack, C.R., Jr., Dickson, D.W., Parisi, J.E., Xu, Y.C., Cha, R.H., O'Brien, P.C., Edland, S.D., 
Smith, G.E., Boeve, B.F., Tangalos, E.G., Kokmen, E. & Petersen, R.C. (2002) 
Antemortem MRI findings correlate with hippocampal neuropathology in typical 
aging and dementia. Neurology 58 750-757. 
Janus, C. (2004) Search strategies used by APP transgenic mice during navigation in the 
Morris water maze. Learn Mem 11 337-346. 
Jellinger, K.A. (2006) Challenges in neuronal apoptosis. Curr Alzheimer Res 3 377-391. 
Kaplan, J., Craven, C., Alexander, J., Kushner, J., Lamb, J. & Bernstein, S. (1988) Regulation 
of the distribution of tissue iron. Lessons learned from the hypotransferrinemic mouse. 
Ann N Y Acad Sci 526 124-135. 
Koeller, D.M., Casey, J.L., Hentze, M.W., Gerhardt, E.M., Chan, L.N., Klausner, R.D. & 
Harford, J.B. (1989) A cytosolic protein binds to structural elements within the iron 
regulatory region of the transferrin receptor mRNA. Proc Natl Acad Sci U S A 86 
3574-3578. 
  
 
 Page 120/137 
Kolsch, H., Heun, R., Kerksiek, A., Bergmann, K.V., Maier, W. & Lutjohann, D. (2004) 
Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. 
Neurosci Lett 368 303-308. 
Kolsch, H., Ludwig, M., Lutjohann, D. & Rao, M.L. (2001) Neurotoxicity of 24-
hydroxycholesterol, an important cholesterol elimination product of the brain, may be 
prevented by vitamin E and estradiol-17beta. J Neural Transm 108 475-488. 
Kolsch, H., Lutjohann, D., von Bergmann, K. & Heun, R. (2003) The role of 24S-
hydroxycholesterol in Alzheimer's disease. J Nutr Health Aging 7 37-41. 
Koo, E.H., Sisodia, S.S., Archer, D.R., Martin, L.J., Weidemann, A., Beyreuther, K., Fischer, 
P., Masters, C.L. & Price, D.L. (1990) Precursor of amyloid protein in Alzheimer 
disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci U S A 87 
1561-1565. 
Kumar-Singh, S., Theuns, J., Van Broeck, B., Pirici, D., Vennekens, K., Corsmit, E., Cruts, 
M., Dermaut, B., Wang, R. & Van Broeckhoven, C. (2006) Mean age-of-onset of 
familial alzheimer disease caused by presenilin mutations correlates with both 
increased Abeta42 and decreased Abeta40. Hum Mutat 27 686-695. 
Kuo, Y.M., Emmerling, M.R., Bisgaier, C.L., Essenburg, A.D., Lampert, H.C., Drumm, D. & 
Roher, A.E. (1998a) Elevated low-density lipoprotein in Alzheimer's disease correlates 
with brain abeta 1-42 levels. Biochem Biophys Res Commun 252 711-715. 
Kuo, Y.M., Emmerling, M.R., Woods, A.S., Cotter, R.J. & Roher, A.E. (1997) Isolation, 
chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from 
neuritic plaques and vascular amyloid deposits. Biochem Biophys Res Commun 237 
188-191. 
Kuo, Y.M., Kokjohn, T.A., Beach, T.G., Sue, L.I., Brune, D., Lopez, J.C., Kalback, W.M., 
Abramowski, D., Sturchler-Pierrat, C., Staufenbiel, M. & Roher, A.E. (2001) 
Comparative analysis of amyloid-beta chemical structure and amyloid plaque 
morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem 276 
12991-12998. 
Kuo, Y.M., Webster, S., Emmerling, M.R., De Lima, N. & Roher, A.E. (1998b) Irreversible 
dimerization/tetramerization and post-translational modifications inhibit proteolytic 
degradation of A beta peptides of Alzheimer's disease. Biochim Biophys Acta 1406 
291-298. 
Kuusisto, J., Koivisto, K., Mykkanen, L., Helkala, E.L., Vanhanen, M., Hanninen, T., 
Kervinen, K., Kesaniemi, Y.A., Riekkinen, P.J. & Laakso, M. (1997) Association 
  
 
 Page 121/137 
between features of the insulin resistance syndrome and Alzheimer's disease 
independently of apolipoprotein E4 phenotype: cross sectional population based study. 
Bmj 315 1045-1049. 
Lahiri, D.K., Maloney, B., Basha, M.R., Ge, Y.W. & Zawia, N.H. (2007) How and when 
environmental agents and dietary factors affect the course of Alzheimer's disease: the 
"LEARn" model (latent early-life associated regulation) may explain the triggering of 
AD. Curr Alzheimer Res 4 219-228. 
Lalonde, R., Dumont, M., Staufenbiel, M., Sturchler-Pierrat, C. & Strazielle, C. (2002) 
Spatial learning, exploration, anxiety, and motor coordination in female APP23 
transgenic mice with the Swedish mutation. Brain Res 956 36-44. 
Lalonde, R., Kim, H.D. & Fukuchi, K. (2004) Exploratory activity, anxiety, and motor 
coordination in bigenic APPswe + PS1/DeltaE9 mice. Neurosci Lett 369 156-161. 
Lalonde, R. & Strazielle, C. (2001) Motor performance and regional brain metabolism of 
spontaneous murine mutations with cerebellar atrophy. Behav Brain Res 125 103-108. 
Lalonde, R. & Strazielle, C. (2005) PS1 knockin mice with the Japanese I213T mutation: 
effects on exploratory activity, motor coordination, and spatial learning. Behav Brain 
Res 162 182-190. 
Langui, D., Girardot, N., El Hachimi, K.H., Allinquant, B., Blanchard, V., Pradier, L. & 
Duyckaerts, C. (2004) Subcellular topography of neuronal Abeta peptide in APPxPS1 
transgenic mice. Am J Pathol 165 1465-1477. 
Launer, L.J., White, L.R., Petrovitch, H., Ross, G.W. & Curb, J.D. (2001) Cholesterol and 
neuropathologic markers of AD: a population-based autopsy study. Neurology 57 
1447-1452. 
Lee, K.W., Lee, S.H., Kim, H., Song, J.S., Yang, S.D., Paik, S.G. & Han, P.L. (2004) 
Progressive cognitive impairment and anxiety induction in the absence of plaque 
deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein. J 
Neurosci Res 76 572-580. 
Lemere, C.A., Blusztajn, J.K., Yamaguchi, H., Wisniewski, T., Saido, T.C. & Selkoe, D.J. 
(1996) Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in 
Down syndrome: implications for initial events in amyloid plaque formation. 
Neurobiol Dis 3 16-32. 
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., 
Gwinn-Hardy, K., Paul Murphy, M., Baker, M., Yu, X., Duff, K., Hardy, J., Corral, 
A., Lin, W.L., Yen, S.H., Dickson, D.W., Davies, P. & Hutton, M. (2000) 
  
 
 Page 122/137 
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice 
expressing mutant (P301L) tau protein. Nat Genet 25 402-405. 
Li, Y., Liu, L., Liu, D., Woodward, S., Barger, S.W., Mrak, R.E. & Griffin, W.S. (2004) 
Microglial activation by uptake of fDNA via a scavenger receptor. J Neuroimmunol 
147 50-55. 
Liu, Y., Peterson, D.A. & Schubert, D. (1998) Amyloid beta peptide alters intracellular 
vesicle trafficking and cholesterol homeostasis. Proc Natl Acad Sci U S A 95 13266-
13271. 
Locatelli, S., Lutjohann, D., Schmidt, H.H., Otto, C., Beisiegel, U. & von Bergmann, K. 
(2002) Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-
dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin 
affects cholesterol metabolism in the human brain. Arch Neurol 59 213-216. 
Lovasic, L., Bauschke, H. & Janus, C. (2005) Working memory impairment in a transgenic 
amyloid precursor protein TgCRND8 mouse model of Alzheimer's disease. Genes 
Brain Behav 4 197-208. 
Lukiw, W.J. & Bazan, N.G. (2000) Neuroinflammatory signaling upregulation in Alzheimer's 
disease. Neurochem Res 25 1173-1184. 
Lund, E.G., Guileyardo, J.M. & Russell, D.W. (1999) cDNA cloning of cholesterol 24-
hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci U 
S A 96 7238-7243. 
Lutjohann, D., Bjorkhem, I., Locatelli, S., Dame, C., Schmolling, J., von Bergmann, K. & 
Fahnenstich, H. (2001) Cholesterol dynamics in the foetal and neonatal brain as 
reflected by circulatory levels of 24S-hydroxycholesterol. Acta Paediatr 90 652-657. 
Lutjohann, D., Brzezinka, A., Barth, E., Abramowski, D., Staufenbiel, M., von Bergmann, K., 
Beyreuther, K., Multhaup, G. & Bayer, T.A. (2002) Profile of cholesterol-related 
sterols in aged amyloid precursor protein transgenic mouse brain. J Lipid Res 43 1078-
1085. 
Maeda, J. (2007) Longitudinal, quantitative assesment of amyloid, neuroinflammation and 
anti.amyloid treatment in a living mouse model of Alzheimer's disease enabled by 
PET. Journal of Neuroscience. 
Mandelkow, E.M., Stamer, K., Vogel, R., Thies, E. & Mandelkow, E. (2003) Clogging of 
axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 
24 1079-1085. 
Marx, J. (2007) Alzheimer's disease. A new take on tau. Science 316 1416-1417. 
  
 
 Page 123/137 
Marz, P., Cheng, J.G., Gadient, R.A., Patterson, P.H., Stoyan, T., Otten, U. & Rose-John, S. 
(1998) Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad 
Sci U S A 95 3251-3256. 
Masters, C.L., Multhaup, G., Simms, G., Pottgiesser, J., Martins, R.N. & Beyreuther, K. 
(1985) Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's 
disease contain the same protein as the amyloid of plaque cores and blood vessels. 
Embo J 4 2757-2763. 
Mattson, M.P. (2004) Metal-catalyzed disruption of membrane protein and lipid signaling in 
the pathogenesis of neurodegenerative disorders. Ann N Y Acad Sci 1012 37-50. 
Mazzali, M., Kipari, T., Ophascharoensuk, V., Wesson, J.A., Johnson, R. & Hughes, J. (2002) 
Osteopontin--a molecule for all seasons. Qjm 95 3-13. 
Meaney, S., Lutjohann, D., Diczfalusy, U. & Bjorkhem, I. (2000) Formation of oxysterols 
from different pools of cholesterol as studied by stable isotope technique: cerebral 
origin of most circulating 24S-hydroxycholesterol in rats, but not in mice. Biochim 
Biophys Acta 1486 293-298. 
Meller, R., Stevens, S.L., Minami, M., Cameron, J.A., King, S., Rosenzweig, H., Doyle, K., 
Lessov, N.S., Simon, R.P. & Stenzel-Poore, M.P. (2005) Neuroprotection by 
osteopontin in stroke. J Cereb Blood Flow Metab 25 217-225. 
Mendell, J.R., Sahenk, Z., Gales, T. & Paul, L. (1991) Amyloid filaments in inclusion body 
myositis. Novel findings provide insight into nature of filaments. Arch Neurol 48 
1229-1234. 
Metzler, M., Li, B., Gan, L., Georgiou, J., Gutekunst, C.A., Wang, Y., Torre, E., Devon, R.S., 
Oh, R., Legendre-Guillemin, V., Rich, M., Alvarez, C., Gertsenstein, M., McPherson, 
P.S., Nagy, A., Wang, Y.T., Roder, J.C., Raymond, L.A. & Hayden, M.R. (2003) 
Disruption of the endocytic protein HIP1 results in neurological deficits and decreased 
AMPA receptor trafficking. Embo J 22 3254-3266. 
Mielke, M.M., Zandi, P.P., Sjogren, M., Gustafson, D., Ostling, S., Steen, B. & Skoog, I. 
(2005) High total cholesterol levels in late life associated with a reduced risk of 
dementia. Neurology 64 1689-1695. 
Miravalle, L., Calero, M., Takao, M., Roher, A.E., Ghetti, B. & Vidal, R. (2005) Amino-
terminally truncated Abeta peptide species are the main component of cotton wool 
plaques. Biochemistry 44 10810-10821. 
Moechars, D., Dewachter, I., Lorent, K., Reverse, D., Baekelandt, V., Naidu, A., Tesseur, I., 
Spittaels, K., Haute, C.V., Checler, F., Godaux, E., Cordell, B. & Van Leuven, F. 
  
 
 Page 124/137 
(1999b) Early phenotypic changes in transgenic mice that overexpress different 
mutants of amyloid precursor protein in brain. J Biol Chem 274 6483-6492. 
Moore, A.H. & O'Banion, M.K. (2002) Neuroinflammation and anti-inflammatory therapy for 
Alzheimer's disease. Adv Drug Deliv Rev 54 1627-1656. 
Moran, P.M., Higgins, L.S., Cordell, B. & Moser, P.C. (1995) Age-related learning deficits in 
transgenic mice expressing the 751-amino acid isoform of human beta-amyloid 
precursor protein. Proc Natl Acad Sci U S A 92 5341-5345. 
Mori, C., Spooner, E.T., Wisniewsk, K.E., Wisniewski, T.M., Yamaguch, H., Saido, T.C., 
Tolan, D.R., Selkoe, D.J. & Lemere, C.A. (2002) Intraneuronal Abeta42 accumulation 
in Down syndrome brain. Amyloid 9 88-102. 
Mori, H., Takio, K., Ogawara, M. & Selkoe, D.J. (1992) Mass spectrometry of purified 
amyloid beta protein in Alzheimer's disease. J Biol Chem 267 17082-17086. 
Mrak, R.E., Sheng, J.G. & Griffin, W.S. (1995) Glial cytokines in Alzheimer's disease: 
review and pathogenic implications. Hum Pathol 26 816-823. 
Murphy, G.M., Jr., Zhao, F., Yang, L. & Cordell, B. (2000) Expression of macrophage 
colony-stimulating factor receptor is increased in the AbetaPP(V717F) transgenic 
mouse model of Alzheimer's disease. Am J Pathol 157 895-904. 
Nguyen, T., Hamby, A. & Massa, S.M. (2005) Clioquinol down-regulates mutant huntingtin 
expression in vitro and mitigates pathology in a Huntington's disease mouse model. 
Proc Natl Acad Sci U S A 102 11840-11845. 
Nishimura, T., Akiyama, H., Yonehara, S., Kondo, H., Ikeda, K., Kato, M., Iseki, E. & 
Kosaka, K. (1995) Fas antigen expression in brains of patients with Alzheimer-type 
dementia. Brain Res 695 137-145. 
Notkola, I.L., Sulkava, R., Pekkanen, J., Erkinjuntti, T., Ehnholm, C., Kivinen, P., 
Tuomilehto, J. & Nissinen, A. (1998) Serum total cholesterol, apolipoprotein E epsilon 
4 allele, and Alzheimer's disease. Neuroepidemiology 17 14-20. 
O'Keeffe, S.T., Kazeem, H., Philpott, R.M., Playfer, J.R., Gosney, M. & Lye, M. (1996) Gait 
disturbance in Alzheimer's disease: a clinical study. Age Ageing 25 313-316. 
Orellana, D.I., Quintanilla, R.A. & Maccioni, R.B. (2007) Neuroprotective effect of 
TNFalpha against the beta-amyloid neurotoxicity mediated by CDK5 kinase. Biochim 
Biophys Acta 1773 254-263. 
Ottino, P., Finley, J., Rojo, E., Ottlecz, A., Lambrou, G.N., Bazan, H.E. & Bazan, N.G. 
(2004) Hypoxia activates matrix metalloproteinase expression and the VEGF system 
  
 
 Page 125/137 
in monkey choroid-retinal endothelial cells: Involvement of cytosolic phospholipase 
A2 activity. Mol Vis 10 341-350. 
Ozmen, L., Woolley, M., Albientz, A., Miss, M.T., Nelboeck, P., Malherbe, P., Czech, C., 
Gruninger-Leitch, F., Brockhaus, M., Ballard, T. & Jacobsen, H. (2005) 
BACE/APPV717F double-transgenic mice develop cerebral amyloidosis and 
inflammation. Neurodegener Dis 2 284-298. 
Papassotiropoulos, A., Lutjohann, D., Bagli, M., Locatelli, S., Jessen, F., Buschfort, R., Ptok, 
U., Bjorkhem, I., von Bergmann, K. & Heun, R. (2002) 24S-hydroxycholesterol in 
cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res 36 27-32. 
Parachikova, A., Agadjanyan, M.G., Cribbs, D.H., Blurton-Jones, M., Perreau, V., Rogers, J., 
Beach, T.G. & Cotman, C.W. (2006) Inflammatory changes parallel the early stages of 
Alzheimer disease. Neurobiol Aging 17 17. 
Paylor, R., Nguyen, M., Crawley, J.N., Patrick, J., Beaudet, A. & Orr-Urtreger, A. (1998) 
Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent 
learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice. 
Learn Mem 5 302-316. 
Penkowa, M., Caceres, M., Borup, R., Nielsen, F.C., Poulsen, C.B., Quintana, A., Molinero, 
A., Carrasco, J., Florit, S., Giralt, M. & Hidalgo, J. (2006) Novel roles for 
metallothionein-I + II (MT-I + II) in defense responses, neurogenesis, and tissue 
restoration after traumatic brain injury: insights from global gene expression profiling 
in wild-type and MT-I + II knockout mice. J Neurosci Res 84 1452-1474. 
Pennanen, C., Kivipelto, M., Tuomainen, S., Hartikainen, P., Hanninen, T., Laakso, M.P., 
Hallikainen, M., Vanhanen, M., Nissinen, A., Helkala, E.L., Vainio, P., Vanninen, R., 
Partanen, K. & Soininen, H. (2004) Hippocampus and entorhinal cortex in mild 
cognitive impairment and early AD. Neurobiol Aging 25 303-310. 
Perlmutter, L.S., Scott, S.A., Barron, E. & Chui, H.C. (1992) MHC class II-positive microglia 
in human brain: association with Alzheimer lesions. J Neurosci Res 33 549-558. 
Perry, V.H., Matyszak, M.K. & Fearn, S. (1993) Altered antigen expression of microglia in 
the aged rodent CNS. Glia 7 60-67. 
Petersen, R.C., Jack, C.R., Jr., Xu, Y.C., Waring, S.C., O'Brien, P.C., Smith, G.E., Ivnik, R.J., 
Tangalos, E.G., Boeve, B.F. & Kokmen, E. (2000) Memory and MRI-based 
hippocampal volumes in aging and AD. Neurology 54 581-587. 
Pettersson, A.F., Engardt, M. & Wahlund, L.O. (2002) Activity level and balance in subjects 
with mild Alzheimer's disease. Dement Geriatr Cogn Disord 13 213-216. 
  
 
 Page 126/137 
Pfaffl, M.W., Horgan, G.W. & Dempfle, L. (2002) Relative expression software tool (REST) 
for group-wise comparison and statistical analysis of relative expression results in 
real-time PCR. Nucleic Acids Res 30 e36. 
Piccini, A., Russo, C., Gliozzi, A., Relini, A., Vitali, A., Borghi, R., Giliberto, L., Armirotti, 
A., D'Arrigo, C., Bachi, A., Cattaneo, A., Canale, C., Torrassa, S., Saido, T.C., 
Markesbery, W., Gambetti, P. & Tabaton, M. (2005) beta-amyloid is different in 
normal aging and in Alzheimer disease. J Biol Chem 280 34186-34192. 
Piccini, A., Zanusso, G., Borghi, R., Noviello, C., Monaco, S., Russo, R., Damonte, G., 
Armirotti, A., Gelati, M., Giordano, R., Zambenedetti, P., Russo, C., Ghetti, B. & 
Tabaton, M. (2007) Association of a presenilin 1 S170F mutation with a novel 
Alzheimer disease molecular phenotype. Arch Neurol 64 738-745. 
Pike, C.J., Overman, M.J. & Cotman, C.W. (1995) Amino-terminal deletions enhance 
aggregation of beta-amyloid peptides in vitro. J Biol Chem 270 23895-23898. 
Pogue, A.I. & Lukiw, W.J. (2004) Angiogenic signaling in Alzheimer's disease. Neuroreport 
15 1507-1510. 
Probst, A., Gotz, J., Wiederhold, K.H., Tolnay, M., Mistl, C., Jaton, A.L., Hong, M., Ishihara, 
T., Lee, V.M., Trojanowski, J.Q., Jakes, R., Crowther, R.A., Spillantini, M.G., Burki, 
K. & Goedert, M. (2000) Axonopathy and amyotrophy in mice transgenic for human 
four-repeat tau protein. Acta Neuropathol (Berl) 99 469-481. 
Raivich, G., Haas, S., Werner, A., Klein, M.A., Kloss, C. & Kreutzberg, G.W. (1998) 
Regulation of MCSF receptors on microglia in the normal and injured mouse central 
nervous system: a quantitative immunofluorescence study using confocal laser 
microscopy. J Comp Neurol 395 342-358. 
Rapoport, M., Dawson, H.N., Binder, L.I., Vitek, M.P. & Ferreira, A. (2002) Tau is essential 
to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A 99 6364-6369.  
Reddy, P.H., Mani, G., Park, B.S., Jacques, J., Murdoch, G., Whetsell, W., Jr., Kaye, J. & 
Manczak, M. (2005) Differential loss of synaptic proteins in Alzheimer's disease: 
implications for synaptic dysfunction. J Alzheimers Dis 7 103-117; discussion 173-
180. 
Cynis, H., Schilling, S., Bodnar, M., Hoffmann, T., Heiser, U., Saido, T.C. & Demuth, H.U. 
(2006) Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian 
cells. Biochim Biophys Acta 1764 1618-1625. 
 
  
 
 Page 127/137 
Refolo, L.M., Pappolla, M.A., LaFrancois, J., Malester, B., Schmidt, S.D., Thomas-Bryant, 
T., Tint, G.S., Wang, R., Mercken, M., Petanceska, S.S. & Duff, K.E. (2001) A 
cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse 
model of Alzheimer's disease. Neurobiol Dis 8 890-899. 
Richards, J.G., Higgins, G.A., Ouagazzal, A.M., Ozmen, L., Kew, J.N., Bohrmann, B., 
Malherbe, P., Brockhaus, M., Loetscher, H., Czech, C., Huber, G., Bluethmann, H., 
Jacobsen, H. & Kemp, J.A. (2003) PS2APP transgenic mice, coexpressing hPS2mut 
and hAPPswe, show age-related cognitive deficits associated with discrete brain 
amyloid deposition and inflammation. J Neurosci 23 8989-9003. 
Romas, S.N., Tang, M.X., Berglund, L. & Mayeux, R. (1999) APOE genotype, plasma lipids, 
lipoproteins, and AD in community elderly. Neurology 53 517-521. 
Rota, E., Bellone, G., Rocca, P., Bergamasco, B., Emanuelli, G. & Ferrero, P. (2006) 
Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in 
Alzheimer's disease patients. Neurol Sci 27 33-39. 
Russo, C., Saido, T.C., DeBusk, L.M., Tabaton, M., Gambetti, P. & Teller, J.K. (1997) 
Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and 
Down's syndrome brains. FEBS Lett 409 411-416. 
Russo, C., Violani, E., Salis, S., Venezia, V., Dolcini, V., Damonte, G., Benatti, U., D'Arrigo, 
C., Patrone, E., Carlo, P. & Schettini, G. (2002) Pyroglutamate-modified amyloid 
beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival. J 
Neurochem 82 1480-1489. 
Saido, T.C., Iwatsubo, T., Mann, D.M., Shimada, H., Ihara, Y. & Kawashima, S. (1995) 
Dominant and differential deposition of distinct beta-amyloid peptide species, A beta 
N3(pE), in senile plaques. Neuron 14 457-466. 
Saido, T.C., Yamao-Harigaya, W., Iwatsubo, T. & Kawashima, S. (1996) Amino- and 
carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. 
Neurosci Lett 215 173-176. 
Sandbrink, R., Monning, U., Masters, C.L. & Beyreuther, K. (1997) Expression of the APP 
gene family in brain cells, brain development and aging. Gerontology 43 119-131. 
Savonenko, A.V., Xu, G.M., Price, D.L., Borchelt, D.R. & Markowska, A.L. (2003) Normal 
cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing 
mutant APP SWE. Neurobiol Dis 12 194-211. 
Scarmeas, N., Albert, M., Brandt, J., Blacker, D., Hadjigeorgiou, G., Papadimitriou, A., 
Dubois, B., Sarazin, M., Wegesin, D., Marder, K., Bell, K., Honig, L. & Stern, Y. 
  
 
 Page 128/137 
(2005) Motor signs predict poor outcomes in Alzheimer disease. Neurology 64 1696-
1703. 
Scarmeas, N., Hadjigeorgiou, G.M., Papadimitriou, A., Dubois, B., Sarazin, M., Brandt, J., 
Albert, M., Marder, K., Bell, K., Honig, L.S., Wegesin, D. & Stern, Y. (2004) Motor 
signs during the course of Alzheimer disease. Neurology 63 975-982. 
Schafer, S., Wirths, O., Multhaup, G. & Bayer, T.A. (2007) Gender dependent APP 
processing in a transgenic mouse model of Alzheimer's disease. J Neural Transm 114 
387-394. 
Schilling, S., Hoffmann, T., Manhart, S., Hoffmann, M. & Demuth, H.U. (2004) Glutaminyl 
cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett 563 
191-196. 
Schilling, S., Lauber, T., Schaupp, M., Manhart, S., Scheel, E., Bohm, G. & Demuth, H.U. 
(2006) On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). 
Biochemistry 45 12393-12399. 
Schilling, S.et.al. (2007) Inhibition of glutaminyl cyclase - a novel therapeutic concept for the 
causative treatment of Alzheimer's disease. Nature, co-submitted. 
Schmitz, C., Rutten, B.P., Pielen, A., Schafer, S., Wirths, O., Tremp, G., Czech, C., 
Blanchard, V., Multhaup, G., Rezaie, P., Korr, H., Steinbusch, H.W., Pradier, L. & 
Bayer, T.A. (2004) Hippocampal neuron loss exceeds amyloid plaque load in a 
transgenic mouse model of Alzheimer's disease. Am J Pathol 164 1495-1502. 
Schonknecht, P., Lutjohann, D., Pantel, J., Bardenheuer, H., Hartmann, T., von Bergmann, K., 
Beyreuther, K. & Schroder, J. (2002) Cerebrospinal fluid 24S-hydroxycholesterol is 
increased in patients with Alzheimer's disease compared to healthy controls. Neurosci 
Lett 324 83-85. 
Selkoe, D.J. (1991) The molecular pathology of Alzheimer's disease. Neuron 6 487-498. 
Selkoe, D.J. (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81 741-
766. 
Selkoe, D.J., Abraham, C.R., Podlisny, M.B. & Duffy, L.K. (1986) Isolation of low-
molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J 
Neurochem 46 1820-1834. 
Semenza, G.L. (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 721-732. 
Shahbazian, M., Young, J., Yuva-Paylor, L., Spencer, C., Antalffy, B., Noebels, J., 
Armstrong, D., Paylor, R. & Zoghbi, H. (2002) Mice with truncated MeCP2 
  
 
 Page 129/137 
recapitulate many Rett syndrome features and display hyperacetylation of histone H3. 
Neuron 35 243-254. 
Shepherd, C.E., Grace, E.M., Mann, D.M. & Halliday, G.M. (2007) Relationship between 
neuronal loss and 'inflammatory plaques' in early onset Alzheimer's disease. 
Neuropathol Appl Neurobiol 33 328-333. 
Silbert, L.C., Quinn, J.F., Moore, M.M., Corbridge, E., Ball, M.J., Murdoch, G., Sexton, G. & 
Kaye, J.A. (2003) Changes in premorbid brain volume predict Alzheimer's disease 
pathology. Neurology 61 487-492. 
Sjogren, M., Mielke, M., Gustafson, D., Zandi, P. & Skoog, I. (2006) Cholesterol and 
Alzheimer's disease--is there a relation? Mech Ageing Dev 127 138-147. 
Solfrizzi, V., Panza, F., D'Introno, A., Colacicco, A.M., Capurso, C., Basile, A.M. & Capurso, 
A. (2002) Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease. 
J Neurol Neurosurg Psychiatry 72 732-736. 
Spittaels, K., Van den Haute, C., Van Dorpe, J., Bruynseels, K., Vandezande, K., Laenen, I., 
Geerts, H., Mercken, M., Sciot, R., Van Lommel, A., Loos, R. & Van Leuven, F. 
(1999) Prominent axonopathy in the brain and spinal cord of transgenic mice 
overexpressing four-repeat human tau protein. Am J Pathol 155 2153-2165. 
St George-Hyslop, P.H. (2000) Molecular genetics of Alzheimer's disease. Biol Psychiatry 47 
183-199. 
Stokin, G.B., Lillo, C., Falzone, T.L., Brusch, R.G., Rockenstein, E., Mount, S.L., Raman, R., 
Davies, P., Masliah, E., Williams, D.S. & Goldstein, L.S. (2005) Axonopathy and 
transport deficits early in the pathogenesis of Alzheimer's disease. Science 307 1282-
1288. 
Streit, W.J., Mrak, R.E. & Griffin, W.S. (2004) Microglia and neuroinflammation: a 
pathological perspective. J Neuroinflammation 1 14. 
Streit, W.J. & Sparks, D.L. (1997) Activation of microglia in the brains of humans with heart 
disease and hypercholesterolemic rabbits. J Mol Med 75 130-138. 
Szczepanik, A.M., Funes, S., Petko, W. & Ringheim, G.E. (2001) IL-4, IL-10 and IL-13 
modulate A beta(1--42)-induced cytokine and chemokine production in primary 
murine microglia and a human monocyte cell line. J Neuroimmunol 113 49-62. 
Sunderland, T., Gur, R.E. & Arnold, S.E. (2005) The use of biomarkers in the elderly: current 
and future challenges. Biol Psychiatry 58 272-276. 
Tabira, T., Chui, D.H. & Kuroda, S. (2002) Significance of intracellular Abeta42 
accumulation in Alzheimer's disease. Front Biosci 7 a44-49. 
  
 
 Page 130/137 
Tahara, K., Kim, H.D., Jin, J.J., Maxwell, J.A., Li, L. & Fukuchi, K. (2006) Role of toll-like 
receptor signalling in Abeta uptake and clearance. Brain 129 3006-3019. 
Takahashi, R.H., Almeida, C.G., Kearney, P.F., Yu, F., Lin, M.T., Milner, T.A. & Gouras, 
G.K. (2004) Oligomerization of Alzheimer's beta-amyloid within processes and 
synapses of cultured neurons and brain. J Neurosci 24 3592-3599. 
Takahashi, R.H., Milner, T.A., Li, F., Nam, E.E., Edgar, M.A., Yamaguchi, H., Beal, M.F., 
Xu, H., Greengard, P. & Gouras, G.K. (2002) Intraneuronal Alzheimer abeta42 
accumulates in multivesicular bodies and is associated with synaptic pathology. Am J 
Pathol 161 1869-1879. 
Takeda, K., Araki, W. & Tabira, T. (2004) Enhanced generation of intracellular Abeta42 
amyloid peptide by mutation of presenilins PS1 and PS2. Eur J Neurosci 19 258-264. 
Tanzi, R.E. (1999) A genetic dichotomy model for the inheritance of Alzheimer's disease and 
common age-related disorders. J Clin Invest 104 1175-1179. 
Tarkowski, E., Issa, R., Sjogren, M., Wallin, A., Blennow, K., Tarkowski, A. & Kumar, P. 
(2002) Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in 
Alzheimer's disease and vascular dementia. Neurobiol Aging 23 237-243. 
Tekirian, T.L., Saido, T.C., Markesbery, W.R., Russell, M.J., Wekstein, D.R., Patel, E. & 
Geddes, J.W. (1998) N-terminal heterogeneity of parenchymal and cerebrovascular 
Abeta deposits. J Neuropathol Exp Neurol 57 76-94. 
Tekirian, T.L., Yang, A.Y., Glabe, C. & Geddes, J.W. (1999) Toxicity of pyroglutaminated 
amyloid beta-peptides 3(pE)-40 and -42 is similar to that of A beta1-40 and -42. J 
Neurochem 73 1584-1589. 
Terwel, D., Lasrado, R., Snauwaert, J., Vandeweert, E., Van Haesendonck, C., Borghgraef, P. 
& Van Leuven, F. (2005) Changed conformation of mutant Tau-P301L underlies the 
moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N 
transgenic mice. J Biol Chem 280 3963-3973. 
Tesseur, I., Van Dorpe, J., Bruynseels, K., Bronfman, F., Sciot, R., Van Lommel, A. & Van 
Leuven, F. (2000) Prominent axonopathy and disruption of axonal transport in 
transgenic mice expressing human apolipoprotein E4 in neurons of brain and spinal 
cord. Am J Pathol 157 1495-1510. 
Teunissen, C.E., De Vente, J., von Bergmann, K., Bosma, H., van Boxtel, M.P., De Bruijn, 
C., Jolles, J., Steinbusch, H.W. & Lutjohann, D. (2003) Serum cholesterol, precursors 
and metabolites and cognitive performance in an aging population. Neurobiol Aging 
24 147-155. 
  
 
 Page 131/137 
Tuppo, E.E. & Arias, H.R. (2005) The role of inflammation in Alzheimer's disease. Int J 
Biochem Cell Biol 37 289-305. 
Urbanc, B., Cruz, L., Le, R., Sanders, J., Ashe, K.H., Duff, K., Stanley, H.E., Irizarry, M.C. & 
Hyman, B.T. (2002) Neurotoxic effects of thioflavin S-positive amyloid deposits in 
transgenic mice and Alzheimer's disease. Proc Natl Acad Sci U S A 99 13990-13995. 
Van Broeck, B., Van Broeckhoven, C. & Kumar-Singh, S. (2007) Current insights into 
molecular mechanisms of Alzheimer disease and their implications for therapeutic 
approaches. Neurodegener Dis 4 349-365. 
Wagner, U., Utton, M., Gallo, J.M. & Miller, C.C. (1996) Cellular phosphorylation of tau by 
GSK-3 beta influences tau binding to microtubules and microtubule organisation. J 
Cell Sci 109 1537-1543. 
Wirths, O., Breyhan, H., Schafer, S., Roth, C. & Bayer, T.A. (2007) Deficits in working 
memory and motor performance in the APP/PS1ki mouse model for Alzheimer's 
disease. Neurobiol Aging Jan. 8. 
Wirths, O., Multhaup, G. & Bayer, T.A. (2004) A modified beta-amyloid hypothesis: 
intraneuronal accumulation of the beta-amyloid peptide--the first step of a fatal 
cascade. J Neurochem 91 513-520. 
Wirths, O., Multhaup, G., Czech, C., Feldmann, N., Blanchard, V., Tremp, G., Beyreuther, 
K., Pradier, L. & Bayer, T.A. (2002) Intraneuronal APP/A beta trafficking and plaque 
formation in beta-amyloid precursor protein and presenilin-1 transgenic mice. Brain 
Pathol 12 275-286. 
Wirths, O., Thelen, K., Breyhan, H., Luzon-Toro, B., Hoffmann, K.H., Falkai, P., Lutjohann, 
D. & Bayer, T.A. (2006) Decreased plasma cholesterol levels during aging in 
transgenic mouse models of Alzheimer's disease. Exp Gerontol 41 220-224. 
Wirths, O., Weis, J., Kayed, R., Saido, T.C. & Bayer, T.A. (2006) Age-dependent axonal 
degeneration in an Alzheimer mouse model. Neurobiol Aging Sept. 8. 
Wirths, O., Weis, J., Szczygielski, J., Multhaup, G. & Bayer, T.A. (2006) Axonopathy in an 
APP/PS1 transgenic mouse model of Alzheimer's disease. Acta Neuropathol 111 312-
319. 
Wung, J.K., Perry, G., Kowalski, A., Harris, P.L., Bishop, G.M., Trivedi, M.A., Johnson, 
S.C., Smith, M.A., Denhardt, D.T. & Atwood, C.S. (2007) Increased expression of the 
remodeling- and tumorigenic-associated factor osteopontin in pyramidal neurons of 
the Alzheimer's disease brain. Curr Alzheimer Res 4 67-72. 
  
 
 Page 132/137 
Wyss-Coray, T. (2006) Inflammation in Alzheimer disease: driving force, bystander or 
beneficial response? Nat Med 12 1005-1015. 
Wyss-Coray, T., Lin, C., Yan, F., Yu, G.Q., Rohde, M., McConlogue, L., Masliah, E. & 
Mucke, L. (2001) TGF-beta1 promotes microglial amyloid-beta clearance and reduces 
plaque burden in transgenic mice. Nat Med 7 612-618. 
Xia, W. (2000) Role of presenilin in gamma-secretase cleavage of amyloid precursor protein. 
Exp Gerontol 35 453-460. 
Yew, D.T., Ping Li, W. & Liu, W.K. (2004) Fas and activated caspase 8 in normal, Alzheimer 
and multiple infarct brains. Neurosci Lett 367 113-117. 
Youssef, I., Florent-Bechard, S., Malaplate-Armand, C., Koziel, V., Bihain, B., Olivier, J.L., 
Leininger-Muller, B., Kriem, B., Oster, T. & Pillot, T. (2007) N-truncated amyloid-
beta oligomers induce learning impairment and neuronal apoptosis. Neurobiol Aging 
23 23. 
Zadeh, G. & Guha, A. (2003) Angiogenesis in nervous system disorders. Neurosurgery 53 
1362-1374; discussion 1374-1366. 
Zhang, R., Barker, L., Pinchev, D., Marshall, J., Rasamoelisolo, M., Smith, C., Kupchak, P., 
Kireeva, I., Ingratta, L. & Jackowski, G. (2004) Mining biomarkers in human sera 
using proteomic tools. Proteomics 4 244-256 
Zhao, B., Stavchansky, S.A., Bowden, R.A. & Bowman, P.D. (2003) Effect of interleukin-
1beta and tumor necrosis factor-alpha on gene expression in human endothelial cells. 
Am J Physiol Cell Physiol 284 C1577-1583.  
Zheng, W.H., Bastianetto, S., Mennicken, F., Ma, W. & Kar, S. (2002) Amyloid beta peptide 
induces tau phosphorylation and loss of cholinergic neurons in rat primary septal 
cultures. Neuroscience 115 201-211. 
 
 
 
 
 
 
 
  
 
 Page 133/137 
7 PUBLICATIONS 
• Breyhan H., Wirths O., Lütjohann D., Bayer T.A. (2005) 
24(S)-Hydroxycholesterol plasma levels in a transgenic mouse model for Alzheimer`s 
disease with neuron loss 
Neurology, Psychiatry and Brain Research, 12:101-104 
 
• Wirths O., Thelen K., Breyhan H., Luzon-Toro B., Hoffmann K.H., Falkai P., Lütjohann 
D., Bayer T.A. (2006) 
Decreased plasma cholesterol levels during aging in transgenic mouse models of 
Alzheimer’s disease 
Experimental Gerontology, 41(2): 220-224 
 
• Bayer T.A., Schäfer S., Breyhan H., Wirths O., Treiber C., Multhaup G. (2006) 
A vicious cycle: Role of oxidative stress, intraneuronal Aβ and Cu in Alzheimer’s 
disease 
Clinical Neuropathology, 25(4): 163-171 
 
• Wirths, O., Breyhan H., Schäfer S., Roth C., Bayer T.A. (2007) 
Deficits in working memory and motor performance in the APP/PS1ki mouse model 
of Alzheimer’s disease 
Neurobiology of Aging, in press  
(Epub 8. Januar 2007, DOI: 10.1016/j.neurobiolaging.2006.12.004) 
 
• Breyhan H.*, Duan K.*, Wirths O.*, Saido T.C., Rettig J., Bayer T.A. 
Dominant aggregation of beta-amyloid starting with pyroglutamate at position 3: 
synaptic deficits, neuron loss and hippocampus atrophy in the APP/PS1KI mouse 
Submitted (*equal contribution) 
 
• Bayer T.A.*, Breyhan H.*, Wirths O.*, Cynis H., Schilling S., Demuth H.U. 
Aβ3(pE)-42 triggers neurodegeneration and lethal neurological deficits in transgenic 
mice 
Submitted (*equal contribution) 
 
 
  
 
 Page 134/137 
• Rohe M., Carlo A.S., Breyhan H., Sporbert A., Militz D., Schmidt V., Wozny C., 
Harmeier A., Erdmann B., Bales K.R., Wolf S., Kempermann G., Paul S., Schmitz D., 
Bayer T.A., Willnow T.E., Andersen O.M.  
SorLA controls APP-dependent stimulation of adult neurogenesis through ERK 
signaling 
Submitted 
 
• Breyhan H., Wirths O., Marcello A., Bayer T.A. 
Pathology-dependent development of neuroinflammation in an APP/PS1KI mouse 
model of Alzheimer’s disease 
In preparation 
 
 
Conference Abstracts 
 
• Bayer T.A., Wirths O, Schäfer S, Breyhan H, Muckenthaler M, Delacourte A, Kayed 
R, Saido T, Multhaup G, Weis J., New lessons from the APP/PS1 transgenic mouse 
model with neuron loss: metal biology, axonal degeneration and intraneuronal N-
modified Abeta aggregation, Alzheimer`s and Dementia 2(3) Suppl. 1: S38-S39, July 
2006 
 
• T.A. Bayer, H. Breyhan, K. Duan, J. Rettig, O. Wirths, Intraneuronal Abeta is a 
Major Risk Factor – Novel Evidence From the APP/PS1KI Mouse Model, 
Neurodegenerative Dis 4(suppl 1) 1-364 (2007) 
 
• Breyhan H., Schäfer S., Wirths O., Muckenthaler M., Multhaup G., Bayer T.A., 
Neuronal loss and changes in metal homeostasis in the APP751SLPS1ki mouse 
model of Alzheimer`s disease, Alzheimer`s and Dementia 2(3) Suppl. 1:S.106, July 
2006 
 
• O.M. Andersen, V. Schmidt, M. Rohe, Sporbert, H. Breyhan, T.A. Bayer, T.E. 
Willnow, SorLA and APP Trafficking, Neurodegenerative Dis 4(suppl 1) 1-364 
(2007) 
 
  
 
 Page 135/137 
• O. Wirths, H. Breyhan, J. Weis, , T.A. Bayer, Age-Dependent Axonal Degeneration 
and Behavioural Impairment in the APP/PS1ki Mouse Model of AD, 
Neurodegenerative Dis 4(suppl 1) 1-364 (2007) 
 
• Bayer TA, Duan K, Breyhan H, Rettig J, Wirths O., Synaptic deficits correlate with 
neuron loss and changes in behaviour in the APP/PS1ki mouse model, IBANGS 9th 
Annual meeting, Doorwerth (Netherlands), May 21-25, 2007-03-19 
 
• Bayer TA, Breyhan H, Duan K, Rettig J, Wirths O. Paradigm shift in Alzheimer’s 
Disease: Intraneuronal Aβ aggregation triggers neuron loss. European 
Neuropsychopharmacology (17) Suppl. 4:205 (2007) 
 
  
 
 Page 136/137 
8 DANKSAGUNG 
 
Sehr herzlich danke ich Herrn Professor Thomas Bayer für Betreung und Begleitung dieser 
Arbeit sowie für die Übernahme des Referates. 
 
Hern Professor Adolfo Cavalié danke ich verbindlich für die Übernahme des Korreferates. 
 
Herrn Doktor Oliver Wirths danke ich besonders für seine ausgezeichnete Kollegialität, seine 
vielseitigen Anregungen zu meiner Arbeit und die gute Zeit, die ich mit ihm gemeinsam 
verbringen durfte. 
 
Herrn Professor Hans-Ulrich Demuth danke ich für die freundliche Aufnahme bei der 
Probiodrug AG sowie den spannenden Einblick in die Unternehmensentwicklung. 
 
Herrn Doktor Stephan Schilling, Herrn Holger Cynis, Frau Katrin Schulz, Frau Birgit Koch, 
Herrn Eike Scheel sowie allen weiteren Kollegen, mit denen ich bei der Probiodrug AG 
zusammenarbeiten durfte, danke ich neben den hervorragenden Arbeitsbedingungen 
insbesondere auch für die ausgezeichnete Arbeitsatmosphäre, die mich zu meinen zahlreichen 
Aufenthalten immer wieder gerne nach Halle zurückgeführt hat. 
 
Frau Katrin Rubly, Frau Doktor Stephanie Schäfer und Herrn Karl-Heinz Hoffmann danke ich 
für die gute Zusammenarbeit. 
 
Diese Promotion wurde ermöglicht durch ein Stipendium der Stiftung der Deutschen 
Wirtschaft (sdw). Für das durch diese Förderung zum Ausdruck gebrachte Vertrauen bedanke 
ich mich sehr herzlich. Besonders möchte ich mich aber für die in der Förderzeit erfahrene 
ideelle Förderung durch die sdw bedanken, welche mich bei meiner persönlichen 
Weiterentwicklung wertvoll unterstützte. Das mir in der sdw gebotene Forum zum 
interdisziplinären Austausch habe ich stets sehr geschätzt. Namentlich danken darf ich 
insbesondere meinen Regionalbetreuern Herrn Dirk Reichel und Frau Doktor Gwendolin 
Mühlinghaus sowie Frau Natalia Smith und Herrn Friedrich Anders für eine inspirierende 
Sommerakademie. 
  
 
 Page 137/137 
9 Curriculum Vitae 
 
Personal Data 
Name:   Henning Breyhan 
Date of Birth : Salzgitter, June 11th 1976 
Nationality:  German 
 
Scientific education 
04/2000 –  03/2002 Basic studies of chemistry at the RWTH Aachen 
04/2002 –  04/2004 Main study period in chemistry at the Rheinische Friedrich-Wilhelms-
Universität in Bonn 
05/2004 – 11/2004 Diploma thesis with Professor Konrad Sandhoff, Rheinische Friedrich-
Wilhelms-Universität Bonn; Degree: Diplom-Chemiker 
11/2004 – 10/2007  Ph.D. thesis with Professor Thomas Bayer in Homburg and Goettingen   
 
Other education 
07/1995 – 04/1996 Military service 
04/1996 – 03/1999 Studies of Economics  at the Fachhochschule der Deutschen 
Bundesbank in Hachenburg/Westerwald (University of Applied 
Sciences); Degree: Diplom-Betriebswirt (FH)  
04/1999 – 03/2000 occupational activity in the Department of Economics in the land 
central bank of Hamburg 
 
Scholarships 
 
12/2005 – 11/2007 Klaus-Murmann-Ph.D.-scholarship of the Foundation of German 
Businesses (sdw)  
 
Göttingen, 10 Oct. 07 
 
 
 
Henning Breyhan 
